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CHAPTER 1
Summary
Activated signal transducer and activator of transcription STAT5 induces the expres-
sion of genes essential for cell di↵erentiation, proliferation and inhibition of apoptosis.
Previous work from our group demonstrated that the deacetylase inhibitor trichostatin
A (TSA) attenuates transcriptional activation of STAT5 target genes at a step following
STAT5 binding to its DNA binding sites by abrogating the recruitment of TBP and RNA
polymerase II. The goal of this thesis was to better understand the mechanism of tran-
scriptional regulation by STAT5 via the characterization of the mechanism underlying its
inhibition by TSA. Specific aims were the identification of (i) the deacetylase (so-called
HDAC) involved and of (ii) the acetylated substrate. The identification of the HDAC
was performed using class-selective HDAC inhibitors and siRNA-mediated knock-down
of HDAC expression. We found that, similarly to TSA, the deacetylase inhibitors val-
proic acid (VPA) and apicidin - but not MGCD0103 and MS-275 - inhibited expression of
STAT5 target genes. However, siRNA-mediated knock-down experiments did not allow
to identify the specific HDAC(s) involved in STAT5 target gene expression. To investigate
whether STAT5 might be the acetylated substrate targeted by HDACs, selected lysine
residues within STAT5 potentially targeted for acetylation were mutated and their ef-
fect on STAT5-mediated transcription was investigated. None of the mutations a↵ected
STAT5 transcriptional activity, arguing against STAT5 being the acetylated substrate
targeted by the sought HDAC. Interestingly however, inhibition of STAT5-mediated tran-
scription by TSA, VPA and apicidin correlated with an increase in global histone H3 and
H4 acetylation. It also correlated with a redistribution of the acetylated-histone-binding
protein BRD2, a member of the bromodomain and extra-terminal (BET) protein family
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described for its role in the recruitment of the transcriptional machinery and transcrip-
tional activation. Notably, chromatin precipitation experiments revealed that BRD2 is
associated with the actively-transcribed STAT5 target gene Cis in a STAT5-dependent
manner, and that BRD2 binding to Cis is lost upon TSA treatment. In agreement with
a role of BRD2 in STAT5-mediated transcription, the BET inhibitor (+)-JQ1 inhibited
STAT5-mediated transcription of the Cis gene. Together, our data support a model in
which the HDAC inhibitors TSA, VPA and apicidin target histone acetylation, result-
ing in a global increase in chromatin acetylation. This change in chromatin acetylation
would result in the redistribution of BRD2 to hyperacetylated chromatin and a departure
of BRD2 from STAT5 target genes. BRD2 loss at STAT5 target genes would in turn pre-
vent the proper recruitment and maintenance of the transcriptional machinery, resulting
in transcriptional inhibition. In summary, this thesis identified BRD2 as an important
co-factor of STAT5-mediated transcription and demonstrated that deacetylase inhibitors
inhibit STAT5-mediated transcription by interfering with BRD2 function. This study
thus identified BRD2 as a potential target for the development of novel therapies against
STAT5-associated cancers.
2
CHAPTER 2
Introduction
2.1 Transcription and chromatin
2.1.1 Eukaryotic transcription
In eukaryotes, transcriptional activation of a protein-coding gene is the result of a
promoter-specific combinatorial interplay between site-specific transcription factors and
the cofactors they recruit (Hill & Treisman, 1995; Me´tivier et al., 2003; Reme´nyi et al.,
2004; Venters & Pugh, 2009). Transcription factors bind to specific DNA recognition
sequences, which are usually located within promoters adjacent to the regulated gene or
within distal enhancers. Enhancers are brought in close proximity to the regulated gene
through long-range chromatin looping (Whalen et al., 2016). DNA-bound transcription
factors recruit co-activators or co-repressors, multiprotein complexes, and components
of the basal transcription machinery to assist the assembly of the pre-initiation complex
and eventually enable initiation of transcription by RNA polymerase II (Pfitzner et al.,
1998; Nakajima et al., 2001; Me´tivier et al., 2003). Many of the interaction partners of
transcription factors are chromatin remodeling or modifying complexes, demonstrating
the importance of chromatin composition and physical accessibility of DNA for
transcription processes (Pfitzner et al., 1998; Xu et al., 2007; Venters & Pugh, 2009;
Tang et al., 2013).
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2.1.2 Transcription factors
Transcription factors are key mediators of transcription initiation. Thus, the regulation
of transcription factor availability and activity is a central control parameter of gene
expression. Transcription factor availability can be regulated, for example, at the level
of their production, degradation or subcellular localization (Baeuerle & Baltimore, 1988;
Wang et al., 1999; Rodriguez et al., 2000). Transcription factor activity is frequently
modulated by post-translational modifications like phosphorylation, acetylation, methy-
lation, ubiquitylation or SUMOylation (Shuai et al., 1993; Rodriguez et al., 2000; Rogers
et al., 2003; Chuikov et al., 2004; Yuan, 2005; Venne et al., 2014). Phosphorylation is
the post-translational modification best known to activate or inhibit transcription fac-
tors, but it is evident that lysine acetylation has also tremendous impact on transcription
factor activity. Acetylation of transcription factors like p53, E2F1, nuclear factor-B
(NF-B), and signal transducers and activators of transcription (STATs) can modulate
their activity at key steps such as protein stability, cellular localization, a nity for DNA
or protein-protein interactions (Mart´ınez-Balba´s et al., 2000; Li et al., 2002; Kiernan
et al., 2003; Kra¨mer et al., 2006; Tang et al., 2007; Spange et al., 2009).
2.1.3 Chromatin
In the eukaryotic nucleus, chromosomal DNA and several associated proteins form a
structure called chromatin. The basic unit of chromatin is the nucleosome consisting of
a histone protein octamer core around which the DNA is wrapped in nearly two turns.
The histone octamer itself consists of two histone H2A / histone H2B heterodimers and
two histone H3 / histone H4 heterodimers (Luger et al., 1997). Successive nucleosomes
and the linker DNA between them produce a beads-on-a-string-like conformation (Olins
& Olins, 1974). Several additional layers of compaction follow until the highly condensed
heterochromatin is formed. By contrast, euchromatin is less compacted and the DNA
is more accessible. It is therefore not surprising that most of the transcribed genes are
found in euchromatin (Grewal & Moazed, 2003; DesJarlais & Tummino, 2016).
Besides its stabilizing and compacting function, chromatin is a level of regulation
for fundamental cellular processes like DNA replication, DNA repair and transcription.
DNA which is tightly wrapped around the histone octamer core is less accessible for
binding of regulatory proteins, transcription factors or other DNA binding proteins (Lorch
et al., 1987; Coˆte´ et al., 1994; Tse et al., 1998; Lorch & Kornberg, 2015; DesJarlais &
Tummino, 2016). For instance, nucleosome depletion increases transcription in vivo (Han
& Grunstein, 1988), and nucleosomes occluding certain elements within the promoter can
inhibit in vitro transcription initiation by RNA polymerase II (Lorch et al., 1987).
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Despite having preferential positioning sequences (Kaplan et al., 2009), nucleosomes
are dynamic in that they can be shifted along the DNA by ATP-dependent chromatin
remodeling complexes such as SWI/SNF (Hirschhorn et al., 1992; Coˆte´ et al., 1994; La¨ngst
& Becker, 2004; Venters & Pugh, 2009) or can be dis- and reassembled through histone
chaperones such as FACT (facilitates chromatin transcription complex) (Belotserkovskaya
et al., 2003) and BRD2 (bromodomain-containing protein 2) (LeRoy et al., 2008). In a
genome-wide analysis it has recently been demonstrated that nucleosome repositioning is
a general mechanism of the regulation of transcription (Nocetti & Whitehouse, 2016). In
addition to remodeling, chromatin can be covalently modified, especially at the accessible
histone N-termini, to create binding sites for specific chromatin binding proteins. In
doing so, chromatin remodelers together with chromatin modifiers establish a chromatin
structure restrictive or permissive for transcription to enable the cell to proceed through
the cell cycle and adapt to external or developmental stimuli (DesJarlais & Tummino,
2016; Nocetti & Whitehouse, 2016).
2.1.4 Chromatin acetylation
Chromatin acetylation is established by a tightly controlled balance between histone
acetyltransferases (HATs, e.g. p300/CBP) and histone deacetylases (HDACs). Acetyla-
tion of histones takes place at their accessible amino-termini, which protrude from the
nucleosomal core. The main acetylation sites of histone H3 are lysine residues K9, K14,
K18 and K23 while histone H4 acetylation sites are K5, K8, K12 and K16 (Thorne et al.,
1990).
The established pattern of histone acetylation together with histone methylation,
ubiquitylation and other post-translational modifications generates a histone modification
pattern (Jenuwein & Allis, 2001; Agalioti et al., 2002; Guccione et al., 2006; Tang et al.,
2013), which can be recognized and bound by certain ”reader” proteins, most of which
have transcriptional, chromatin maintenance or sca↵olding functions (Jacobson et al.,
2000; Jacobs & Khorasanizadeh, 2002; Kasten et al., 2004; Denis et al., 2006; Zeng et al.,
2008).
Bromodomains, for example, recognize acetylated lysine residues of proteins and
thus direct di↵erent bromodomain-containing proteins to acetylated chromatin (Jacob-
son et al., 2000). The double bromodomain-containing protein BRD2, member of the
bromodomain and extra terminal (BET) family of proteins, favors binding to acetylated
H4K12 and is as such a specific chromatin ”reader” protein (Kanno et al., 2004).
In general, histone acetylation has been correlated with transcriptional activity (All-
frey et al., 1964; Allegra et al., 1987; Hebbes et al., 1988; Schu¨beler et al., 2004; Roh
et al., 2005). It has been postulated that lysine acetylation of histones, reducing the
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positive charge of the histone tail, decondenses the chromatin structure and thus facil-
itates access of regulatory proteins to chromatin (Luger et al., 1997; Tse et al., 1998;
Shogren-Knaak et al., 2006). However, upon histone deacetylase inhibitor treatment,
inducing global histone hyperacetylation, the expression of only a small subset of genes
is changed, and in most cases about half of the a↵ected genes are downregulated (Glaser
et al., 2003; Peart et al., 2005; Daly & Shirazi-Beechey, 2006; Rada-Iglesias et al., 2007;
Halsall et al., 2015). When looking at the promoter context, it is evident that both,
acetylation as well as deacetylation processes are associated with transcriptional activity
(Agalioti et al., 2000; Deckert & Struhl, 2001; Rascle et al., 2003; Kurdistani et al., 2004;
Aoyagi & Archer, 2007; Lin et al., 2014; Greer et al., 2015).
2.1.5 Bromodomain and extra-terminal (BET) proteins
One protein family of acetyl-histone binding proteins is the bromodomain and extra-
terminal (BET) protein family. The mammalian BET family consists of bromodomain-
containing protein 2 (BRD2), BRD3, BRD4 and BRDT. Their two N-terminal bromod-
omains bind to "-amino-acetylated lysine residues of histones (Dey et al., 2003; Pivot-
Pajot et al., 2003; Kanno et al., 2004; LeRoy et al., 2008; Morinie`re et al., 2009). In
addition, they have a conserved extra-terminal domain, which mediates protein-protein
interactions (Belkina & Denis, 2012). BET proteins are transcriptional regulators. They
interact with chromatin modifying and remodeling complexes, transcriptional cofactors
or components of the transcription machinery (Crowley et al., 2002; Denis et al., 2006;
Peng et al., 2007; LeRoy et al., 2008; Rahman et al., 2011; Wang et al., 2012; Hnilicova´
et al., 2013; Greer et al., 2015).
BET proteins are very similar, especially BRD2 and BRD4 whose bromo- and extra-
terminal domains are about 80% identical by sequence (Belkina & Denis, 2012). This
structural similarity might contribute to a certain degree of functional redundancy be-
tween members of the BET family, for example during inflammation responses (Belkina
et al., 2013). By contrast, their developmental functions are rather specific, since other
family members cannot rescue embryonic lethal BRD2null or BRD4null knockout mice
(Houzelstein et al., 2002; Gyuris et al., 2009; Shang et al., 2009).
2.2 Histone deacetylases (HDACs)
2.2.1 HDAC function
Histone deacetylases (HDACs) remove covalently attached acetyl groups from "-amino-
acetylated lysine residues of proteins. Besides acetylated histones, they have hundreds
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of cytosolic as well as nuclear non-histone substrates, many of which are transcription
factors (Choudhary et al., 2009; Spange et al., 2009). Although HDACs are part of
several co-repressor complexes (Kelly & Cowley, 2013) and their opposing HATs are gen-
erally seen as co-activators (Holmqvist & Mannervik, 2013), HDACs as well as HATs
are both associated with transcriptional repression and activation (Nusinzon & Horvath,
2003; Zupkovitz et al., 2006; Aoyagi & Archer, 2007; Wang et al., 2009; Holmqvist &
Mannervik, 2013; Lin et al., 2014). Owing to the many proteins and genes regulated
by acetylation, HDACs are essential regulators of important cellular processes such as
cell-cycle progression and apoptosis (Dangond et al., 1998; Lagger et al., 2002; Zhu et al.,
2004; Huang et al., 2005; Ropero & Esteller, 2007; Ji et al., 2014; Dasgupta et al., 2016).
Furthermore, HDACs a↵ect homeostasis and di↵erentiation of various cell types, for in-
stance in cardiovascular, immune, and nervous system, in kidney and in epidermis (Bai
et al., 2005; Chen et al., 2011; Robertson et al., 2012; Nural-Guvener et al., 2014; Sun
et al., 2014; Mathias et al., 2015; Hull et al., 2016).
Mammalian deacetylases can be grouped into 4 di↵erent HDAC classes based on
primary structure and phylogenetic analysis (Gregoretti et al., 2004). HDAC class 1
contains HDAC1, 2, 3, and 8, which are ubiquitously expressed in most tissues and
localize predominantly to the nucleus. Class II HDACs are subdivided into subclass
IIA, containing HDAC4, 5, 7, and 9, and into subclass IIB, containing HDAC6 and 10.
Class II HDACs show a higher degree of cell type-specific expression and typically shuttle
between nucleus and cytoplasm. HDAC11 is the most recently discovered HDAC and the
sole member of class IV HDACs. HDAC’s class III contains the sirtuins (SIRT1-7) which
are unrelated to the eleven classical HDACs (class I, II and IV) in terms of sequence and
catalytic mechanism (Frye, 2000; Tanner et al., 2000; Ropero & Esteller, 2007).
Class IIA HDACs (HDAC4, 5, 7, 9) have only minor enzymatic deacetylase activity
towards acetylated histone tails (Fischle et al., 2001, 2002; Lahm et al., 2007; Lobera
et al., 2013; Di Giorgio et al., 2015), and HDAC6 is localized predominantly in the cyto-
plasm (Verdel et al., 2000), where ↵-tubulin is one of its main substrates (Liu et al., 2015).
Therefore the major HDACs responsible for histone deacetylation are the mainly nuclear
class I HDACs. HDAC1 and HDAC2 proteins are 80% identical in sequence (Dovey
et al., 2013) and catalytic members of the same multiprotein chromatin modifying com-
plexes. Those complexes are NuRD (nucleosome remodeling and deacetylation), CoRest
(co-repressor for element-1- silencing transcription factor) and Sin3 (Kelly & Cowley,
2013). Biochemically, HDAC1 and HDAC2 make up most of the cellular HDAC activity.
Their co-knockdown in T cells leads to almost 60% reduction of total nuclear histone
deacetylase activity (Dovey et al., 2013). HDAC3 deacetylates histones as catalytic core
of SMRT/NCoR (silencing mediator of retinoid and thyroid hormone receptors/nuclear
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receptor co-repressor) (You et al., 2013), while HDAC8 also deacetylates histones, but
seems to be active without incorporation into a protein complex (Wolfson et al., 2013).
2.2.2 Deacetylase inhibitors
Classical HDACs (class I, II and IV) have a similar catalytic core and contain a catalytic
divalent metal ion like Zn2+ in their active center (Arrowsmith et al., 2012; Nechay
et al., 2016). Deacetylase inhibitors occupy the acetyl-lysine channel of the active site
and can be classified based on the metal ion binding group into hydroxamic acids (e.g.
trichostatin A (TSA), suberoylanilide hydroxamic acid (SAHA)), benzamides (e.g. MS-
275, MGCD0103), carboxylic acids (e.g. valproic acid and butyrate), and cyclic peptides
(e.g. apicidin). Due to their di↵erent catalytic mechanism, which depends on NAD+ as
cofactor, sirtuins are not inhibited by the same inhibitors as the classical deacetylases
(Tanner et al., 2000; Mai et al., 2005; Arrowsmith et al., 2012).
Several deacetylase inhibitors are currently undergoing clinical trials and four deacety-
lase inhibitors (SAHA, Romidepsin, Belinostat and Panbinostat) have been approved by
the United States Food and Drug Administration for the treatment of certain hema-
tologic cancers (Grant et al., 2007; Laubach et al., 2015; Lee et al., 2015; Foss et al.,
2016; Yoon & Eom, 2016). Deacetylase inhibitors a↵ect cancer at several di↵erent levels
(Bolden et al., 2006). They induce cell death of cancer cells through various pathways
(Ruefli et al., 2001; Ungerstedt et al., 2005; Gaymes et al., 2006), and lead to cell cycle
arrest and senescence (Peart et al., 2005; Xu et al., 2005; Romanov et al., 2010). In
addition, deacetylase inhibitors impair tumor angiogenesis as well as cancer cell migra-
tion and invasion (Kim et al., 2001; Jeon & Lee, 2010; Han et al., 2014; Hakami et al.,
2016). In contrast to cancer cells, normal cells are relatively weakly a↵ected by deacety-
lase inhibitor-mediated cell death, which contributes to the big interest in deacetylase
inhibitors for therapeutic intervention in malignant neoplastic diseases (Burgess et al.,
2004; Ungerstedt et al., 2005; Bolden et al., 2006; Gaymes et al., 2006).
2.3 The JAK/STAT signaling pathway
Signaling pathways allow cells to communicate and to react to external stimuli. Signals
are transmitted via membrane bound receptor into the cell and further into the nucleus
where the gene expression profile is changed in response to the respective signal. Of special
importance and conserved from slime molds and insects to mammals is the JAK/STAT
signaling pathway (Perrimon & Mahowald, 1986; Hou et al., 1996; Yan et al., 1996;
Darnell, 1997; Kawata et al., 1997; Luo & Dearolf, 2001).
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In mammals, the family of Janus kinases (JAK) is constituted by four nonreceptor
tyrosine kinases (JAK1, JAK2, JAK3 and Tyk2). They associate with the cytosolic
domain of class I and class II cytokine receptors, which themselves lack a catalytic kinase
domain. The cytokine receptor undergoes conformational changes upon ligand binding,
which brings the associated JAKs in close proximity and thus enables JAK activation
by trans-autophosphorylation. Subsequently, JAKs phosphorylate tyrosine residues in
the cytoplasmic domain of the receptor, creating docking sites for signal transducers and
activators of transcription (STAT) (Hou et al., 1994; Lin et al., 1995).
There are seven known STATs in mammalian cells: STAT1, STAT2, STAT3, STAT4,
STAT5A, STAT5B and STAT6. In the unstimulated cell, they reside as latent transcrip-
tion factors in the cytoplasm. Following binding to the phosphorylated receptor, STATs
themselves are phosphorylated by the JAK kinases at a highly conserved tyrosine residue
in the C-terminal domain. This phosphorylation activates STAT proteins. It provides the
prerequisite for STAT homo- or heterodimerization, nuclear translocation, DNA binding
and induction of target genes (Grimley et al., 1999; Haan et al., 2006; Schindler & Plum-
lee, 2008). STAT heterodimers have been described between STAT1 and STAT2, STAT1
and STAT3, as well as between STAT5A and STAT5B (Ghislain et al., 2001; Ginter et al.,
2012; Boehm et al., 2014).
2.3.1 Activation of STAT5 by interleukin-3
STAT5, originally named mammary gland-specific nuclear factor (MGF) (Schmitt-Ney
et al., 1992) is an essential mediator of many di↵erent cytokines, growth factors or hor-
mones like interleukin(IL)-2, IL-3, IL-5, granulocyte-macrophage colony-stimulating fac-
tor (GM-CSF), growth hormone, erythropoietin and prolactin. Proliferation and sur-
vival of the murine pro-B cell line Ba/F3, the model system of this work, depends on
interleukin-3 (IL-3) and the subsequent activation of STAT5 (Rodriguez-Tarduchy et al.,
1990; Mui et al., 1995; Nelson et al., 2004).
The IL-3 receptor consists of the IL-3-specific receptor ↵-chain and the common
 -chain (shared by IL-3, IL-5 and GM-CSF). As class I cytokine receptor, the IL-3
receptor does not have intrinsic tyrosine kinase activity, which is instead provided by
the associated cytoplasmic tyrosine kinase JAK2. JAK2 is the predominant  -chain-
activating kinase and the most common JAK kinase involved in the activation of STAT5
by class I cytokines (Grimley et al., 1999; Martinez-Moczygemba & Huston, 2003).
Besides activating the STAT pathway, signaling through the common  -chain receptor
also activates the mitogen-activated protein kinase (MAPK) and phosphatidylinositol
3-kinase/AKT signaling pathways (Dijkers et al., 1999). Downstream of the MAPK
pathway, IL-3-inducible genes such as c-Fos and JunB are activated (Hodge et al., 1998;
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Rascle et al., 2003).
2.3.2 Structure of STAT5
Like all STAT proteins, STAT5 has a modular structure of seven conserved protein do-
mains (Fig. 4.9): N-terminal domain, coiled-coil domain, DNA binding domain, linker-
domain, Src-homology-2 domain (SH-2), phosphotyrosine tail segment and transactiva-
tion domain (Grimley et al., 1999). Structural and functional information of STATs is
derived mainly from crystallographic data on STAT1, STAT3 and STAT4 (Becker et al.,
1998; Chen et al., 1998; Vinkemeier et al., 1998) as well as mutagenic and biochemical
studies (Moriggl et al., 1996).
The N-terminal domain is an independently folded structure, which is involved in
nuclear export (Shin & Reich, 2013) and STAT tetramerization. Tetramerization is me-
diated through N-terminal interactions between STAT dimers and thus promotes coop-
erativity upon binding to tandem response elements, for instance during the STAT5-
dependent regulation of Cis or the IL-2 receptor ↵ gene (Xu et al., 1996; Matsumoto
et al., 1997; Verdier et al., 1998; Vinkemeier et al., 1998; John et al., 1999; Soldaini et al.,
2000; Lin et al., 2012).
The SH-2 domain, a phosphotyrosine binding domain, is the most conserved domain
among the members of the STAT family. It is essential for STAT recruitment to the
phosphorylated receptor and for subsequent formation of the transcriptionally active
STAT dimer. STAT dimerization occurs through reciprocal interactions between the
SH-2 domain of one monomer and the phosphotyrosine of the other monomer (Grimley
et al., 1999).
The short phosphotyrosine tail segment between SH-2 and transactivation domain
contains the conserved tyrosine (Y694 of STAT5A and Y699 of STAT5B) whose phos-
phorylation is required for STAT dimerization (Grimley et al., 1999).
The transactivation domain, located at the C-terminus, is the most divergent domain
between the members of the STAT family in general and between STAT5A and B in
particular (Grimley et al., 1999; Lim & Cao, 2006). It is required and su cient for induc-
tion of gene expression. C-terminally truncated STAT5 isoforms are dominant-negative
transcriptional regulators (Moriggl et al., 1996; Meyer et al., 1998; Epling-Burnette et al.,
2002), and GAL-4 fusion proteins containing only the C-terminal transactivation domain
of STAT5A can activate reporter genes in GAL-4 luciferase reporter assays (Moriggl et al.,
1996).
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2.3.3 Function of STAT5A and STAT5B
Duplication of the STAT progenitor gene, giving rise to the homologous Stat5a and Stat5b
genes, seems to be the most recent event in the evolution of STATs (Barillas-Mury et al.,
1999). Human STAT5A and B proteins share a sequence similarity of 95% (Grimley
et al., 1999).
STAT5A and B are important regulators of cell proliferation, di↵erentiation and apop-
tosis (Grimley et al., 1999; Nosaka et al., 1999) and are relevant for liver metabolism (Udy
et al., 1997), mammary gland development (Liu et al., 1997), immunoregulation (Snow
et al., 2003) and hematopoiesis (Moriggl et al., 1999; Shelburne et al., 2003; Li et al.,
2007). STAT5A and B have many overlapping, but also independent functions (Schindler
& Plumlee, 2008). The most striking di↵erence is the predominant role of STAT5A for
prolactin signaling during mammary gland development and lactation (Liu et al., 1997;
Metser et al., 2015), while STAT5B plays a key role in the development of T cells and
growth hormone-dependent regulation of body growth (Udy et al., 1997; Chia et al.,
2006; Nadeau et al., 2011; Villarino et al., 2016). In addition, it becomes increasingly
appreciated that STAT5A and B exert distinct roles during carcinogenesis (Leong et al.,
2002; Ren et al., 2002; Kazansky et al., 2003; Tang et al., 2010).
2.3.4 Transcriptional regulation by STAT5
Functional DNA recognition sites for STAT5 are usually located within the promoter
of regulated genes like Cis, Osm and Spi2.1, but can also be found within introns or
distal enhancers, as the case for Id-1 and c-Myc (Basham et al., 2008; Pinz et al., 2016).
Consistently, genome-wide analysis of STAT5 distribution using ChIP-sequencing showed
a clustering of STAT5 binding around transcription start sites, and STAT5 binding was
also detected at distal loci (Nelson et al., 2004; Villarino et al., 2016).
STAT5A and STAT5B recognize the same consensus DNA binding sequence (TTC-
NNNGAA) (Soldaini et al., 2000; Ehret et al., 2001), but subtle DNA sequence variations
can favor one STAT5 over the other (Frasor et al., 2001). In addition to their di↵er-
ent specificity regarding the DNA binding sequence, the STAT5A and STAT5B homo-
and heterodimers also have di↵erent specificity regarding the presence of dimeric versus
tetrameric STAT5 binding sites (Boucheron et al., 1998; Verdier et al., 1998; Soldaini
et al., 2000). Accordingly, our group and others (Nelson et al., 2004; Basham et al., 2008;
Kanai et al., 2014) demonstrated that STAT5A and STAT5B di↵erentially contribute
to the regulation of di↵erent STAT5 target genes. While some genes show redundant
regulation by STAT5A and STAT5B, other genes require the presence of both STAT5
paralogs or show a preference for STAT5A or STAT5B (Nelson et al., 2004; Basham et al.,
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2008; Kanai et al., 2014). Cell type-specific protein levels of STAT5A and STAT5B shift
the balance between the di↵erent STAT5 dimers and thus influence STAT5 target gene
expression (Metser et al., 2015; Villarino et al., 2016). The carboxy-terminal transactiva-
tion domain of STAT5 is the most divergent domain between STAT5A and STAT5B and
might contribute to di↵erences in gene regulation (Grimley et al., 1999), possibly through
di↵erent interactions with regulatory proteins. However, no paralog-specific cofactor has
been described so far.
During regulation of transcription, STAT5 proteins interact or cooperate with other
transcription factors (Mukhopadhyay et al., 2001; Wyszomierski & Rosen, 2001; Magne´
et al., 2003), nuclear receptors (Engblom et al., 2007), transcriptional co-activators or
-repressors (Pfitzner et al., 1998; Nakajima et al., 2001) as well as chromatin modifiers
and remodelers (Xu et al., 2007; Mandal et al., 2011). For instance, during the well-
studied induction of the STAT5 target gene  -casein during mammary epithelial di↵er-
entiation, STAT5 cooperates with the transcription factor c-EBP  and interacts with the
nuclear glucocorticoid receptor (GR), the chromatin remodeling complex SWI/SNF, as
well as the coactivators p300/CBP and NCoA-1 (Pfitzner et al., 1998; Wyszomierski &
Rosen, 2001; Litterst et al., 2003; Xu et al., 2007). Consistent with the current model of
transcriptional regulation (Venters & Pugh, 2009), STAT5 is a core element of promoter-
specific multifunctional protein complexes which induce gene expression (Villarino et al.,
2015).
It has been shown that a deacetylase activity is required for transcriptional activation
by STAT5 (Rascle et al., 2003; Sebastia´n et al., 2008). Within a treatment of up to 2 h,
the deacetylase inhibitor trichostatin A (TSA) reduced expression of all normally induced
STAT5 target genes in IL-3-stimulated Ba/F3 cells, while only few non-target genes were
inhibited (Rascle et al., 2003). Deacetylase inhibitor treatment leaves STAT5 phospho-
rylation, nuclear translocation and DNA binding una↵ected. Instead, it inhibits STAT5
target gene expression by impairing the recruitment of the transcription machinery to
the transcription start site of STAT5 target genes. Interestingly, further experiments
indicated that the HDAC inhibitor TSA does not increase histone H3 and H4 acetyla-
tion levels around the promoter of the STAT5 target gene Cis and Osm (Rascle & Lees,
2003; Rascle et al., 2003), nor does it a↵ect chromatin remodeling at the Cis promoter
(Rascle et al., 2003). These findings suggested that the observed inhibition of STAT5
target gene expression by deacetylase inhibitors is not mediated through chromatin and
hyperacetylated histones, but rather through an acetylated non-histone protein.
Despite a predominant role in transcriptional activation, STAT5 can also repress tran-
scription. Alternative splicing or proteolytic cleavage can lead to loss of the C-terminal
transactivation domain of STAT5, producing dominant negative STAT5 isoforms (Moriggl
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et al., 1996; Meyer et al., 1998; Epling-Burnette et al., 2002). Furthermore, in pro-B cells,
STAT5 tetramers recruit the histone methyltransferase EZH2 to guide H3K27me3 modifi-
cations to the Igk locus (encoding the immunoglobulin -chain complex) and thus repress
transcription of this locus (Mandal et al., 2011). Based on genome-wide ChIP-sequencing
data, it was further proposed that for many genes recruitment of STAT5 to tetrameric
binding sites correlates with H3K27 trimethylated histones and gene repression (Mandal
et al., 2011). By contrast, another report demonstrated that in T cells STAT5 tetramers
preferentially mediate transcriptional activation (Lin et al., 2012). Thus, the functional
role of STAT5 tetramers has not yet been clarified. Interaction of STAT5 with the nuclear
receptor co-repressor SMRT has been reported, but the function of SMRT seems to be sig-
nal attenuation and downregulation of STAT5 activity, rather than active transcriptional
gene repression (Nakajima et al., 2001).
2.3.5 Regulation of STAT5 activity
Tight control of STAT5 activity is essential to ensure an appropriate signal intensity
and duration. In a normal cell, rapid STAT5 phosphorylation, nuclear accumulation and
induction of target gene expression is followed by gradual signal decay involving consti-
tutively expressed regulators such as phosphatases and PIAS, as well as the inducible
members of the suppressors of cytokine signaling (SOCS) protein family. STAT5 signal-
ing is furthermore attenuated by degradation of nuclear STAT5 via ubiquitin-proteasome
pathway (Chen et al., 2006) and by receptor down-regulation (Martinez-Moczygemba
et al., 2007).
Phosphatases from three di↵erent families have been implicated in negatively regu-
lating the JAK/STAT pathway. First, there are the mainly cytoplasmic Src homology
phosphatases SHP-1 and SHP-2, which can directly dephosphorylate STAT5 or act on
the tyrosine phosphorylated JAK and receptor (Yi et al., 1993; Klingmu¨ller et al., 1995;
Paling & Welham, 2002; Chen et al., 2004). Second, phosphotyrosine phosphatase 1B
(PTP1B), T cell protein tyrosine phosphatase (TC-PTP) and the nuclear splice variant
TCP45 dephosphorylate and thus inactivate JAK kinases (Myers et al., 2001; Simon-
cic et al., 2002; Johnson et al., 2010) or STATs (ten Hoeve et al., 2002; Kra¨mer et al.,
2009). Third, the transmembrane phosphotyrosine phosphatase CD45 dephosphorylates
and inactivates JAKs (Irie-Sasaki et al., 2001).
Protein inhibitor of activated STAT 3 (PIAS3) interacts with STAT5 and represses its
transcriptional activity probably through interference with STAT5 DNA binding ability
(Rycyzyn & Clevenger, 2002).
Among the eight SOCS family members, cytokine-induced SH2-domain-containing
protein (CIS), SOCS1, SOCS2 and SOCS3 were shown to be direct STAT5 target genes
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and negative feedback regulators involved in the attenuation of STAT5 signaling (Mat-
sumoto et al., 1997; Tam et al., 2001; Vidal et al., 2007; Basham et al., 2008; Bachmann
et al., 2011; Vitali et al., 2015). They compete with STAT5 for binding sites at the re-
ceptor, or inhibit the kinase activity of JAKs (Endo et al., 1997; Matsumoto et al., 1997;
Ram & Waxman, 1999; Sasaki et al., 1999).
2.3.6 Post-translational modifications of STAT proteins
Phosphorylation of a highly conserved tyrosine residue within the phosphotyrosine tail
segment is required for the formation of transcriptionally active STAT dimers (Grimley
et al., 1999). In addition, serine phosphorylation within the transactivation domain has
been shown to influence the activity of several STAT proteins (Decker & Kovarik, 2000).
Serine phosphorylation of STAT5 has been demonstrated, but its biological significance
remains to be clarified (Yamashita et al., 1998; Beuvink et al., 2000; Xue et al., 2002;
Berger et al., 2013).
SUMOylation has been demonstrated to negatively regulate the activity of STAT1
and STAT5 (Ungureanu et al., 2005; Gro¨nholm et al., 2012; Van Nguyen et al., 2012).
The proposed SUMOylated lysine K696 of STAT5A (K701 of STAT5B) is also a target
for acetylation (Ma et al., 2010; Van Nguyen et al., 2012).
2.3.6.1 STAT acetylation
The last decade has established acetylation as an important post-translational modifica-
tion for the regulation of STAT proteins. STAT proteins were shown to be acetylated
at one or multiple lysine residues in di↵erent domains (Wieczorek et al., 2012). The
functional characterization of acetylation sites is usually undertaken by site-directed mu-
tagenesis of candidate lysine residues. Mutation to arginine prevents acetylation through
its mesomerically stabilized guanidino group. At the same time arginine retains a positive
charge like the unmodified lysine residue. Mutation to the neutral amino acid glutamine
mimics lysine acetylation, especially the loss of the positive charge. Furthermore, glu-
tamine and acetylated lysine both contain an amide group in their side-chain (Li et al.,
2002; Wang & Hayes, 2008; Kra¨mer et al., 2009; Kra¨mer & Heinzel, 2010). There are
numerous examples where mutations to arginine or glutamine were successfully used to
mimick deacetylated or acetylated lysine residues (Li et al., 2002; Wang & Hayes, 2008;
Kra¨mer et al., 2009). For instance, a STAT1 mutant carrying lysine to arginine muta-
tions at lysine residues K410 and K413 behaves similarly as the unmodified wild-type
STAT1 protein, while a STAT1 mutant carrying lysine to glutamine mutations at the
same residues behaves similarly as the acetylated wildtype protein (Kra¨mer et al., 2006,
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2009).
Acetylation can a↵ect di↵erent steps of the activation of STATs like STAT protein
interactions, phosphorylation, dimerization, or transcriptional activity (Wieczorek et al.,
2012). An additional level of regulation is added by the interplay of STAT acetylation
with other STAT post-translational modifications like phosphorylation or SUMOylation
(Kra¨mer et al., 2009; Van Nguyen et al., 2012). The functional consequence of STAT
acetylation is specific for each STAT family member (Ray et al., 2005; Yuan, 2005; Tang
et al., 2007; Kra¨mer et al., 2009; Nie et al., 2009; Ma et al., 2010; Ginter et al., 2012;
Van Nguyen et al., 2012; Wieczorek et al., 2012). Furthermore, several controversial
reports exist regarding specific STAT acetylation sites and their functional role (Nusinzon
& Horvath, 2003; Klampfer et al., 2004; Ray et al., 2005; Yuan, 2005; Catania et al., 2006;
Kra¨mer et al., 2009; Nie et al., 2009; Gupta et al., 2012; Wieczorek et al., 2012; Kosan
et al., 2013). This is probably a consequence of the complexity of STAT acetylation,
which might be influenced by experimental conditions such as the activating cytokine
(Ginter et al., 2012), the investigated cell-type (Nakajima et al., 2001; Rascle et al.,
2003; Kosan et al., 2013) or treatment duration with deacetylase inhibitors (Nusinzon &
Horvath, 2003; Klampfer et al., 2004; Sakamoto et al., 2004; Ginter et al., 2012).
Acetylation of STAT1 and STAT2
Acetylation of STAT1 within its DNA binding domain at K410 and K413 counteracts
STAT1 phosphorylation and transcriptional activity. Acetylation supports the interaction
of STAT1 with the T cell tyrosine phosphatase (TCP45) which correlates with STAT1
dephosphorylation and thus inactivation (Kra¨mer et al., 2009; Ginter et al., 2012). While
the finding of these studies that deacetylase inhibition of STAT1 acetylation impairs
STAT1 phosphorylation is consistent with data from Klampfer et al. (2004), others use
shorter deacetylase inhibitor treatments and report that deacetylase inhibition does not
a↵ect STAT1 phosphorylation (Nusinzon & Horvath, 2003; Chang et al., 2004; Sakamoto
et al., 2004). Nevertheless, all cited reports are consistent in that deacetylase inhibitor
treatment blocks interferon-induced transcriptional activity of STAT1.
Several acetylation sites of STAT2 were identified by mass spectrometry upon over-
expression of STAT2 and the HATs CBP or p300 (Tang et al., 2007). Furthermore,
it was shown that acetylation at K390 of STAT2 modulates the interaction between
STAT2 and STAT1 and is required for the formation of transcriptionally active inter-
feron stimulated gene factor 3 complex (ISGF3 consisting of STAT1, STAT2 and IRF9)
upon interferon-↵ signaling (Tang et al., 2007).
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Acetylation of STAT3
STAT3 was shown to be acetylated at K685 but not at nearby lysine residues, and this
acetylation positively a↵ects its transcriptional activity (Wang et al., 2005; Yuan, 2005).
Mutation of K685 to arginine, leading to acetylation-deficient STAT3, does not a↵ect
STAT3 phosphorylation, but impairs its dimerization, DNA binding, and consequently
its transcriptional activity (Yuan, 2005). By contrast, Nie et al. (2009) found by mass
spectrometry that K679, K707 and K709 of STAT3 can also be acetylated. Mutation of
all those lysine residues together with K685 to arginine reduced STAT3 phosphorylation
much more than single or double mutations, suggesting that acetylation of all four lysine
residues is functionally required for STAT3 phosphorylation and activity (Nie et al., 2009).
In parallel it was found that K49 and K87 are acetylated, but that mutation of K49
and K87 to arginine does not a↵ect STAT3 phosphorylation (Nie et al., 2009). Others
investigated K49 and K87 in more details and found that besides slightly diminishing
STAT3 phosphorylation, mutation of these lysines does not a↵ect STAT3 dimerization
or DNA binding, but abrogates the IL-6-induced transcriptional activity of STAT3 at its
target gene hAGT (Ray et al., 2005). Ray and coworkers suggested that acetylation is
required for stable interaction of STAT3 with p300 and subsequent recruitment of RNA
polymerase II and transcription induction (Ray et al., 2005; Hou et al., 2008).
All of the above mentioned studies on STAT3 are consistent in that deacetylase in-
hibitors and thus increased acetylation positively a↵ect STAT3 activity. By contrast,
Catania et al. (2006) found that deacetylase inhibitors interfere with PDGF-induced
transcriptional activity of STAT3, while phosphorylation, nuclear translocation and DNA
binding remained intact, and Gupta et al. (2012) found that in di↵use large B cell lym-
phoma deacetylase inhibitors lead to increased K685 acetylation and attenuate STAT3
tyrosine phosphorylation and transcriptional activity. Altogether the reports are contro-
versial regarding which STAT3 lysine residue is acetylated and regarding the consequence
of STAT3 acetylation on its transcriptional activity.
Acetylation of STAT5
STAT5B acetylation at K359, K694 and K701 (corresponding to K359, K689 and K696
of STAT5A) was demonstrated by Ma et al. (2010) through mass spectrometry and
acetylation-site-specific antibodies. Mutation of K359, K694, and to a lesser extent K701
to arginine reduced prolactin-induced STAT5 activity in a luciferase reporter assay. Mu-
tation of K694 or K701 (both localized within the phosphotyrosine tail segment near the
SH-2 domain) was further demonstrated to impair dimerization of STAT5B, thus giving
a possible explanation for the diminished STAT5 downstream activity (Ma et al., 2010).
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By contrast, mutation of K359, which is located within the DNA binding domain, had
a minimal positive e↵ect on STAT5 dimerization but nevertheless abrogated the abil-
ity of STAT5 to induce a luciferase reporter gene. STAT5A acetylation at K696 and
the negative e↵ect of K696 arginine mutation on STAT5A transcriptional activity was
independently demonstrated elsewhere in a luciferase reporter assay in growth hormone-
stimulated mouse embryonic fibroblasts (Van Nguyen et al., 2012). K696 acetylation
of STAT5A after deacetylase inhibitor treatment was additionally confirmed in a global
quantitative mass spectrometric approach (Choudhary et al., 2009).
While Ma et al. (2010) and Van Nguyen et al. (2012) concluded that acetylation has
a positive e↵ect on STAT5 activity, Sebastia´n et al. (2008) and our group (Rascle et al.,
2003) found in GM-CSF-dependent macrophages and in the IL-3-dependent pro-B cell
line Ba/F3 respectively that deacetylase inhibitors block STAT5 transcriptional activity.
Both groups consistently reported that deacetylase inhibitor treatment inhibits expression
of STAT5 target genes by preventing the recruitment of RNA polymerase II. Upstream
STAT5 activating events, however, remain una↵ected, including STAT5 phosphorylation,
nuclear translocation and binding to DNA target sites. Similar findings have been re-
ported for STAT1, STAT2 and STAT3 after deacetylase inhibitor treatment (Nusinzon
& Horvath, 2003; Sakamoto et al., 2004; Catania et al., 2006).
2.3.7 STAT5 in cancer
Aberrant continuous activity of STAT5 can be found in many hematologic malignancies
and in solid tumor cancers like breast cancer, prostate cancer, squamous cell carcinoma
of the head and neck, hepatocellular carcinoma and melanoma (Koppikar et al., 2008;
Ferbeyre & Moriggl, 2011). Activating mutations within STAT5 have been described
(Rajala et al., 2013; Kontro et al., 2014), however, it is much more common that STAT5
is activated downstream of constitutively active oncogenic tyrosine kinases like BCR-
ABL or JAK2(V617F) (Gesbert & Gri n, 2000; Funakoshi-Tago et al., 2010; Hoelbl
et al., 2010; Walz et al., 2012). In other cancers, STAT5 is activated by autocrine or
paracrine cytokine loops (Li et al., 2004; Bernichtein et al., 2010). In addition, SOCS
proteins, transcriptional negative feedback regulators of the JAK/STAT pathway, are
often downregulated in cancers (Galm et al., 2003; Tokita et al., 2007; Zhang et al., 2015;
Kang et al., 2016). Persistent STAT5 activation directly contributes to cancer initiation
and progression (Hoelbl et al., 2010; Ferbeyre & Moriggl, 2011; Walz et al., 2012; Weber
et al., 2015), most likely through the influence of STAT5 on key genes regulating cell
proliferation and survival such as cyclin D1, Bcl-x, c-Myc and Pim-1 (Mui et al., 1996;
Matsumura et al., 1999; Nosaka et al., 1999; Gesbert & Gri n, 2000; Kontro et al., 2014;
Pinz et al., 2016).
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Several inhibitors of the STAT pathway are approved or currently under clinical trial,
most of them targeting the upstream kinase (Savage & Antman, 2002; O’Shea et al.,
2015). Additional inhibitors repressing STAT5 function at the transcriptional level have
been described, including the natural compound sulforaphane, the bromodomain inhibitor
(+)-JQ1, or deacetylase inhibitors (Rascle et al., 2003; Liu et al., 2014; Pinz et al., 2014b).
The synthetic chalcones ↵-Br-TMC and ↵-CF3-TMC inhibit IL-3-induced JAK2 and
STAT5 phosphorylation (Pinz et al., 2014a; Jobst et al., 2016). Although there is progress
in the development of compounds which inhibit STAT5 function by directly binding to
STAT5, targeting transcription factors like STAT5 remains di cult (Weber et al., 2013;
Elumalai et al., 2015; Liao et al., 2015). Transcription factors exert most of their functions
through protein-protein and protein-DNA interactions and accordingly lack well-defined
hydrophobic binding pockets which typically serve as target for conventional membrane-
permeable small molecules (Arkin & Wells, 2004; Buchwald, 2010; Liao et al., 2015).
The identification of better druggable cofactors thus contains major potential for the
development of specific therapies against STAT5-associated diseases.
2.4 Objectives
Deacetylase inhibitors inhibit STAT5-mediated transcription by impairing the recruit-
ment of the transcription machinery to STAT5 target genes, while STAT5 binding to
DNA remains una↵ected (Rascle et al., 2003). However, the factors involved and their
role in the inhibition of STAT5-mediated transcription remain unknown. The goal of
this thesis was to characterize the molecular mechanism of inhibition of STAT5-mediated
transcription by deacetylase inhibitors. Specific aims were to identify and characterize
(i) the HDAC(s) involved and (ii) its/their acetylated substrate(s).
To identify the deacetylase(s) involved in STAT5-mediated transcription, the e↵ect of
selective deacetylase inhibitors on expression of STAT5 target genes was analyzed. This
should allow the identification of possible candidates among the 11 known HDAC family
members. To further identify HDAC candidates, the e↵ect of siRNA-mediated knockdown
of HDAC expression on the regulation of STAT5 target genes was investigated.
The acetylated substrate targeted for deacetylation might be STAT5 itself, a STAT5-
specific cofactor or histone proteins. To assess a possible implication of STAT5 acetyla-
tion, several potential acetylation sites within STAT5 were mutated and the transcrip-
tional activity of the generated mutants was analyzed either using luciferase reporter as-
says or by RT-qPCR of endogenous STAT5 target genes. Persistent acetylation of STAT5
or of an unknown STAT5-specific cofactor upon deacetylase inhibitor treatment might
disrupt protein interactions between STAT5 and components of the transcriptional ma-
18
CHAPTER 2. INTRODUCTION
chinery. To analyze whether deacetylase inhibitor treatment might disrupt STAT5- and
RNA polymerase II-containing protein complexes and to obtain clues towards the possi-
ble involvement of an acetylated STAT5-specific cofactor, gel filtration chromatography
was performed, comparing the composition of untreated and deacetylase-inhibitor-treated
nuclear complexes. To investigate whether histones might be the acetylated substrate,
the e↵ect of deacetylase inhibitors on histone acetylation was assessed globally by western
blot and locally at STAT5 target and control genes by chromatin immunoprecipitation.
Together, this study will contribute to a better understanding of the mechanism of
STAT5-mediated transcription and of its inhibition by deacetylase inhibitors. Ultimately,
it should provide the molecular basis for the development of novel therapies against
STAT5-associated cancers.
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Material and methods
3.1 Material
3.1.1 Chemicals and reagents
Standard chemicals not mentioned in the following list were purchased from Sigma-
Aldrich, Merck, or AppliChem.
Chemical/Reagent Manufacturer
 -Mercaptoethanol (14,3 M) Sigma-Aldrich
Acrylamid/Bisacrylamid Rotiphorese Gel 30 Roth
Agarose, LE Biozym
Ammonium persulfate (APS) Sigma-Aldrich
Ampicillin sodium salt Sigma-Aldrich
Bovine serum albumin (BSA) Sigma-Aldrich
Bromphenolblue Merck
Coomassie Brilliant Blue R-250 AppliChem
Dimethyl sulfoxide (DMSO) Sigma-Aldrich
Dithiothreitol (DTT) Sigma-Aldrich
DMEM Gibco, Life Sciences
DNA ladder, 100 bp and 1 kb ladder New England Biolabs
Doxycycline Sigma-Aldrich
Dry skimmed milk Sucofin
Ethidum bromide Promega
Fetal calf serum (FCS) PAN Biotech and Life Technology
G418 disulfate salt Sigma-Aldrich
Gene Pulser Electroporation bu↵er Bio-Rad
Glycogen A metrix
Hygromycin B PAN Biotech
Insulin Sigma-Aldrich
Kanamycin sulfate Gibco, Life Technology
LB-agar (Luria/Miller) Roth
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Chemical/Reagent Manufacturer
LB-medium (Luria/Miller) Roth
Lipofectamine 2000 Invitrogen
N,N,N,N-Tetramethylethylenediamine (TEMED) Sigma-Aldrich
Penicillin-Streptomycin solution (100x) Invitrogen
Phenol/chlorophorm/isoamyl alcohol (25/24/1) Roth
Phenylmethylsulfonylfluoride (PMSF) Sigma-Aldrich
PicTIXX Pluster & LinerPen C. Kreuel
Ponceau S Sigma-Aldrich
Protein Marker VI (10-245) prestained AppliChem
Protein-A sepharose beads GE Healthcare
recombinant murine Interleukin-3 (rmIL-3) ImmunoTools
Roti-Quant, 5x Bradford reagent Roth
ROX passive reference dye, 50x Bio-Rad
RPMI 1640 PAN Biotech
Salmon Sperm DNA Invitrogen
Sodium fluoride Sigma-Aldrich
Sodium orthovanadate Sigma-Aldrich
Trypsin/EDTA PAN Biotech
Tween-20 AppliChem
WST-1 cell proliferation reagent Roche
3.1.2 Bu↵ers
All bu↵ers were prepared with ultrapure water purified with Milli-Q-Synthesis Water
Purification System (Millipore).
Table 3.1: Bu↵ers
Bu↵er Composition
150 mM NaCl wash bu↵er 20 mM Tris pH 8.0, 150 mM NaCl, 5 mM EDTA, 0.2% w/v
SDS, 1% w/v Triton X-100, 10 µg/mL aprotinin, 10 µg/mL
leupeptin, 0.5 mM PMSF, 10 mM NaF
500 mM NaCl wash bu↵er 20 mM Tris pH 8.0, 500 mM NaCl, 5 mM EDTA, 0.2% w/v
SDS, 1% w/v Triton X-100, 10 µg/mL aprotinin, 10 µg/mL
leupeptin, 0.5 mM PMSF, 10 mM NaF
Brij lysis bu↵er 10 mM Tris/HCl pH 7.5, 150 mM NaCl, 2 mM EDTA pH 8.0,
0.875% v/v Brij 97, 0.125% v/v NP40, 10 µg/mL aprotinin,
10 µg/mL leupeptin, 0.5 mM PMSF, 10 mM NaF, 1 mM
Na3VO4
bu↵er A 10 mM Hepes pH 7.6, 15 mM KCl, 2 mM MgCl2, 0.1 mM
EDTA, 10 µg/mL aprotinin, 10 µg/mL leupeptin, 0.5 mM
PMSF, 10 mM NaF, 1 mM Na3VO4
bu↵er B nuclei prep bu↵er A, 0.1-0.2% NP40
bu↵er C 50 mM Hepes pH 7.9, 400 mM KCl, 0.1 mM EDTA, 10%
glycerol, 10 µg/mL aprotinin, 10 µg/mL leupeptin, 0.5 mM
PMSF, 10 mM NaF, 1 mM Na3VO4
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Bu↵er Composition
bu↵er CBB 100 mM Tris pH 9.4, 100 mM DTT, 10 µg/mL aprotinin,
10 µg/mL leupeptin, 0.5 mM PMSF, 10 mM NaF
bu↵er MA 10 mM Hepes pH 6.5, 10 mM EDTA, 0.25% Triton X-100,
10 µg/mL aprotinin, 10 µg/mL leupeptin, 0.5 mM PMSF,
10 mM NaF
bu↵er MB 10 mM Hepes pH 6.5, 1 mM EDTA, 200 mM NaCl, 10 µg/mL
aprotinin, 10 µg/mL leupeptin, 0.5 mM PMSF, 10 mM NaF
Coomassie Blue staining
solution
0.25% w/v Coomassie Brilliant Blue R-250, 45% v/v methanol,
10% v/v acetic acid
DMEM-based medium DMEM supplemented with 10% v/v heat inactivated fetal calf
serum, 1x penicillin/streptomycin and 2 mM glutamine
DNA loading dye, 10x 50 mM Tris/HCl pH 7.6, 60% glycerol, bromphenol blue, xylene
cyanol
FT bu↵er 600 mM NaCl, 20 mM Tris/HCl pH 8.0, 20% v/v glycerol,
10 µg/mL aprotinin, 10 µg/mL leupeptin, 0.5 mM PMSF
GF bu↵er 25 mM Hepes pH 7.2, 0.1 M KCl, 0.1 mM EDTA, 5% v/v
glycerol, 1 mM DTT, 100 µg/mL insulin, 2 mM
benzamidine-HCl, 1 mM PMSF
HDG 150 20 mM Hepes pH 7.6, 150 mM KCl, 10% v/v glycerol, 0.5 mM
DTT, 10 µg/mL aprotinin, 10 µg/mL leupeptin, 0.5 mM PMSF,
10 mM NaF
IP bu↵er 1/3 Triton dilution bu↵er, 2/3 SDS bu↵er
La¨mmli loading dye, 4x 250 mM Tris/HCl pH 6.8, 40% v/v glycerol, 5% w/v SDS,
0.005% w/v bromphenol blue, 10% v/v  -mercaptoethanol
La¨mmli SDS running bu↵er, 5x 125 mM Tris, 960 mM glycine, 0.5% w/v SDS
LB agar plates LB-agar (Luria/Miller) from Roth: 10 g/L tryptone, 5 g/L yeast
extract, 10 g/L NaCl, 15 g/L agar
LB medium LB-medium (Luria/Miller) from Roth: 10 g/L tryptone, 5 g/L
yeast extract, 10 g/L NaCl
LiCl wash bu↵er 10 mM Tris pH 8.0, 250 mM LiCl, 1 mM EDTA, 0.5% v/v
NP-40, 0.5% w/v Deoxycholic acid (sodium salt), 10 µg/mL
aprotinin, 10 µg/mL leupeptin, 0.5 mM PMSF, 10 mM NaF
MNase Reconstitution bu↵er 5 mM Tris pH 6.8, 50 mM NaCl, 50% v/v glycerol
P1 50 mM Tris/HCl pH 8.0, 10 mM EDTA
P2 200 mM NaOH, 1% w/v SDS
P3 3 mM potassiumacetate, pH 5.5
PBS, 10x 1.37 M NaCl, 27 mM KCl, 100 mM Na2HPO4, 18 mM KH2PO4,
adjust to pH 7.4
PBST 1x PBS, 0.02% v/v Tween 20
RPMI-based medium RPMI 1640 supplemented with 10% v/v heat inactivated fetal
calf serum, 1x penicillin/streptomycin and 2 mM glutamine
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Bu↵er Composition
SDS bu↵er 50 mM Tris pH 8.0, 100 mM NaCl, 5 mM EDTA, 0.5% w/v
SDS, 10 µg/mL aprotinin, 10 µg/mL leupeptin, 0.5 mM PMSF,
10 mM NaF
SDS-PAGE separation gel, 10% same as 8% with the following exceptions: 3.3 mL
Acrylamid/Bisacrylamid (30%, 49:1), 2.9 mL H2O
SDS-PAGE separation gel, 15% same as 8% with the following exceptions: 5 mL
Acrylamid/Bisacrylamid (30%, 49:1), 0.6 ml H2O
SDS-PAGE separation gel, 8% 2.7 mL Acrylamid/Bisacrylamid (30%, 49:1), 2.9 mL H2O, 3.75
mL 1 M Tris-HCl pH 8.8, 574 µL 85% glycerol, 100 µL 10% w/v
SDS, 50 µL 10% w/v APS, 10 µL TEMED)
SDS-PAGE stacking gel 1.3 mL Acrylamid/Bisacrylamid (30%, 49:1), 7.3 mL H2O, 1.25
mL 1 M Tris-HCl pH 6.8, 100 µL 10% w/v SDS, 50 µL 10% w/v
APS, 10 µL TEMED
TAE, 50x 2 M Tris, 50 mM EDTA, 1 M acetic acid
TBS, 10x 500 mM Tris, 1.5 M NaCl, adjust to pH 7.5 with HCl
TBST 1x TBS, 0.02% v/v Tween 20
TE 20 mM Tris pH 8.0, 1 mM EDTA
TFBI + glycerol 1xTFBI, 15% v/v glycerol
TFBI, 10x 300 mM potassium acetate, 1 M RbCl, 100 mM CaCl2 x 2 H2O,
500 mM MnCl2 x 4 H2O
TFBII + glycerol 1xTFBII, 15% v/v glycerol
TFBII, 5x 50 mM MOPS, 50 mM RbCl, 370mM CaCl2
Towbin/SDS transfer bu↵er 25 mM Tris, 0.02% w/v SDS, 192 mM glycine, 20% v/v
methanol
Triton dilution bu↵er 100 mM Tris pH 8.0, 100 mM NaCl, 5 mM EDTA, 5% w/v
Triton X-100, 10 µg/mL aprotinin, 10 µg/mL leupeptin, 0.5 mM
PMSF, 10 mM NaF
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3.1.3 Deacetylase inhibitors and other small molecule
compounds for cell treatment
Table 3.2: Deacetylase inhibitors and other small molecule compounds
Compound Supplier Stock C.1 Vehicle2
(+)-JQ1 BIOMOL GmbH (BPS Bioscience #27401) 5 mM DMSO
↵-Br-TMC3 provided by Sabine Amslinger (Al-Rifai et al., 2013) 100 mM DMSO
Apicidin Enzo Life Sciences (BML-GR340) 10 mM DMSO
MGCD0103 Absource Diagnostics GmbH (Selleck S1122) 50 mM DMSO
MS-275 Enzo Life Sciences (ALX-270-378) 25 mM DMSO
Salermide Cayman Chemicals (No. 13178) 500 mM DMSO
trans-Resveratrol Cayman Chemicals (No. 70675) 500 mM DMSO
Trichostatin A (TSA) Sigma-Aldrich (T8552) 1 mM DMSO
Valproic Acid (VPA) Enzo Life Sciences (ALX-550-304) 300 mM H2O
1 The compounds were diluted at the indicated stock concentration (Stock C.) in the vehicle DMSO, or
in the case of VPA in H2O. Final compound concentration is indicated in the figure legends.
2 Vehicle concentration was adjusted to 0.02% DMSO in all TSA experiments. All other vehicle concen-
trations are indicated in the figure legends.
3 ↵-Bromo-2’,3,4,4’-Tetramethoxychalcone
3.1.4 Nucleic acids
3.1.4.1 Nucleotides
Desoxynucleotides from Fermentas were used in thermo-cycling- or PCR-based DNA
synthesis for cloning purposes. Desoxynucleotides for quantitative PCR reactions were
obtained from Qiagen.
3.1.4.2 DNA-oligonucleotides
All DNA-oligonucleotides were purchased from Metabion and reconstituted in
ultrapure water at a concentration of 100 µM. Oligonucleotides for cloning and
sequencing were designed with the NetPrimer software provided by Premier Biosoft
(www.premierbiosoft.com/netprimer/).
Primers for site-directed mutagenesis were designed with the
QuikChange Primer Design Program (Agilent) available at
www.genomics.agilent.com/primerDesignProgram.jsp. In case the program did not find
optimal primers, they were designed manually according to the manual of the
QuikChange II Site-Directed Mutagenesis Kit from Agilent. Quantitative real-time
PCR primers for gene expression analysis and ChIP experiments were designed by
Dr. Anne Rascle using Primer Express software (Applied Biosystems).
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Table 3.3: Mouse gene expression primers for quantitative RT-PCR
Refer to 3.2.1.4
Gene ID Expression primer1, sequence 5’-3’
36b4
O5 forward GCGTCCTGGCATTGTCTGT
O6 reverse GCCGCAAATGCAGATGG
c-Fos
O15 forward CGAAGGGAACGGAATAAGATGG
O16 reverse AGACCTCCAGTCAAATCCAGGG
c-Myc
O11 forward AACAGGAACTATGACCTCG
O12 reverse AGCAGCTCGAATTTCTTC
Cis
O9 forward CTGGACTCTAACTGCTTGTC
O10 reverse TAGGCAGCACCGAGTCAC
Hdac1
O50 forward AACAGAGGATGAGAAAGAGAAAGATC
O51 reverse TCAGGCCAACTTGACCTCTTC
Hdac2
O52 forward AAGAAGACAAGAAGGAGACAGAGG
O53 reverse TCAAGGGTTGCTGAGTTGTTC
Hdac3
O54 forward TCCCGGCAGACCTCCTGACG
O55 reverse TTTCCTTGTCGTTGTCATGGTCGC
Hdac4
O178 forward CACTCCTGCGTCCTGCCTT
O179 reverse CGCCTGCTGTCCCTTTGTAC
Hdac5
O150 forward ACGCCTCCCTCCTACAAATTG
O151 reverse GGAAAGTCATCACGGCTGTCA
Hdac6
O58 forward GGCCAAGATTCTTCTACTAGACAGCG
O59 reverse CTAGATTGGGGCTGGAGTGGG
Hdac7
O60 forward GCCCTGCCCTCCAGCCAGAC
O61 reverse GGTGTTGCAGGGTCAGCAGCG
Hdac8
O62 forward CTGCGACTCCCTTGTGAAGG
O63 reverse GCAGGGCATAGGCTTCGAT
Hdac9
O129 forward AGTTCACCAAACAATGGCCC
O130 reverse TGAAGCCTCATTTTCGGTCAC
Hdac10
O156 forward GCCTGTGTTTGTCAGCTTGTG
O157 reverse GGGCTATATATTCCGGGCTGT
Hdac11
O158 forward GGTGACCTCGGGTGGGTAC
O159 reverse GAGACGCAGGGAAACTCAGG
JunB
O46 forward CAGCTACTTTTCGGGTCAGGG
O47 reverse GGCTAGCTTCAGAGATGCGC
Osm
O13 forward AGATACCTGAGCCCACACAGACAG
O14 reverse ATCGTCCCATTCCCTGAAGACC
S9
O1 forward GCAAGATGAAGCTGGATTAC
O2 reverse GGGATGTTCACCACCTG
Spi2.1
O48 forward GGCAGTGCCCTGTTTATTGAA
O49 reverse GCTGGAAATCTGCTGTGAAGG
Spp1
O64 forward CACTTTCACTCCAATCGTCCC
O65 reverse AAGCCAAGCTATCACCTCGG
1 The amplicon length is 51 - 254 bp.
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Table 3.4: ChIP primers used to quantify mouse genomic DNA from ChIP
Refer to 3.2.7
Amplic.1 Gene Position2 ID ChIP primer3, sequence 5’-3’
A Cis
-831/-755, distal
promoter
O84 for AGGGCTGTCTGGGAGCTGA
O85 rev TCTCTGAGTGGACCGACAGTTG
B Cis
-259/-199, STAT5
binding site
O86 for CAACTCTAGGAGCTCCCGCC
O87 rev AACACCTTTGACAGATTTCCAAGAAC
C Cis
-188/-104, STAT5
binding site
O88 for GTCCAAAGCACTAGACGCCTG
O89 rev TTCCCGGAAGCCTCATCTT
D Cis -18/+55, TSS
O90 for GTTCGCACCACAGCCTTTCAGTCC
O91 rev GTCCAGGGGTGCGAAGGTCAGG
E Cis +261/+322, ORF
O263 for GGACTTCGAGTGGTGTGCCTA
O264 rev GGCTCCGTTTCCCTATCCA
F Cis +502/+553, ORF
O241 for CATTCCTCCGTCCCAGGTC
O242 rev ACCTCAGGCTGGCTTCCTAAG
G Cis +1061/+1112, ORF
O245 for AATTTTCGGACTCTTCGGCA
O246 rev CACCCAAGAAAGGAAGGCAG
H Cis +2236/+2308, ORF
O249 for GAGGACACTGCCTTCCCTCA
O250 rev AAGCTTCTACCCACTCCGGC
I Cis +3963/+4029, ORF
O92 for TACCCCTTCCAACTCTGACTGAGC
O93 rev TTCCCTCCAGGATGTGACTGTG
J Osm
-184/-122, STAT5
binding site
O138 for CATCATCCTTGGGCGTGGGGC
O139 rev CGCTCCTCCTCCCGTTTTCTTCG
K Osm +25/+87, TSS
O140 for GCTGCCAGCCTGCAGGACAC
O141 rev GTACTCTGGCCCGTGCCTCTCAG
L c-Fos
-259/-200, prox.
promoter
O144 for GACCATCTCCGAAATCCTACACGC
O145 rev CACATTTGGGATCTTAGGGGGTCTC
M c-Fos -70/-1, TSS
O146 for GGAAGTCCATCCATTCACAGCG
O147 rev CAGTCGCGGTTGGAGTAGTAGGC
N p21
-120/-61, prox.
promoter
O293 for GAGGGCGGGCCAGCGAGTC
O294 rev CTCAGAGGCAGGACCAACCCACTC
O p21 +75/+136, TSS
O295 for ATCCAGACATTCAGAGGTGAGAGC
O296 rev CATTGCTACGGGGAAGAACTATTG
1 Amplicon name as depicted in Figure 4.17.
2 The position of the amplified region is indicated relative to the TSS.
3 The amplicon length is 52 - 85 bp.
Table 3.5: Mutagenesis primers
Refer to 3.2.1.15
ID Mutations Position Mutagenesis primer, sequence 5’-3’ RS1
O26 K675Q STAT5A
TAD
for TTATCTACGTGTTCCCCGATCGA-
CCCCAGGACGAGGTCTTTGC
PvuI
O27 K675Q STAT5A
TAD
rev GCAAAGACCTCGTCCTGGGGTC-
GATCGGGGAACACGTAGATAA
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ID Mutations Position Mutagenesis Primer, Sequence 5’-3’ RS1
O28 K675R STAT5A
TAD
for CTTATCTACGTGTTCCCCGATCGA-
CCCCGGGACGAGGTCTTTGCCA
PvuI
O29 rev CGTATCCGTCAACTGCTCGCGCA-
AGTACTGGAGTGTAATACTTGGC
O30 K681Q STAT5A
TAD
for AGGACGAGGTCTTTGCCCAGTAC-
TACACTCCTGTACTTGC
ScaI
O31 rev GCAAGTACAGGAGTGTAGTACTG-
GGCAAAGACCTCGTCCT
O32 K681R STAT5A
TAD
for ACGAGGTCTTTGCCCGGTATTAC-
ACTCCAGTACTTGCGAAAG
ScaI
O33 rev CTTTCGCAAGTACTGGAGTGTAA-
TACCGGGCAAAGACCTCGT
O34 K689Q STAT5A
TAD
for CCAAGTATTACACTCCAGTACTT-
GCGCAAGCAGTTGACGGATA
ScaI
O35 rev TATCCGTCAACTGCTTGCGCAA-
GTACTGGAGTGTAATACTTGG
O36 K689R STAT5A
TAD
for GCCAAGTATTACACTCCAGTACT-
TGCGCGAGCAGTTGACGGATACG
ScaI
O37 rev CGTATCCGTCAACTGCTCGCGCA-
AGTACTGGAGTGTAATACTTGGC
O38 K696Q STAT5A
TAD
for CGAAAGCAGTTGACGGATACGTA-
CAGCCACAGATCAAGC
SnaBI
O39 rev GCTTGATCTGTGGCTGTACGTAT-
CCGTCAACTGCTTTCG
O40 K696R STAT5A
TAD
for GCGAAAGCAGTTGACGGATACGT-
ACGGCCACAGATCAAGCAAGT
SnaBI
O41 rev ACTTGCTTGATCTGTGGCCGTAC-
GTATCCGTCAACTGCTTTCGC
O42 K700Q STAT5A
TAD
for TGAAGCCACAGATCCAGCAAGTG-
GTACCTGAGTTCGTCAA
KpnI
O43 rev TTGACGAACTCAGGTACCACTTG-
CTGGATCTGTGGCTTCA
O44 K700R STAT5A
TAD
for CGTGAAGCCACAGATCCGGCAAG-
TGGTACCTGAGTTCGTCAATG
KpnI
O45 rev CATTGACGAACTCAGGTACCACT-
TGCCGGATCTGTGGCTTCACG
O110 Y694F STAT5A
TAD
for CCTGTACTTGCGAAAGCAGTCGA-
CGGATTCGTGAAGCCAC
SalI
O111 rev GTGGCTTCACGAATCCGTCGACT-
GCTTTCGCAAGTACAGG
O229 K675Q, K681Q STAT5A
TAD
for CAGACCGACCCCAGGACGAGG-
TCTTTGCCCAATATTACACTC
SspI
O230 rev GAGTGTAATATTGGGCAAAGACC-
TCGTCCTGGGGTCGGTCTG
O231 K675R, K681R STAT5A
TAD
for CAGACCGACCCCGGGACGAGGT-
CTTTGCCAGGTATTACAC
SmaI/
XmaI
O232 rev GTGTAATACCTGGCAAAGACCTC-
GTCCCGGGGTCGGTCTG
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ID Mutations Position Mutagenesis Primer, Sequence 5’-3’ RS1
O233 K696Q, K700Q STAT5A
TAD
for GACGGATACGTACAGCCACAGAT-
CCAGCAAGTGGTCC
SnaBI
O234 rev GGACCACTTGCTGGATCTGTGGC-
TGTACGTATCCGTC
O235 K696R, K700R STAT5A
TAD
for GACGGATACGTAAGGCCACAGAT-
CAGGCAAGTGGTCC
SnaBI
O236 rev GGACCACTTGCCTGATCTGTGGC-
CTTACGTATCCGTC
O273 K84Q STAT5A
N-term
for ATGGGTTTTTGCTGCAGATCAAG-
CTTGGGCACTATGCCAC
HindIII
O274 rev GTGGCATAGTGCCCAAGCTTGAT-
CTGCAGCAAAAACCCAT
O275 K84R STAT5A
N-term
for GGGAAGATGGGTTTTTGCTGAG-
GATCAAGCTTGGGCACTATGC
HindIII
O276 rev GCATAGTGCCCAAGCTTGATCCT-
CAGCAAAAACCCATCTTCCC
O277 K359Q STAT5A
DBD
for CCACCGTGCGCCTACTAGTGGG-
GGGACAGCTGAATG
SpeI
O278 rev CATTCAGCTGTCCCCCCACTAGT-
AGGCGCACGGTGG
O279 K359R STAT5A
DBD
for CACCGTGCGCCTACTAGTGGGG-
GGAAGGCTGAATGTG
SpeI
O280 rev CACATTCAGCCTTCCCCCCACTA-
GTAGGCGCACGGTG
O281 K384Q STAT5A
DBD
for GTCCCTGCTCCAGAATGAGAACA-
CGCGTAATGAGTGCAGC
MluI
O282 rev GCTGCACTCATTACGCGTGTTCT-
CATTCTGGAGCAGGGAC
O283 K384R STAT5A
DBD
for GTCCCTGCTCAGGAATGAGAAC-
ACGCGTAATGAGTGCAGC
MluI
O284 rev GCTGCACTCATTACGCGTGTTCT-
CATTCCTGAGCAGGGAC
1 Restriction site created within the primer for screening.
Table 3.6: PCR Primers for cloning
Refer to 3.2.1.10
ID Position Cloning primer, sequence 5’-3’ RS1
O22 STAT5A CDS incl. AA666 for GCGAATTCTTATCTACGTGTTCCC EcoRI
O23 STAT5A CDS incl. stop codon rev CAAGTAAGCTTCAGGACAGGGAG HindIII
O24 STAT5A CDS incl. AA666 for GGCGAATTCTTATATATGTGTTTCC EcoRI
O25 STAT5A CDS incl. stop codon rev CCGATAAGCTTCATGACTGTGC HindIII
1 Restriction site created within the primer for restriction digest and subsequent ligation of the PCR-
amplicon with a vector backbone.
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Table 3.7: Sequencing primers
ID Sequencing primer1, sequence 5’-3’ Position2
O17 for CGACATCATCATCGGAAGAGAGTAG pFA-CMV, 5’ of MCS
O18 rev ATGAGCCTTGGGACTGTGAATC pFA-CMV, 3’ of MCS
O19 for GAACTGCTCCTCAGTGGATGTTG pME18S, 5’ of MCS
O20 rev TATGTTTCAGGTTCAGGGGGAG pME18S, 3’ of MCS
O21 for CGGAAGCAGCAGACCATCATC STAT5A/B CDS
1 In addition to the listed sequencing primers, primers provided by the sequencing service GeneArt
(Thermo Fischer Scientific, Regensburg) were used: T7-Promotor, SP6, N-CMV-30 and BGHrev.
MCS, multiple cloning site; CDS, coding sequence.
2 The sequencing primer recognizes the indicated parental plasmid and all plasmids derived thereof.
3.1.4.3 Plasmids
All plasmids used in this study were verified by sequencing (GeneArt Sequencing Service,
Regensburg). The plasmid pFA-mSTAT5A 666-793 (P20) expressing the fusion protein
GAL4-STAT5A666 was generated by PCR cloning (3.2.1.10) as follows: The insert com-
prising amino acids 666-793(Stop) of mouse STAT5A was amplified by PCR (3.2.1.10)
using the template pME18S-mSTAT5A (P02) and the primers O22 and O23 (shown in
Table 3.6). The vector backbone was pFA-CMV (P04), which expresses the yeast GAL4
DNA binding domain (amino acids 1-147). The insert as well as the vector backbone
were digested with the restriction enzymes EcoRI and HindIII (3.2.1.13), and subse-
quently ligated (3.2.1.14) to generate the plasmid. pFA-mSTAT5B 666-786 (P21) was
generated likewise using the template pME18S-mSTAT5B (P03) as well as the primers
O24 and O25.
Single or multiple lysine-to-glutamine or lysine-to-arginine mutations in GAL4-
STAT5A666 (generating plasmids P22-P31) and in STAT5A-1⇤6 (generating plasmids
P120-P135 and P152-P157) were made by site-directed mutagenesis (3.2.1.15) using plas-
mid template and primers indicated in Table 3.8. As a positive control for an
inactivating mutation, the tyrosine residue Y694 of STAT5A-1⇤6 was mutated to
phenylalanine, generating pcDNA3-mSTAT5A-1⇤6-Y694F- FLAG (P151).
Table 3.8: Plasmids
ID Plasmid Generation/Details Function Reference
P02 pME18S-mSTAT5A subcloning S.
Watanabe
P03 pME18S-mSTAT5B subcloning S.
Watanabe
P04 pFA-CMV empty vector
control
Stratagene
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ID Plasmid Generation/Details Function Reference
P05 pFA-mSTAT5A 709-793 Watanabe et al. (2001) expression
vector for
GAL4-
STAT5A709
S. Watan-
abe/
Tohru Itoh
P20 pFA-mSTAT5A 666-793 PCR amplicon from P02
with primers O22/O23
inserted into P04, see
above
expression
vector for
GAL4-
STAT5A666
S. Pinz
P21 pFA-mSTAT5B 666-786 PCR amplicon from P03
with primers O24/O25
inserted into P04, see
above
expression
vector
S. Pinz
P22 pFA-mSTAT5A 666-793 K675Q made from P20 by SDM1
with primers O26/O27
expression
vector
S. Pinz
P23 pFA-mSTAT5A 666-793 K675R made from P20 by SDM1
with primers O28/O29
expression
vector
S. Pinz
P24 pFA-mSTAT5A 666-793 K681Q made from P20 by SDM1
with primers O30/O31
expression
vector
S. Pinz
P25 pFA-mSTAT5A 666-793 K681R made from P20 by SDM1
with primers O32/O33
expression
vector
S. Pinz
P26 pFA-mSTAT5A 666-793 K689Q made from P20 by SDM1
with primers O34/O35
expression
vector
S. Pinz
P27 pFA-mSTAT5A 666-793 K689R made from P20 by SDM1
with primers O36/O37
expression
vector
S. Pinz
P28 pFA-mSTAT5A 666-793 K696Q made from P20 by SDM1
with primers O38/O39
expression
vector
S. Pinz
P29 pFA-mSTAT5A 666-793 K696R made from P20 by SDM1
with primers O40/O41
expression
vector
S. Pinz
P30 pFA-mSTAT5A 666-793 K700Q made from P20 by SDM1
with primers O42/O43
expression
vector
S. Pinz
P31 pFA-mSTAT5A 666-793 K700R made from P20 by SDM1
with primers O44/O45
expression
vector
S. Pinz
P33 pcDNA3 empty vector
control
Invitrogen
P37 pMX.neo.mStat5Awt-FLAG subcloning T.
Kitamura
P40 pMX.neo.mStat5A-1⇤6-FLAG subcloning T.
Kitamura
P49 phRL-CMV Renilla
luciferase
reporter
Promega
P50 pRL-null Renilla
luciferase
reporter
Promega
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ID Plasmid Generation/Details Function Reference
P54 pcDNA3-mSTAT5Awt-FLAG subcloned from P37 into
P33 by EcoRI/NotI
digest
expression
vector
S. Unser
P55 pcDNA3-mSTAT5A-1⇤6-FLAG subcloned from P40 into
P33 by EcoRI/NotI
digest
expression
vector
S. Unser/
L. Besl
P66 pGL4.35 contains 9 x GAL4 UAS
and the Firefly luciferase
luc2P gene
Firefly
luciferase
reporter
Promega
P103 pGVB-CisA-Luc contains wt mouse Cis
promoter fragment
(-608/+67), Matsumoto
et al. (1997)
Firefly
luciferase
reporter
A.
Yoshimura
P106 pGVB-CisD-Luc contains mouse Cis
promoter fragment
(-608/+67) with mutated
STAT5 bs, Matsumoto
et al. (1997)
Firefly
luciferase
reporter
A.
Yoshimura
P111 pGVB- -casein-Luc contains rat  -casein
promoter fragment
(-105/+1), Chida et al.
(1998)
Firefly
luciferase
reporter
A.
Yoshimura
P120 pcDNA3-mSTAT5A-1⇤6-
K696Q-FLAG
made from P55 by SDM1
with primers O38/O39
expression
vector
S. Pinz/ L.
Besl
P121 pcDNA3-mSTAT5A-1⇤6-
K696R-FLAG
made from P55 by SDM1
with primers O40/O41
expression
vector
S. Pinz/ L.
Besl
P122 pcDNA3-mSTAT5A-1⇤6-
K700Q-FLAG
made from P55 by SDM1
with primers O42/O43
expression
vector
S. Pinz/ L.
Besl
P123 pcDNA3-mSTAT5A-1⇤6-
K700R-FLAG
made from P55 by SDM1
with primers O44/O45
expression
vector
S. Pinz/ L.
Besl
P124 pcDNA3-mSTAT5A-1⇤6-
K681Q-FLAG
made from P55 by SDM1
with primers O30/O31
expression
vector
S. Pinz/ L.
Besl
P125 pcDNA3-mSTAT5A-1⇤6-
K681R-FLAG
made from P55 by SDM1
with primers O32/O33
expression
vector
S. Pinz/ L.
Besl
P126 pcDNA3-mSTAT5A-1⇤6-
K689Q-FLAG
made from P55 by SDM1
with primers O34/O35
expression
vector
S. Pinz
P127 pcDNA3-mSTAT5A-1⇤6-
K689R-FLAG
made from P55 by SDM1
with primers O36/O37
expression
vector
S. Pinz/ L.
Besl
P128 pcDNA3-mSTAT5A-1⇤6-
K675Q-FLAG
made from P55 by SDM1
with primers O26/O27
expression
vector
S. Pinz
P129 pcDNA3-mSTAT5A-1⇤6-
K675R-FLAG
made from P55 by SDM1
with primers O28/O29
expression
vector
S. Pinz/ L.
Besl
P130 pcDNA3-mSTAT5A-1⇤6-
K696/700Q-FLAG
made from P55 by SDM1
with primers O233/O234
expression
vector
S. Pinz
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ID Plasmid Generation/Details Function Reference
P131 pcDNA3-mSTAT5A-1⇤6-
K696/700R-FLAG
made from P55 by SDM1
with primers O235/O236
expression
vector
S. Pinz
P132 pcDNA3-mSTAT5A-1⇤6-
K689/696/700Q-FLAG
made from P126 by SDM1
with primers O233/O234
expression
vector
S. Pinz
P133 pcDNA3-mSTAT5A-1⇤6-
K689/696/700R-FLAG
made from P127 by SDM1
with primers O235/O236
expression
vector
S. Pinz
P134 pcDNA3-mSTAT5A-1⇤6-
K675/681/689/696/700Q-FLAG
made from P132 by SDM1
with primers O229/O230
expression
vector
S. Pinz
P135 pcDNA3-mSTAT5A-1⇤6-
K675/681/689/696/700R-FLAG
made from P133 by SDM1
with primers O231/O232
expression
vector
S. Pinz
P151 pcDNA3-mSTAT5A-1⇤6-Y694F-
FLAG
made from P55 by SDM1
with primers O110/110
expression
vector
S. Pinz
P152 pcDNA3-mSTAT5A-1⇤6-K84Q-
FLAG
made from P55 by SDM1
with primers O273/O274
expression
vector
S. Pinz
P153 pcDNA3-mSTAT5A-1⇤6-K84R-
FLAG
made from P55 by SDM1
with primers O275/O276
expression
vector
S. Pinz
P154 pcDNA3-mSTAT5A-1⇤6-
K359Q-FLAG
made from P55 by SDM1
with primers O277/278
expression
vector
S. Pinz
P155 pcDNA3-mSTAT5A-1⇤6-
K359R-FLAG
made from P55 by SDM1
with primers O279/280
expression
vector
S. Pinz
P156 pcDNA3-mSTAT5A-1⇤6-
K384Q-FLAG
made from P55 by SDM1
with primers O281/282
expression
vector
S. Pinz
P157 pcDNA3-mSTAT5A-1⇤6-
K384R-FLAG
made from P55 by SDM1
with primers O283/284
expression
vector
S. Pinz
1 Site-directed mutagenesis, described in 3.2.1.15. Mutagenesis primers are listed in Table 3.5.
3.1.4.4 RNA-oligonucleotides
Control and mouse HDAC-specific siRNAs were double-stranded RNAs with dTdT
overhangs on the 3’ end of both strands. The siRNAs were obtained from Sigma Aldrich
(MISSION siRNA), except for HD2.1 and ScI, which were from Dharmacon. The
lyophilized siRNA was reconstituted in nuclease free H2O to a concentration of 100 µM.
Table 3.9: siRNAs for transfections
Refer to 3.2.3.8.
Gene ID Antisense sequence 5’-3’
Hdac1 HD1.3 GCAGCGUCUCUUUGAGAAC[dT][dT]
Hdac2 HD2.1 GCAUCAGGGUUCUGCUAUG[dT][dT]
Hdac3 HD3.1 GUAUCCUGGAGCUGCUUAA[dT][dT]
Hdac5 HD5.1 CCUAGUCUCCGCUGGGUUU[dT][dT]
Hdac5 HD5.2 GUGACACGGUGUGGAAUGA[dT][dT]
Scramble I control ScI CAGUCGCGUUUGCGACUGG[dT][dT]
33
CHAPTER 3. MATERIAL AND METHODS
3.1.5 Enzymes
Table 3.10: Enzymes
Enzyme Manufacturer
DNaseI Roche
DpnI New England Biolabs
HotStar Taq Polymerase Qiagen
MNase Sigma-Aldrich
Phusion High-Fidelity DNA Polymerase Thermo Scientific
Proteinase K Sigma-Aldrich
Restriction enzymes New England Biolabs
RNaseA Sigma-Aldrich
T4 DNA Ligase New England Biolabs
Trypsin/EDTA PAN Biotech
3.1.6 Antibodies
Table 3.11: Primary antibodies for western blot or ChIP
Refer to 3.2.5.6 or 3.2.7.
Antibody target ID Species Company, order number WB dilution1
acetylated histone H3 AB31 rabbit Millipore, #06-599 1:5000
acetylated histone H4 AB32 rabbit Millipore, #06-866 1:2000
↵-tubulin AB07 mouse Santa Cruz, sc-32293 1:200
BRD2 AB61 rabbit Bethyl, A302-583A 1:2000
FLAG AB12 mouse Sigma-Aldrich, F-1804 1:500
GAL4 AB11 mouse Santa Cruz, sc-510 1:200
histone H3 AB40 rabbit Abcam, ab1791 1:10000
HDAC1 AB08 mouse Millipore, #05-100 1:1000
HDAC2 AB30 rabbit Zymed/Invitrogen, 51-5100 1:1000
HDAC3 AB27 rabbit Cell Signaling, #2632 1:500
HDAC5 AB39 rabbit Abcam, ab1439 1:500
HDAC11 AB42 rabbit Abgent, AP1111b 1:200
RNA Pol II (N-20) AB34 rabbit Santa Cruz, sc-899 1:1000
pSTAT5 AB06 rabbit Cell Signaling, #9351 1:1000
STAT5 (C-17) AB02 rabbit Santa Cruz, sc-835 1:1000
STAT5A (L-20) AB01 rabbit Santa Cruz, sc-1081 1:1000
STAT5B (G-2) AB45 mouse Santa Cruz, sc-1656 1:200
IgG from rabbit serum AB33 rabbit Sigma-Aldrich, I-5006
1 Antibody dilution used for western blot (WB) (refer to 3.2.5.6).
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Table 3.12: Secondary antibodies for western blot
Refer to 3.2.5.6
Secondary antibody Enzyme1 Company, order number WB dilution2
anti-mouse IgG HRP Sigma-Aldrich, A-8924 1: 10 000
anti-rabbit IgG HRP Sigma-Aldrich, A-0545 1: 20 000
1 All secondary antibodies were coupled to horseradish peroxidase (HRP).
2 Antibody dilution used for western blot (WB) (refer to 3.2.5.6).
3.1.7 Instruments
Only basic instruments are listed. All other method-specific instruments are mentioned
in the respective method part.
Instrument Manufacturer
-20 C freezer Liebherr
-80 C freezer, Forma 900 Series Thermo Scientific
4 C fridge Liebherr
Cell cryo-tank, 810 ETERNE with TEC 2000 monitor Chart MVE
Centrifuges 5417R, 5810R Eppendorf
CO2 Incubator, BBD 6220 Heraeus
Heating Block Thermostat, Bio TDB-100 Biosan
Heating oven Binder GmbH
Hybridization oven GFL 7601
Ice Flaker, AF8 Scotsman, Hubbard Systems
Liquid N2 tank, EURO-CYL 230/4 Chart MVE
Magnetic Stirrer Heidolph
MaxQ 4000 Benchtop Orbital Shaker for E. coli Thermo Scientific
Microwave Panasonic
Milli-Q-Synthesis Water Purification System Millipore
Mini-Centrifuge Sprout Kisker
NanoPhotometer P300 Implen
pH meter, inoLab WTW
Pipet-Lite P2, P20, P200, P1000 Rainin
Pipet-X Lightweight controler Rainin
Power supply, PowerPac 300 Bio-Rad
Power supply, PowerPac Basic Bio-Rad
Power supply, PowerPac HC Bio-Rad
Precision scale, CP224S Sartorius AG
Scale, EMB 220-1 KERN
Sterile bench, Hera Safe Thermo Scientific
Thermocycler, MyCycler Bio-Rad
ThermoMixer 5436 Eppendorf
Vortex Genie2 Scientific Industries
3.1.8 Consumables
Standard plastic consumables not mentioned in the following list were from Sarstedt.
Consumable Manufacturer
0.1 mL PCR-Tubes and Caps for RotorGene Q Kisker
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Consumable Manufacturer
384-well plate for quantitative PCR Applied Biosystems, Peqlab
96-well microplate, black Berthold Technologies
Cannula BD
Cell culture flasks, T25, T75, T125 Sarstedt
Cell culture plates, 6-well, 24-well, 96-well, P10 Falcon, Fisher Scientific
Collodion Bags Sartorius
Cryo vials Sarstedt
Cuvettes for electroporation, 1 mm or 4 mm gap VWR
Cuvettes, polystyrene 10 x 4 mm, 10 mm optical pathway Sarstedt
Immobilon-P PVDF Membrane, 0.45 µm Millipore
Optical adhesive cover for 384-well plate Applied Biosystems, Bio-Rad
Pipette tips, LTS Rainin
Syringe BD
Whatman blotting paper A. Hartenstein
3.2 Methods
3.2.1 DNA and RNA analysis and methods
3.2.1.1 RNA preparation
0.04 x 106 cells were washed in 1 mL PBS and centrifuged at 2000 rcf for 1 min at 4 C.
100 µL iScript RT-qPCR Sample Preparation Reagent (170-8899, Bio-Rad) was added to
the cell pellet and the sample was vortexed for 30 sec at medium speed. The lysate was
cleared by centrifugation at 15000 rcf for 2 min at 4 C. Usually it was immediately pro-
ceeded with cDNA synthesis (3.2.1.2). The remaining stabilized RNA-containing lysate
was snap-frozen in liquid nitrogen and stored at -80 C.
Where indicated, total RNA was purified with MN NucleoSpin RNA II kit as recom-
mended by the manufacturer.
3.2.1.2 cDNA synthesis
cDNA was synthesized from 1 µL RNA preparation (from 3.2.1.1) according to Bio-Rad’s
recommendations for the iScript cDNA Synthesis Kit (170-8891, Bio-Rad). In brief, 1 µL
RNA-template was added to 14 µL nuclease free H2O and then mixed with 4 µL 5x iScript
reaction mix and 1 µL reverse transcriptase. The sample was placed in a thermocycler
with the following program: 5 min at 25 C, 30 min at 42 C, 5 min at 85 C, hold at 16 C.
The cDNA samples were stored at -20 C.
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3.2.1.3 Quantitative real-time polymerase chain reaction (qPCR)
Quantitative real-time PCR (qPCR) was performed on a RotorGene Q (Qiagen), except
for a few initial experiments on a 7900HT Real-Time PCR System (Applied Biosystems).
The obtained data were very similar on both systems.
For analysis on the RotorGene Q, qPCR reactions were performed in 20 µL final vol-
ume in 0.1 mL tubes. A reaction contained 0.02 U/µL HotStarTaq Polymerase (Qiagen),
0.25 µL of a 1:500000 SYBR-Green I-dilution in DMSO (starting from a 10000x SYBR
Green I stock solution from Roche), 1x PCR bu↵er (Qiagen), 1 mM additional MgCl2
(already 1.5 mM MgCl2 from 1x PCR bu↵er), 0.2 mM dNTPs (each), 0.4 µM forward
and reverse primer as well as 0.3 - 0.6 µL cDNA (3.2.1.2) or 2.5 - 5 µL genomic ChIP
DNA (3.2.7).
For analysis on the 7900HT Real-Time PCR System, qPCR reactions were performed
in 10 µL final volume in 384-well plates. The reaction mix had the same composition as
for RotorGene Q, except that 1x ROX passive reference dye was added and 0.3 µL cDNA
were used per analysis.
PCR and signal acquisition were performed with the following parameters: An initial
step of 15 min at 95 C was followed by a 2-step cycling program (15 s at 95 C, 60 s at
60 C), which was repeated 40 times. Eventually a program was added to determine the
melt curve of the generated amplicons.
Amplification curves and threshold cycles (Ct) were calculated with the basic Quanti-
tation Analysis Tool of the Rotor-Gene Q Series Software 2.0.3 or the equivalent software
of the 7900HT Real-Time PCR System.
3.2.1.4 Gene expression analysis by quantitative reverse transcription PCR
(quantitative RT-PCR)
RNA was prepared with iScript RT-qPCR sample preparation reagent (Bio-Rad) as
described in 3.2.1.1, followed by reverse transcription cDNA synthesis as described in
3.2.1.2. The cDNA was used as template for quantitative PCR (3.2.1.3) using expression
primers listed in Table 3.3. The obtained threshold cycle (Ct) for the gene of interest
was normalized to the Ct of the reference gene mouse ribosomal protein S9 using the
 Ct method with the following formula: expression target gene/reference gene=2- Ct ,
where  Ct=Ct(target gene)-Ct(reference gene). To improve the clarity of the graphs, the ob-
tained values were multiplied by 10000. qPCR was performed in duplicate or triplicate,
and data shown are mean +/- standard deviation from one representative of at least two
independent experiments.
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3.2.1.5 Phenol extraction
After addition of one volume phenol/chloroform/isoamyl alcohol (25/24/1, pH 8.0) to
an aqueous DNA solution, the sample was vortexed for 10-30 s and then centrifuged at
20000 rcf for 60 s at RT. The upper, DNA-containing, aqueous phase was transferred to
a new reaction tube and the DNA was subjected to ethanol precipitation (3.2.1.6).
3.2.1.6 Ethanol precipitation
0.06 µg/µL glycogen, 1/10th volume 3 M sodiumacetate pH 5.2, and 2.5 volumes ethanol
(pre-cooled at -20 C) were added to an aqueous DNA solution. After vortexing and
incubation at -20 C for 15 min, the DNA was precipitated by centrifugation at 20000 rcf
for 10 min at 4 C. The DNA pellet was washed in 500 µL 70% v/v ethanol (pre-cooled
at -20 C), air-dried, and dissolved in TE or ultrapure H2O for further applications.
3.2.1.7 Isopropanol precipitation
DNA was precipitated from an aqueous solution by addition of 1 volume isopropanol,
followed by vortexing and centrifugation at 20000 rcf for 10 min at RT. The DNA pellet
was washed in 500 µL 70% v/v ethanol (pre-cooled at -20 C), air-dried, and dissolved in
TE or ultrapure H2O for further applications.
3.2.1.8 Plasmid preparation
Small scale plasmid preparations for screening purposes were prepared from 1.5 mL E. coli
LB-culture (3.2.2.1) using bu↵ers listed in Table 3.1. The bacteria were pelleted at
9000 rcf for 3 min at 4 C and resuspended in 250 µL bu↵er P1 supplemented with
10 µg/mL RNase1. 250 µL bu↵er P2 were added, and the sample was mixed by gently
inverting the tube. After incubation for 4-5 min at RT, addition of 250 µL bu↵er P3, and
gentle inversion of the tube, the samples were incubated for 15 min on ice and debris was
removed by centrifugation (20000 rcf, 10 min, RT). The supernatant was subjected to
isopropanol precipitation (3.2.1.7), and the DNA pellet was dissolved in 50 µL ultrapure
H2O. 2-5 µL of the plasmid preparation were analyzed by agarose gel electrophoresis
(3.2.1.11).
Expression plasmid DNA was prepared according to the high yield protocol of the
Qiagen Plasmid Pure Midi Kit. All required bu↵ers and consumables were included in
the kit. In brief, E. coli from 35 mL LB-culture (3.2.2.1) were lysed using 4 mL each of kit
bu↵er P1, P2 and P3. After clearing the lysate through a filter-cartridge, 2 mL binding
bu↵er BB were added, and the DNA was purified on a Qiagen Plasmid Plus spin column.
The DNA was eluted from the column with 200 µL bu↵er EB. The DNA concentration of
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the plasmid preparation was measured by UV spectroscopy (3.2.1.9). The total amount
of eluted DNA usually varied between 100 and 400 µg.
3.2.1.9 DNA quantification by UV spectroscopy
The DNA concentration of aqueous DNA solutions was determined by UV spectroscopy
on a NanoPhotometer P300 (Implen). After measuring the absorbance at 260 nm, the
DNA concentration was calculated by the instrument according to the Lambert-Beer
Law:
A="*c*L  ! c= A/ ("*L)
A: Absorbance (measured at 260 nm)
c: concentration
": extinction coe cient ( "DNA, 260 nm = 0.02 mL/(µg*cm)
L: length of the light path through the sample
In addition, absorbance at 280 nm was measured to determine the purity of the sample.
For pure DNA, the A260/A280 ratio is 1.8.
3.2.1.10 PCR cloning
Polymerase chain reaction (PCR) was used to amplify DNA sequences for plasmid cloning.
The used cloning primers (Tab. 3.6) contained 5’ overhanging restriction sites for later
restriction enzyme digest and ligation into the equally digested plasmid backbone. A
50 µL PCR reaction was set up, containing 1x Taq Bu↵er, 250 nM of each dNTP, 250 nM
forward and reverse primer, 30 pg plasmid DNA template, and 1 µL Taq (prepared by AG
Hehlgans from the Institute of Immunology). The PCR was performed in a thermocycler
with the following parameters: An initial step of 4 min denaturation at 95 C was followed
by 35 repeats of a cycling program (30 sec at 95 C, 30 sec at 52 C and 60 sec at 72 C).
The program closed with a final elongation at 72 C for 10 min and a cooling-down to
16 C.
The PCR reaction was separated by agarose gel elecrophoresis and the DNA fragment
of expected size was purified from the gel (3.2.1.12) for further digest (3.2.1.13) and
ligation (3.2.1.14).
3.2.1.11 Agarose gel electrophoresis
Agarose was dissolved in 0.5x TAE at a concentration of 0.7 to 2.0% w/v in a microwave
oven. 0.2 µg/mL ethidium bromide was added and the gel was casted in a horizontal gel
chamber ((Wide) Mini-Sub Cell GT, Bio-Rad). DNA samples were adjusted to 1x DNA
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loading dye, loaded onto the gel, and separated at 100-120 V in 0.5x TAE as running
bu↵er. In addition to the samples, a DNA ladder (1 kb or 100 bp DNA ladder from
NEB) was loaded onto the gel, which allowed to estimate the size and quantity of the
DNA fragments if interest. The DNA was visualized in the GeneGenious Gel Imaging
System (Syngene) through the fluorescent, DNA-intercalating ethidium bromide, which
emits light at 605 nm after excitation with ultraviolet light.
3.2.1.12 Purification of DNA fragments from agarose gel
The DNA was separated according to size by agarose gel electrophoresis (3.2.1.11). The
fragment of expected size was excised from the gel and purified with the column-based
Wizard SV Gel and PCR Clean-Up System (Promega) according to the manufacturer’s
recommendations. Eventually, the DNA was eluted from the purification column us-
ing 50 µL ultrapure H2O. The DNA concentration was determined by UV spectroscopy
(3.2.1.9).
3.2.1.13 Restriction enzyme digest
All sequence specific restriction endonucleases were from NEB. 1-2 units restriction en-
zyme were used to digest 1 µg plasmid DNA. To limit enzyme inhibition by glycerol
contained in the enzyme storage bu↵er, the volume of enzyme should not exceed 10%
of the total reaction volume. For a test digest, 0.5 µg plasmid DNA were digested in
10 µL total volume within 1 h incubation. A preparative digest involved 20 µg DNA and
40 units restriction enzyme in 50 µL final volume, as well as 2 h incubation. Incubation
temperature, bu↵er and BSA content of the reaction were adjusted for each enzyme as
recommended by the manufacturer.
3.2.1.14 Ligation
Digested (3.2.1.13) and purified (3.2.1.12) vector-backbone and insert were ligated in a
ratio of 1:1.5 - 1:6 (vector:insert), while the total DNA amount was adjusted to 50 ng.
The final volume of the reaction was 15 µL including 1.5 µL 10x T4 DNA ligase bu↵er
(NEB) and 1 µL T4 DNA ligase (NEB). The reaction was placed in an insulating box,
which was closed at RT and kept O/N at 4 C.
3.2.1.15 Site-directed mutagenesis
Three steps were required to introduce mutations into a plasmid by site-directed muta-
genesis.
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First, the mutant DNA was synthesized by thermal cycling using a DNA polymerase
and mutagenesis primers (for a list of all mutagenesis primers see Table 3.5). In addition
to the point mutation leading to the desired amino acid exchange, each primer contained a
silent mutation which created a restriction site for screening. A reaction of 50 µL volume
contained 1x HF-Bu↵er (Thermo Fischer Scientific), 0.5 mM additional MgCl2 (1.5 mM
MgCl2 provided by HF-bu↵er), 250 µM of each dNTP, 1 U Phusion High-Fidelity DNA
Polymerase, 125 ng forward and reverse primer, and 10-50 ng plasmid DNA template.
The reaction conditions were 1 min initial denaturation at 95 C, followed by 16 cycles
of denaturation at 95 C for 30 s, primer annealing at 58 C for 1 min, and elongation at
68 C for 5-8 min (1 min elongation per kb plasmid template), finishing with a final hold
at 16 C.
Second, 1 U methylation sensitive endonuclease DpnI was added, and the reaction was
incubated for 1 hour at 37 C. DpnI cuts only parental methylated or hemimethylated
DNA, while leaving newly synthesized, unmethylated DNA intact.
Third, 10 µL of the digested sample was used for transformation (3.2.2.4) of 100 µL
chemically competent XL1-Blue E. coli . Plasmid DNA was prepared (3.2.1.8) and
screened by digestion with the restriction endonuclease whose recognition site was created
in the mutagenesis primer (Tab. 3.5). The correct coding sequence of the STAT5A-1⇤6
mutants was verified with the forward primers T7P, O21 and the reverse primer SP6
by sequencing (GeneArt Sequencing Service, Thermo Fischer Scientific, Regensburg). In
case of the GAL4-STAT5A666 mutants, the sequence was verified with O18 (for a list of
sequencing primers see Table 3.7).
3.2.2 Manipulation of Escherichia coli
3.2.2.1 Escherichia coli (E. coli) cultures in LB medium
LB medium was inoculated with E. coli and incubated O/N at 37 C on a shaker. In
case the culture was designated for plasmid isolation (3.2.1.8) or glycerol-stock (3.2.2.2),
antibiotics had been added to the LB medium at a concentration of 200 µg/mL ampicillin
or 25 µg/mL kanamycin.
3.2.2.2 E. coli glycerol-stock
1 mL E. coli LB-culture (3.2.2.1) was added to 500 µL 60% v/v glycerol to yield a final
glycerol concentration of 20% v/v. The glycerol-stock was first cooled to -20 C and then
stored at -80 C.
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3.2.2.3 Chemically competent E. coli
100 mL LB medium were inoculated with 500 µL XL1-Blue E. coli culture (3.2.2.1) and
incubated at 37 C on a shaker until an OD600 of 0.5 - 0.6 was reached. The flask was
placed in an ice bath and stirred for 15 min, followed by centrifugation at 3200 rcf for
5 min at 4 C. After resuspending the pellet in 40 mL TFBI + glycerol (pre-cooled on
ice) and 15 min incubation on ice, the bacteria were centrifuged as before. The pellet
was resuspended in 4 mL TFBII + glycerol. Aliquots were snap frozen in liquid nitrogen
and stored at -80 C.
3.2.2.4 Transformation of E. coli
100 µL chemically competent XL1-Blue E. coli (3.2.2.3) were mixed with 5 µL ligation
reaction (3.2.1.14). 30 min incubation on ice were followed by a heat shock of 1.5 min
at 42 C and immediate cooling on ice for 3-5 min. 500 µL LB medium were added, and
the bacteria were allowed to recover for 1 h at 37 C. To concentrate the bacteria prior to
plating, they were pelleted (8000 rcf, 30 sec, RT) and 400 µL supernatant was removed.
The E. coli were resuspended in the remaining 200 µL volume and plated on an LB
agar plate containing 200 µg/mL ampicillin or 25 µg/mL kanamycin, depending on the
resistance gene encoded on the plasmid. The plates were incubated at 37 C O/N.
In case purified plasmid DNA was to be transformed instead of a ligation reaction, the
same protocol applied, except for the following changes: A few ng of the plasmid DNA
and 50 µL chemically competent XL1-Blue were used. For recovery, 250 µL LB-medium
were added and 50 µL of the sample were plated, omitting the centrifugation step.
3.2.3 Eukaryotic cell culture
3.2.3.1 Cell maintenance
All eukaryotic cells were cultured in a humidified incubator at 37 C under 5% CO2.
Cell lines based on the murine pro B-cell line Ba/F3 were grown in RPMI 1640
supplemented with 10% v/v heat inactivated FCS, 1x penicillin/streptomycin (100 U/mL
penicillin, 100 µg/mL streptomycin) and 2 mM glutamine. This cell culture medium will
be referred to as RPMI-based medium thereafter. RPMI-based medium for the parental
non-tumorigenic, immortalized, IL-3-dependent cell line Ba/F3 contained additionally
2 ng/mL rmIL-3 (IL-3). The Ba/F3-1⇤6 cell line (clone F7, described in Pinz et al.,
2014a), expressing stably integrated, FLAG-tagged, constitutively active mouse STAT5A-
1⇤6, was grown in RPMI-based medium containing 0.6 mg/mL G418. Ba/F3-tet-on-1⇤6
cells (clone D4.1, described in Pinz et al., 2015) express the rtTA- Advanced transactivator
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and carry stably integrated FLAG-tagged mouse STAT5A-1⇤6, whose expression can
be induced conditionally upon addition of tetracycline. During maintenance, Ba/F3-
tet-on-1⇤6 cells were grown in RPMI-based medium supplemented with 2 ng/mL IL-3,
0.6 mg/mL G418, and 0.8 mg/mL hygromycin. For induction of STAT5A-1⇤6, the cells
were cultured in RPMI-based medium containing 1 µg/mL of the tetracycline doxycycline.
The Ba/F3-G4-Luc2P cell line, carrying the stably integrated Firefly luciferase Luc2P
gene together with its 9xUAS (upstream activating sequences), was generated by stably
transfecting Ba/F3 cells by electroporation with the plasmid pGL4.35 (P66). Stable
clones were selected in the presence of hygromycin B and screed for basal luciferase
activity. Clone 2.A was chosen for this study. Ba/F3-G4-Luc2P cells were maintained
in RPMI-based medium containing 2 ng/mL IL-3 and 0.6 mg/mL hygromycin B (This
cell line was generated together with Susanne Bru¨ggemann and Dr. Anne Rascle). All
Ba/F3-derived suspension cells were split every 2-3 days and grown to a cell density of
maximally 1 x 106 cells/mL.
Cos-7 cells were cultured in DMEM supplemented with 10% v/v heat inactivated FCS,
1x penicillin/streptomycin (100 U/mL penicillin, 100 µg/mL streptomycin), and 2 mM
glutamine (referred to as DMEM-based medium thereafter). The adherently growing
Cos-7 cells were trypsinized for passaging at 70-90% confluency (every 2-3 days). After
3-5 min incubation in Trypsin/EDTA at 37 C, the reaction was stopped by addition of
two volumes DMEM-based medium. The cells were pelleted by centrifugation at 300 rcf
for 5 min, resuspended in DMEM-based medium, and seeded in the appropriate cell
culture flasks or plates.
3.2.3.2 Cryopreservation of mammalian cells
Cells were pelleted (suspension cells directly, adherent cells after trypsinization (3.2.3.1))
and suspended in FCS containing 10% v/v DMSO. 1 mL aliquots of the cells were frozen
in cryo vials at -80 C. They were transferred to the liquid nitrogen tank for long term
storage. For Ba/F3 cells, 5 x 106 cells were frozen per aliquot. In case of Cos-7 cells,
seven 1 mL aliquots were prepared per 70-90% confluent T75 flask.
3.2.3.3 Thawing of mammalian cells
Cryopreserved cells (3.2.3.2) were thawed and immediately transferred to the appropriate
cell culture medium (10 mL for suspension cells, 5 mL for adherent cells) in a T25 flask.
The culture medium required for the di↵erent cell lines is described in 3.2.3.1, however,
selection antibiotics were omitted. After 4-6 h recovery, suspension cells were spun down
(300 rcf, 5 min). The DMSO-containing supernatant was aspirated, and the cells were
43
CHAPTER 3. MATERIAL AND METHODS
cultured in fresh culture medium with the appropriate selection antibiotics. In case of
adherent Cos-7 cells, the supernatant was aspirated and substituted with fresh DMEM-
based medium as soon as the cells had attached to the plate.
3.2.3.4 Cell resting and IL-3 stimulation
Ba/F3 or Ba/F3-tet-on-1⇤6 cells were washed twice in RPMI 1640 (centrifugation at
300 rcf, 5 min) and subsequently cultured for 6-12 h in RPMI-based medium before
cytokine stimulation with 2 ng/mL rmIL-3. The duration of stimulation depended on
the downstream assay and is indicated in the figure legends.
3.2.3.5 WST1 cytotoxicity assay
The WST-1 cytotoxicity assay (Roche) was performed as recommended by the manufac-
turer. 0.75 x 105 rested Ba/F3 cells were pre-incubated for 30 min with the deacetylase
inhibitor in 100 µL RPMI-based medium in a clear flat-bottom 96-well cell culture plate.
10 µL WST-1 reagent plus IL-3 (for 2 ng/mL final IL-3 concentration) were added, fol-
lowed by another 90 min incubation. This protocol reflects the IL-3 stimulation setting
used in other experiments, while allowing su cient incubation for cleavage of the WST-1
reagent. The stronger the cytotoxic e↵ect of the inhibitor, the less active are the mito-
chondrial dehydrogenases of the cells and the less WST-1 (a tetrazolium salt) is cleaved.
The water-soluble cleavage product (formazan) leads to a strong increase in absorbance
at 450 nm, which was measured with a multiplate reader (Mithras LB 940, Berthold
Technologies). To account for background signals, absorbance at 620 nm was subtracted
from the value obtained at 450 nm. Cytotoxicity was calculated relative to vehicle con-
trol (0% cytotoxicity) and treatment with 1% Triton X-100 (100% cytotoxicity) according
to the following equation: (Asample-Avehicle control)/(ATriton X-100-Avehicle control)x100. WST-1
reactions were performed in duplicate (quadruplicate for vehicle controls) and data shown
are mean +/- standard deviation from one representative of at least two independent ex-
periments.
3.2.3.6 Plasmid transient transfection of Cos-7 cells by Lipofectamine 2000
On the day before transfection, 0.25 x 106 Cos-7 cells were seeded per well of a 6-well plate
in 2.5 mL DMEM-based medium. Thus, the cells reached 70% confluency for transfection.
2 µL Lipofectamine 2000 (Invitrogen) were mixed gently with 248 µL DMEM and
incubated for 5 min at RT. The Lipofectamine dilution was combined with 1-2 µg plasmid
DNA diluted in 250 µL DMEM (500 µL final volume). The Lipofectamine-DNA-mix was
incubated for 20 min at RT. The mix was then added to the Cos-7 cells, whose medium
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had been changed to 1 mL DMEM. The cells were incubated for 4 h in the humidified
cell culture incubator at 37 C and 5% CO2. Eventually, 1 mL DMEM supplemented
with 25% v/v heat inactivated FCS, 1x penicillin/streptomycin and 2 mM glutamine was
added to each well to yield the usual FCS concentration of 10%. The cells were harvested
24 h after transfection.
3.2.3.7 Plasmid transient transfection of Ba/F3 cells by electroporation
Ba/F3 or Ba/F2-G4-Luc2P cells (grown to a cell density of 0.7-0.9 x 106 cells/mL) were
pelleted at 300 rcf for 5 min and washed once in RPMI 1640. 4 x 106 cells were mixed with
8-10 µg plasmid DNA in 800 µL RPMI 1640 and incubated for 10 min at RT. The cells
were transferred to a 4 mm gap electroporation cuvette, and a pulse of 320 V, 950 µF was
delivered using the exponential decay program of the Gene Pulser Xcell with CE module
(Bio-Rad). The pulsed samples were incubated for 5 min at RT and then transferred to
RPMI - based medium containing IL-3 where indicated but no selection antibiotics. The
incubation time until cell harvest depended on the downstream assay.
The only exception were transient transfections of Ba/F3 cells with the expression
vectors for pFA-CMV (P04), GAL4-STAT5A666 (P20) and GAL4-STAT5A709 (P05)
(Fig. 4.10B). They were performed as described for siRNA transfection (3.2.3.8), except
that per transfection 2 µg DNA were used instead of siRNA. For luciferase assays, 3 trans-
fections were performed per condition, and the cells were harvested 8 h after transfection.
For analysis of protein levels, 2 transfections were performed per condition, and the cells
were harvested 24 h after transfection.
3.2.3.8 siRNA transfection by electroporation
Ba/F3-1⇤6 cells were transfected with siRNA (Tab. 3.9) twice in an interval of 24 h.
48-72 h after the first transfection, the cells were harvested to analyze gene expression
and protein levels.
Ba/F3-1⇤6 cells, grown to a cell density of 0.7-0.9 x 106 cells/mL, were pelleted at
300 rcf for 5 min and washed once in PBS. Per transfection, 1 x 106 cells were resuspended
in 100 µL Gene Pulser Electroporation bu↵er (Bio-Rad) containing 0.5 µM (single knock-
down) or 0.6 µM (multiple knockdown) siRNA. The sample was transferred to a 1 mm
gap electroporation cuvette, and a pulse was delivered with the following parameters of
the Gene Pulser Xcell with CE module (Bio-Rad): square wave program, 95 V, 5 ms,
2 pulses, 0.1 s interval. The sample was transferred to a 6-well plate containing 3 mL
RPMI-based medium per well. After 24 h there were usually 1-1.2 x 106 cells per condi-
tion. The cells were washed and transfected again as described.
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48-72 h after the first transfection, the cells were harvested. One aliquot of each
sample was processed for gene expression analysis by quantitative RT-PCR (3.2.1.4).
The remaining cells were lysed for subsequent analysis of protein levels by western blot
(3.2.5.6).
3.2.4 Preparation of cell lysates
3.2.4.1 Whole-cell brij lysate
Cells were pelleted (2000 rcf, 1 min, 4 C) and washed once in PBS. 2 x 106 cells were
suspended in 40-50 µL Brij lysis bu↵er and kept on ice for 30 min. The lysate was
centrifuged at full speed (20000 rcf) for 10 min at 4 C, and the pellet was discarded. The
protein concentration of the lysate was determined by Bradford protein assay (3.2.5.1).
3.2.4.2 Freeze-thaw lysate for analysis of histone acetylation
Cells were pelleted (2000 rcf, 1 min, 4 C), washed once in PBS, and then suspended in
50 µL FT-bu↵er per 1 x 106 cells. In case the cells had been treated with deacetylase
inhibitors, the FT-bu↵er was supplemented with the same inhibitor concentrations. The
samples were subjected to three freeze-thaw cycles in liquid nitrogen and at 37 C respec-
tively. The MgCl2 concentration was adjusted to 5 mM, and DNaseI was added to yield a
concentration of 0.1 µg/µL. The samples were incubated for 45 min at 4 C on a rotating
wheel, adjusted to 1x La¨mmli loading dye, heated for 10 min at 95 C, and eventually
centrifuged at maximum speed (20000 rcf) for 15 min at 10 C to remove cell debris.
This lysis procedure extracts histones from chromatin so that they can be separated by
15% SDS-PAGE (3.2.5.2) and analyzed by western blot (3.2.5.6).
3.2.4.3 Nuclear and cytosolic lysate
1 x 107 cells were pelleted (350 rcf, 5 min, 4 C) and washed once in PBS. The cells
were washed once in bu↵er A with centrifugation at 350 rcf for 30 s at 4 C. Then, they
were resuspended gently in 200 µL bu↵er B until a homogenous suspension was obtained.
Bu↵er B disrupts the plasma membrane while leaving the nuclear envelope intact. The
nuclei were pelleted at 350 rcf, 30 s, 4 C, and the supernatant, representing the cytosolic
fraction, was collected. After a wash in bu↵er A (350 rcf, 30 s, 4 C), the nuclei were lysed
in 50 µL bu↵er C for 30 min on ice with occasional vortexing. Eventually, the nuclear
lysate was cleared by centrifugation at maximum speed (20000 rcf) for 15 min at 4 C.
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3.2.5 Protein analysis and methods
3.2.5.1 Protein quantification by Bradford protein assay
1 to 2 µL cell lysate (and the same volume of lysis bu↵er as a control) was mixed with
1 mL 1x Roti-Quant Bradford reagent in polystyrene cuvettes with 10 mm optical path-
way and incubated for at least 6 min at RT. In parallel, a standard curve was generated
by addition of 2 µg, 3 µg, 5 µg, 10 µg and 15 µg BSA to 1 mL 1x Bradford reagent each.
Absorbance was measured at 595 nm with a UV/Vis spectrophotometer (NanoPhotome-
ter P300, Implen). The protein content of the lysate was derived from the standard curve.
The value of the lysis bu↵er control was subtracted to obtain the corrected protein con-
centration of the lysates.
3.2.5.2 SDS - polyacrylamide gel electrophoresis (SDS-PAGE)
A discontinuous polyacrylamide gel was casted between gel plates with 0.75 mm, 1 mm
or 1.5 mm spacer (10- and 15-well: Mini-PROTEAN system from Bio-Rad, or 20-well
system: PeqLab Biotechnologie GmbH). It consisted of the upper stacking-gel containing
4% acrylamide, and the lower separating-gel containing 8 - 15% polyacrylamide (see
Table 3.1 for recipes). The protein lysate (3.2.4) was adjusted to 1x La¨mmli loading dye
and heated for 5 min at 95 C prior to loading on the polyacrylamide gel. In addition to
the samples, 3 µL prestained Protein Marker VI (AppliChem) was loaded onto the gel as
molecular weight protein marker. Application of voltage led to vertical separation of the
proteins according to their approximate molecular weight. The gel was run in La¨mmli
SDS running bu↵er for 15 min at 80 V and for ⇠1h at 180-200 V until the bromphenol
blue running front reached the end of the gel.
3.2.5.3 Coomassie staining
Proteins separated by SDS-PAGE (3.2.5.2) can be stained by incubating the polyacry-
lamide gel in Coomassie Blue staining solution for 30 min, followed by destaining of the
background through several changes of distilled H2O. The gel was dried on Whatman
paper in a gel dryer (Slab Dryer Model 483, Bio-Rad) for 1 h at 60 C under vacuum.
3.2.5.4 Semi-dry transfer of proteins
Semi-Dry transfer of proteins is a method to transfer the separated proteins from an
SDS-PAGE gel (3.2.5.2) onto a membrane for further protein-specific analysis.
The gel was equilibrated in Towbin/SDS transfer bu↵er for 5-10 min, depending on
the thickness of the gel. A PVDF membrane (Immobilon-P, 0.45 µm) was first soaked
47
CHAPTER 3. MATERIAL AND METHODS
in methanol, then in transfer bu↵er. Three transfer bu↵er-soaked Whatman papers were
placed on the anode plate of the Trans-Blot SD Semi-Dry Transfer Cell (Bio-Rad), fol-
lowed by the membrane, the gel, and again three soaked Whatman papers. The system
was closed with the cathode plate, and 24 V were applied for 1 h.
3.2.5.5 Ponceau staining
To verify consistent protein transfer from an acrylamide gel onto a membrane (3.2.5.4),
the membrane was stained by 2 min incubation with Ponceau S directly after the transfer.
The stained membrane was washed in H2O to remove the background stain and thus
visualize the protein bands. A wash in 5% dry skimmed milk in PBST finally destained
the membrane completely, so that the membrane could be used for western blot analysis
(3.2.5.6).
3.2.5.6 Western blot
Proteins in cell lysates (3.2.4) were separated by SDS-PAGE (3.2.5.2) and transferred
onto a PVDF membrane (3.2.5.4). The membrane was blocked in PBST + 5% w/v dry
skimmed milk for 30 min at RT, or O/N at 4 C. It was incubated with the primary
antibody diluted in PBST + 3% w/v dry skimmed milk for 1 h at RT, or O/N at 4 C.
After two 5 min and two 10 min washes in PBST, the membrane was incubated with the
secondary antibody diluted in PBST + 3% w/v dry skimmed milk for 1 h at RT. The
membrane was washed again as before.
As exception, the phospho-STAT5 specific antibody (AB06) required the use of
3% w/v BSA in TBST (instead of dry skimmed milk in PBST) for blocking of the
membrane and dilution of primary and secondary antibody. In that case the membrane
washes took place in TBST.
While the primary antibody bound the protein of interest, the secondary, horseradish
peroxidase-coupled antibody was directed against the IgG species of the respective pri-
mary antibody. A list of primary and secondary antibodies and their dilutions in western
blot can be found in Table 3.11 and Table 3.12.
The membrane was rinsed in distilled H2O prior to signal detection with the ECL
reagents Amersham ECL Prime (GE Healthcare) or SuperSignal West Femto Maximum
Sensitivity Substrate (Thermo Fisher Scientific) according to the manufacturer’s recom-
mendations. The membrane was incubated in the ECL reagent for 5 min. The prestained
protein marker bands were retraced using the phosphorescent PicTIXX Pluster & Lin-
erPen. Images were captured with an ImageQuant LAS 4000 mini imaging system (GE
Healthcare).
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3.2.5.7 Co-immunoprecipitation
For co-immunoprecipitation using non-crosslinked cells, 250 µg nuclear protein lysate
(3.2.4.3) from Ba/F3-tet-on-1⇤6 cells, which had been grown for 9 h in the presence of
1 µg/mL doxycycline and in the absence of IL-3, was adjusted to 625 µL with Brij bu↵er
(⇠1:10 dilution). The lysate was pre-cleared by rotating at 4 C for 1 h with 25 µL protein-
A sepharose beads (50% slurry containing 500 µg/µL fatty acid free BSA and 200 µg/µL
salmon sperm DNA). The beads were removed by centrifugation (500 rcf, 1 min, 4 C).
1.2 µg antibody was added to the pre-cleared lysate, followed by rotating at 4 C for 3 h
without, and for 2 h with 25 µ L protein-A sepharose beads (50% slurry as above). The
beads, containing the immunocomplexes, were pelleted (500 rcf, 1 min, 4 C), and the
supernatant (SN fraction) was collected. The beads were washed 3 times in 900 µL Brij
bu↵er and then boiled in 60 µL 2 x La¨mmli loading dye (bead fraction). 50% of the bead
fraction as well as 3% of supernatant and an equal amount of input (corresponding to
8 µg nuclear proteins) were separated by SDS-PAGE (3.2.5.2) and subsequently analyzed
by western blot (3.2.5.6).
Co-immunoprecipitation using formaldehyde-crosslinked cells was performed following
the ChIP (3.2.7) protocol with the following changes: Per immunoprecipitation nuclei
from 7 x 106 formaldehyde-crosslinked Ba/F3-1⇤6 cells, 2.4 µg anti-STAT5A, anti-BRD2
or rabbit IgG antibody, and 50 µL protein-A sepharose beads were used. 40% of the
washed immunocomplex-containing beads were boiled in La¨mmli loading dye and the
immunoprecipitated proteins were analyzed by western blot. In parallel to the bead
fractions, 3% supernatant and an equal amount of input were analyzed. 20% of the
washed beads were processed by ChIP protocol to analyze co-precipitated DNA by qPCR.
3.2.5.8 Gel filtration chromatography
Gel filtration chromatography was performed to analyze size-di↵erences of native STAT5-
containing protein complexes in nuclear lysate from deacetylase inhibitor-treated or un-
treated cells. First, nuclear lysate was prepared from 5 x 107 TSA- or vehicle-treated
Ba/F3-1⇤6 cells as described in 3.2.4.3. The nuclear lysate was dialyzed in collodion
bags against 250 mL GF bu↵er. For dialyzes of TSA-treated samples, the GF bu↵er was
supplemented with 20 nM TSA. After 50 min dialyzes, the conductivity of the samples
was similar as the conductivity of fresh GF bu↵er, indicating that dialysis was su cient.
The volume of the lysate was adjusted to 600 µL with GF bu↵er (20 nM TSA was added
for TSA-treated samples) and cleared from cell debris by centrifugation (13000 rpm,
15 min, 4 C). 500 µL of the cleared lysate was loaded onto an A¨KTA FPLC system (GE
Healthcare) with TSK Gel 4000SW column (Tosoh Bioscience). Protein separation was
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performed at a flow rate of 0.5 mL/min in GF bu↵er (+ 20 nM TSA for TSA-treated sam-
ples). 30 x 500 µL elution fractions were collected and analyzed by western blot. Purified
thyroglobulin (669 kDa) and BSA (66 kDa) were analyzed in a separate chromatogra-
phy run and served as molecular weight protein markers. Gel filtration chromatography
experiments were performed at the institute of Biochemistry III of the University of
Regensburg with the support of Dr. Joachim Giesenbeck.
3.2.6 Dual-luciferase reporter assay
Cos-7 cells were transiently co-transfected with 125 ng GAL4-STAT5A expression vector
(pFA-CMV based vectors, see Table 3.8), 1 µg pGL4.35 (Firefly luciferase reporter, P66)
and 1.5 ng phRL-CMV (constitutive Renilla luciferase reporter, P49). pGL4.35 contains
9 repeats of the GAL4 UAS, which can be bound by the GAL4 moiety (yeast GAL4
DNA binding domain, amino acids 1-147) of the GAL4-STAT5A fusion proteins and thus
drive expression of the Firefly luciferase reporter gene. phRL-CMV shows constitutive
Renilla luciferase expression and serves as internal control reporter. Cos-7 transfection
by Lipofectamine 2000 was performed as described in 3.2.3.6. 24 h after transfection, the
cells were washed once in ice-cold PBS, before addition of 100 µL PLB, and lysis during
a 5 min incubation on a shaker at RT.
Ba/F3 cells were transiently co-transfected by electroporation (3.2.3.7) with a plasmid
mix consisting of 1 µg FLAG-tagged STAT5A expression vector (pcDNA3-based vectors,
see Table 3.8), 8 µg Firefly luciferase reporter (pGVB-based vectors, P103, P106, P111)
and 0.15 µg constitutive Renilla luciferase reporter (pRL-null, P50). pRL-null, like phRL-
CMV, shows constitutive Renilla luciferase expression and thus serves as internal control
reporter upon co-transfection with a STAT5-inducible pGVB-based Firefly luciferase re-
porter containing a Cis (P103 and P106) or  -casein (P111) promoter. For luciferase
assays with GAL4-STAT5A fusion proteins, Ba/F3 cells were transiently co-transfected
with 1.3 µg GAL4-STAT5A expression vector (pFA-based vectors, see Table 3.8), 0.5 µg
pGL4.35 Firefly luciferase reporter (P66), and 0.2 µg pRL-null (P50, constitutive Renilla
luciferase reporter). Ba/F3-G4-Luc2P cells were transiently transfected with 10 µg ex-
pression vector for GAL4-STAT5A fusion proteins (pFA-CMV based vectors, see Table
3.8) and 10 ng phRL-CMV. 8-24 h after transfection, as indicated in the figure legends,
the Ba/F3 or Ba/F3-G4-Luc2P cells were harvested by centrifugation at 200 rcf for 5 min
at 4 C. The cells were washed in 1 mL PBS, pelleted at 2000 rcf for 1 min at 4 C and
resuspended in 35-75 µL passive lysis bu↵er (PLB, Promega Dual-Luciferase Reporter
Assay) with or without 10 mM NaF and 1 mM Na3VO4. The cells were lysed by shaking
for 10 min at RT in a thermo-mixer. The lysate was cleared by centrifugation at 20000 rcf
for 3 min at 4 C.
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Luciferase activity of the Ba/F3, Ba/F3-G4-Luc2P, or Cos-7 PLB-lysates was ana-
lyzed with the Dual-Luciferase Reporter Assay System (Promega) as recommended by
the manufacturer. Protein concentration of the lysates was determined by Bradford pro-
tein assay (3.2.5.1). Equal protein amounts were plated in the wells of a black 96-well
plate, and all volumes were adjusted to 20 µL with PLB. Each reaction was performed
in duplicate. Using a double-injector luminometer (GloMax 96 Microplate Luminometer,
Promega), 100 µL of LARII as well as Stop& Glo reagent were dispensed to the lysate,
followed by 2 s measurement delay, and 10 s read time after each reagent addition.
After subtraction of the background luminescence measured with PLB bu↵er, Fire-
fly luciferase RLUs were normalized to the Renilla luciferase internal control reporter.
Eventually, data was represented as fold induction relative to the sample transfected with
the corresponding empty vector (pcDNA3 or pFA-CMV). All samples were measured in
duplicate and data shown are mean + standard deviation from one representative of at
least two independent experiments.
3.2.7 Chromatin immunoprecipitation (ChIP)
For chromatin-crosslinking, 1% formaldehyde was added directly to the culture medium
of 50 x 106 Ba/F3-1⇤6 cells, followed by incubation for 10 min at RT. To stop the
crosslinking, glycine was added to a final concentration of 125 mM. After 5 min incubation
at RT, the cells were pelleted at 2000 rcf for 2 min at 4 C and washed twice in ice-cold
PBS.
To enrich for nuclei of formaldehyde-crosslinked Ba/F3-1⇤6 cells, a protocol was es-
tablished based on a publication by Me´tivier et al. (2003). The crosslinked cells were
resuspended by vortexing in 1 mL cell collection bu↵er (CBB). The samples were incu-
bated for 15 min on ice, vortexed, incubated for 15 min at 30 C and again vortexed.
After centrifugation at 2000 rcf for 1 min at 4 C, the supernatant was aspirated, while
the nuclei pellet was washed first in 1 mL bu↵er MA and then in 1 mL bu↵er MB. In
each bu↵er, the pellet was resuspended by vortexing (Fig. 3.1A).
A protocol from Okada & Fukagawa (2006), describing chromatin-fragmentation by
MNase digest, was adapted for formaldehyde-crosslinked Ba/F3-1⇤6 nuclei. First, the
nuclei were sonicated in 1 mL HDG 150 bu↵er in the absence of SDS with a Branson
Sonifier 250 (Branson) and 3 mm microtip in an ice-bath. 6 pulses of 20 sec duration/
40 sec pause were delivered at 50% duty cycle and output setting 3, leading to a limited
shearing of DNA to fragments of more than 10 kb length (Fig. 3.1B and data not shown).
The CaCl2 concentration was adjusted to 3 mM, and the chromatin was digested during
a 1 h rotation at 4 C using 0.25 U micrococcal nuclease (MNase) per 1x 106 cells to
obtain DNA fragments of about 500 bp length (Fig. 3.1B). The MNase (Sigma N-3755)
51
CHAPTER 3. MATERIAL AND METHODS
IgG STAT5 IgG STAT5
Sonication MNase
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5 ChIP Cis
STAT5 bs (C)
ORF (I)
%
 i
n
p
u
t 
D
N
A
Sonication: -
MNase:
SupernatantP
Ba/F3-1*6
3 N
2 N
1 N
+ + + + + +
- - -
Inp
1000 bp
500 bp
400 bp
300 bp
200 bp
100 bp
Ba/F3-1*6C
Cyt. Nucl.
90 kDa
65 kDa
55 kDaα-tubulin
FLAG
HDAC1
B
Ba/F3-1*6A
Figure 3.1: DNA fractionation by MNase digest instead of sonication strongly improves
the detection of STAT5 binding to DNA by ChIP.
(A) Nuclei from formaldehyde-crosslinked Ba/F3-1⇤6 cells were prepared as described in the ChIP proto-
col (Material and methods 3.2.7). An aliquot of nuclear (Nucl.) as well as cytosolic (Cyt., supernatant in
CBB bu↵er) fraction was analyzed by western blot using antibodies directed against the nuclear marker
HDAC1 and the cytosolic marker ↵-tubulin to verify cell fractionation e ciency. In addition, an anti-
body directed against the FLAG tag of STAT5A-1⇤6 was used to monitor STAT5A-1⇤6 expression and
to confirm that this protein of interest is present in the analyzed nuclear fraction. (B) Optimization of
MNase-based DNA digest for ChIP. Nuclei from formaldehyde-crosslinked Ba/F3-1⇤6 cells were sonified
in HDG 150 bu↵er and digested with increasing amounts of MNase, as described in the ChIP protocol
(Material and methods 3.2.7). The MNase amount was 0.125, 0.25, 0.5 and 1 U MNase per 1 x 106 cells.
Before the MNase digest, the samples had been spun at 20 000 rcf for 10 min at 4 C. The supernatant
was subjected to MNase digest. MNase digested supernatant, the pellet (P) from the centrifugation step
and non-sonified input (Inp) were treated with 0.1 µg/µL proteinase K in the presence of 0.06 µg/µL
glycogen during a 3.5 h incubation at 55 C. The formaldehyde crosslink was reversed O/N at 65 C. DNA
was isolated by phenol extraction (Material and methods 3.2.1.5) and subjected to ethanol precipitation
(Material and methods 3.2.1.6). 1 µg/µL RNase A was added and RNA was digested for 60 min at
37 C. All samples were analyzed in parallel to a 100 bp DNA ladder (reference marker) by agarose gel
electrophoresis as described in Material and methods 3.2.1.11. 0.25 U MNase per 1x 106 cells was the
optimal condition for the ChIP protocol. 1N, mono-nucleosome; 2N di-nucleosome; 3N tri-nucleosome.
(C) Nuclei from Ba/F3-1⇤6 cells were isolated according to the optimized ChIP protocol, as described
in Material and methods (3.2.7). DNA was either fragmented by MNase digest after sonication in HDG
150 bu↵er according to the ChIP protocol or DNA was fragmented by sonication. In the latter case,
the sonication took place in SDS bu↵er (instead of HDG 150 bu↵er) using the sonication parameters
described in the protocol, and the MNase digest was omitted. The DNA fragments were about 500 bp of
size. STAT5 was immunoprecipitated using 3 µg STAT5 plus 3 µg STAT5A antibody. The rabbit-IgG
control antibody served to determine the background signal. Co-precipitated DNA of the Cis locus was
detected by qPCR using primers specific for the STAT5 binding site (bs) (amplicon C) or for the distal
open reading frame (ORF) (amplicon I). The location of the respective amplicons C and I along Cis is
depicted in Figure 4.17. (Figure modified after Pinz & Rascle (2017) fig. 1 and fig. 2.)
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was reconstituted in MNase Reconstitution bu↵er and stored at -20 C. The calcium ion-
dependent DNA digest was stopped through addition of EGTA to a final concentration
of 5 mM. The cell concentration was adjusted to 0.01 x 106 cells/µL with IP bu↵er,
and the samples were rotated for 20 min at 4 C. The lysate was cleared from debris by
centrifugation at 3220 rcf for 10 min at 4 C.
For preclearing of the lysate, 500 µL protein-A sepharose beads (50% slurry containing
500 µg/µL fatty-acid-free BSA and 200 µg/µL salmon sperm DNA) were added per
50 x 106 cells, and the samples were rotated for 1 h at 4 C. The samples were spun at
500 rcf for 1 min at 4 C and the pelleted beads were discarded. For immunoprecipitation,
precleared lysate from 3.5 x 106 cells was used and adjusted to 500 µL with IP bu↵er.
1.2 µg anti-STAT5A, 3 µg anti-BRD2 or 3 µg rabbit IgG antibody were added, and the
samples were rotated for 3 h at 4 C. 25 µL protein-A sepharose beads (50% slurry, as
above) were added, followed by another 2 h rotation at 4 C. The beads were pelleted at
500 rcf for 1 min at 4 C, and the supernatant was aspirated. The beads were washed in
900 µL of each of the following bu↵ers: IP bu↵er, 150 mM NaCl wash bu↵er, 500 mM
NaCl wash bu↵er, LiCl wash bu↵er and TE. In 500 mM NaCl wash bu↵er and LiCl wash
bu↵er, the beads were rotated for 5 min at 4 C.
In parallel to the ChIP samples, 20 µL of the precleared lysate was processed as input
sample from this step on. 120 µL 1%SDS, 0.1 M NaHCO3 and 6 µL 5 M NaCl were
added to the ChIP samples. 100 µL 1%SDS, 0.1 M NaHCO3 and 6 µL 5 M NaCl were
added to the input. All samples were incubated O/N at 65 C to reverse the crosslinking.
The beads were pelleted at 500 rcf, for 1 min at 4 C. 30 µg RNase A was added to the
supernatants, and they were incubated for 1-2 h at 37 C. 50 µg Proteinase K was added,
followed by 1-2 h incubation at 55 C.
The DNA was purified with MN nucleospin PCR clean-up kit and MN NTB bu↵er
(both from MACHEREY-NAGEL). 600 µL NTB bu↵er was added to each sample, which
was then loaded onto the purification column. It was proceeded as recommended by the
manufacturer. Elution was performed twice with 50 µL pre-warmed (70 C) bu↵er NE.
200 µL H2O was added to each ChIP sample, while the input samples were diluted with
600 µL H2O and 200 µL bu↵er NE.
Eventually, the samples were analyzed by quantitative PCR in duplicate or trip-
licate on a RotorGene Q (Qiagen) (3.2.1.3), using primers listed in Table 3.4. Co-
immunoprecipitated DNA was calculated as percentage of total input DNA. Data from
one representative experiment are shown as mean +/- standard deviation of the qPCR
performed in duplicate or triplicate.
This optimized ChIP protocol, which combines nuclei isolation and MNase digest-
based DNA fractionation, improved the detection of STAT5 binding to DNA, as mani-
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fested in the increased amount of co-precipitated DNA (% input) and in the increased
enrichment relative to IgG background (Fig. 3.1C). A detailed description of this opti-
mized ChIP protocol has been recently published (Pinz & Rascle, 2017).
3.2.8 Sequence alignments
Human and mouse STAT3 (accession No. NP 644805.1 and AAL59017.1), STAT5A (ac-
cession No. NP 001275647.1 and AAF78237.2) and STAT5B (accession No. NP 036580.2
and AAF62911.2) multiple sequence alignment of the region covering K675-K700 of
STAT5A was performed using the online tool Clustal Omega (version 1.2.1) with preset
standard settings.
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Results
4.1 Characterization of the experimental system
4.1.1 Deacetylase inhibitors repress STAT5 target gene expres-
sion in Ba/F3 and Ba/F3-1⇤6 cells
To study the mechanism of deacetylase inhibitor-induced repression of STAT5-mediated
transcription, the IL-3-dependent mouse pro-B cell line Ba/F3 was used. Its proliferation
and survival depends on interleukin-3 (IL-3) and the subsequent activation of STAT5
(Rodriguez-Tarduchy et al., 1990; Nelson et al., 2004). By removing IL-3 from the cul-
ture medium of Ba/F3 cells, the STAT5 pathway is turned o↵. Addition of IL-3 to those
IL-3-withdrawn, rested cells activates the STAT5 pathway and induces the expression of
STAT5 target genes. Treatment of Ba/F3 cells with deacetylase inhibitors such as tri-
chostatin A (TSA) represses STAT5 target gene induction upon IL-3 stimulation (Rascle
et al., 2003). Thus, this system is well suited to study the mechanism of deacetylase
inhibitor-induced repression of STAT5-mediated transcription.
In addition to Ba/F3 cells, the IL-3-independent Ba/F3-1⇤6 cell line was used, which
stably expresses the well-described constitutively active mouse STAT5A-1⇤6 mutant (On-
ishi et al., 1998). STAT5A-1⇤6 carries two point mutations (H298R and S710F), which
make its activation independent of cytokine signaling (Onishi et al., 1998). The advantage
of this cell line is the IL-3-independent, constitutive expression of STAT5 target genes.
By contrast, in the parental Ba/F3 cell line growing in the presence of IL-3, basal expres-
sion of STAT5 target genes is low (data not shown) and IL-3 withdrawal followed by IL-3
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stimulation is needed to stimulate expression of STAT5 target genes. However, whether
deacetylase inhibitors repress STAT5A-1⇤6-mediated expression of STAT5 target genes
has not been shown so far.
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Figure 4.1: TSA inhibits the transcriptional activity of wild-type STAT5 and of constitu-
tively active STAT5A-1⇤6
Rested Ba/F3 cells were pre-treated for 30 min with 200 nM TSA and then stimulated for 60 min with
IL-3 (in total 90 min TSA treatment). Ba/F3-1⇤6 cells, expressing constitutively active STAT5A-1⇤6,
received 90 min treatment with 200 nM TSA. RNA and cDNA were prepared and analyzed by quanti-
tative RT-PCR as described in Material and methods 3.2.1.4, using primers for the STAT5 target genes
Cis and c-Myc as well as for the housekeeping gene 36b4. Vehicle was 0.02% DMSO.
To confirm that STAT5A-1⇤6-mediated transcription is sensitive to deacetylase in-
hibitors, Ba/F3-1⇤6 cells were treated with the deacetylase inhibitor trichostatin A (TSA)
or vehicle (dimethyl sulfoxide (DMSO)) for 90 min. Expression of the STAT5 target genes
Cis and c-Myc (Matsumoto et al., 1997; Pinz et al., 2016) as well as the housekeeping gene
36b4 was analyzed at the RNA level by cell lysis and RNA stabilization followed by cDNA
synthesis and quantitative PCR (quantitative RT-PCR) (Fig. 4.1). Gene expression of
the housekeeping gene 36b4 served as a negative control (Rascle et al., 2003) throughout
this study. Its expression should not change in response to experimental factors such
as deacetylase inhibitors or IL-3 stimulation. Ba/F3 cells, and thus wild-type STAT5,
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served as a positive control for TSA-sensitivity. Ba/F3 cells were first withdrawn from
IL-3 to turn o↵ the STAT5 pathway, then pre-treated with TSA or vehicle for 30 min, and
finally stimulated with IL-3 for 60 min to activate STAT5. In Ba/F3-1⇤6 cells, similarly
as in Ba/F3 cells, expression of the STAT5 target genes Cis and c-Myc were downreg-
ulated upon TSA treatment, while, as expected, the housekeeping gene 36b4 remained
una↵ected (Fig. 4.1). This demonstrates, that STAT5A-1⇤6-mediated transcription is
similarly sensitive to TSA as transcription mediated by wild-type STAT5.
Our group demonstrated before that upon deacetylase inhibitor treatment DNA bind-
ing of wild-type STAT5 is not a↵ected but that RNA polymerase II is lost from STAT5
target genes in Ba/F3 cells (Rascle et al., 2003; Rascle & Lees, 2003). We could now
confirm that DNA binding of STAT5A-1⇤6 was also una↵ected by deacetylase inhibitor
treatment and that RNA polymerase II was also lost from the STAT5 target gene Cis in
Ba/F3-1⇤6 cells (Fig. 4.19A and data not shown, Dr. Anne Rascle and Samy Unser, Pinz
et al., 2015, fig. 1). Together, these data confirm that STAT5A-1⇤6 and wild-type STAT5
behave similarly in response to TSA and that the Ba/F3 and the Ba/F3-1⇤6 cell line are
good model systems to investigate how deacetylase inhibitors repress STAT5-mediated
transcription.
4.2 Identification of the HDAC involved in
deacetylase inhibitor-mediated inhibition of
STAT5-mediated transcription
Our group demonstrated before that STAT5-mediated transcription is inhibited by the
deacetylase inhibitors trichostatin A (TSA), suberoylanilide hydroxamic acid (SAHA)
and sodium butyrate (Rascle et al., 2003). These inhibitors are pan-inhibitors targeting
all eleven classical HDACs, HDAC1-11, from classes I, IIA, IIB and IV (Witt et al.,
2009), suggesting that one or several of those classical HDACs (referred to as HDAC(s)
thereafter) are involved in STAT5-mediated transcription. The first goal of this study
was to identify the HDAC among the eleven family members which is involved in STAT5-
mediated transcription and responsible for the inhibitory e↵ect of deacetylase inhibitors.
4.2.1 Selective deacetylase inhibitors di↵erentially impair
STAT5-mediated transcription
To identify HDAC candidates possibly involved in inhibition of STAT5-mediated tran-
scription, several selective deacetylase inhibitors were tested for their ability to inhibit
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induction of STAT5 target gene expression in IL-3-stimulated Ba/F3 cells. Inhibition of
gene expression by deacetylase inhibitors can be observed best when the analyzed IL-3-
dependent genes are well induced. Therefore, to determine the optimal IL-3 stimulation
duration to analyze the e↵ect of deacetylase inhibitor treatment in our cells, the gene
induction profiles of STAT5 target and control genes was determined. STAT5 target
genes with early, sustained (Cis and c-Myc), early, transient (Osm), and late, sustained
(Spi2.1 ) IL-3 induction profile were chosen (Rascle et al., 2003; Basham et al., 2008).
The IL-3-inducible, STAT5-independent control genes JunB and c-Fos are early, tran-
sient genes (Rascle et al., 2003), while the control gene Spp1 (osteopontin) is a late
IL-3-induced gene. Spp1 expression begins to increase at about 2 h IL-3 stimulation in
Ba/F3- derived Ba/F3-  cells (Rascle et al., 2003), and Spp1 is expressed within 3 h
IL-3 stimulation in primary IL-3-dependent mouse bone marrow cells (Lin et al., 2000).
The housekeeping gene 36b4 served as a negative control, since its expression should not
change in response to any experimental factors such as IL-3 (Rascle et al., 2003).
Rested Ba/F3 cells (withdrawn from IL-3 to turn o↵ the STAT5 pathway) were stimu-
lated with IL-3 for 0.5, 1 or 2 hours or left unstimulated and gene expression was analyzed
by quantitative RT-PCR as described above. All genes behaved as expected (Rascle et al.,
2003; Basham et al., 2008). The STAT5 target genes Cis, c-Myc and Osm were well in-
duced and Spi2.1 was significantly induced after 1 h IL-3 stimulation (Fig. 4.2A). After 1 h
stimulation the IL-3-inducible, MAPK-regulated control genes c-Fos and JunB showed
partial and maximal induction respectively (Fig. 4.2B). The IL-3-inducible but late re-
sponding gene Spp1 and the housekeeping gene 36b4 did not change their expression
levels in the course of this experiment (Fig. 4.2B and C). In summary, all IL-3-inducible
STAT5 target genes and all IL-3-inducible control genes except for the late responding
Spp1 were well induced after 1 h IL-3 stimulation. Consequently, 1 h IL-3 stimulation
was used for the following study investigating the e↵ect of deacetylase inhibitors on the
expression of these genes.
To narrow down the HDAC candidates possibly involved in inhibition of STAT5-
mediated transcription, deacetylase inhibitors from di↵erent chemical classes and with
di↵erent HDAC selectivity were chosen for the following experiments. The selective
deacetylase inhibitor valproic acid (VPA) is a carboxylic acid (Gottlicher et al., 2001;
Phiel et al., 2001), apicidin is a cyclic peptide (Darkin-Rattray et al., 1996; Han et al.,
2000), and MS-275 (Saito et al., 1999; Suzuki et al., 1999) as well as MGCD0103 (Four-
nel et al., 2008) contain a benzamide group mediating deacetylase inhibition. All these
inhibitors inhibit predominantly class I HDACs with di↵erent selectivity towards the
members of this class. In addition, they inhibit some non-class I HDACs (Gurvich et al.,
2004; Hess-Stumpp et al., 2007; Khan et al., 2008; Arts et al., 2009). Their di↵erent se-
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Figure 4.2: Expression profile of STAT5 target genes and control genes in Ba/F3 cells upon
IL-3 stimulation
Ba/F3 cells were rested for 6 h before stimulation with IL-3. Cells were harvested at 0, 0.5, 1 and 2 hours
IL-3 stimulation, and expression of STAT5 target genes and control genes was analyzed by quantitative
RT-PCR. Primers were used, specific for the STAT5 target genes Cis, c-Myc, Osm and Spi2.1 (A), for
the IL-3-inducible control genes JunB, c-Fos and Spp1 (late induced gene, expression starts to increase
at about 2 h IL-3 stimulation in Ba/F3-derived cells (Rascle et al., 2003))(B), or for the housekeeping
gene 36b4 (C). Since all genes were well expressed after 1 h IL-3 stimulation, this stimulation duration
was chosen for the analysis of the inhibitory e↵ect of deacetylase inhibitors on these genes.
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lectivity will allow us, by combination of the data from all inhibitors, to more specifically
identify the HDAC possibly involved in inhibition in STAT5-mediated transcription. The
pan-inhibitor TSA (Yoshida et al., 1990; Khan et al., 2008), a hydroxamic acid, was used
as a positive control, since our group showed before that it inhibits STAT5-mediated
transcription (Rascle et al., 2003).
The inhibitory potency of a substance can be described by the half maximal inhibitory
concentration (IC50), which is the inhibitor concentration required to inhibit a biological
process by 50% (Cheng & Pruso↵, 1973). The reported IC50 of deacetylase inhibitors
towards di↵erent HDACs have to be taken with caution as they were obtained in vitro
for purified recombinant human HDACs (Gurvich et al., 2004; Khan et al., 2008; Arts
et al., 2009), while this study was conducted in a murine cell line. Furthermore, IC50
values of deacetylase inhibitors vary a lot between some publications (Fournel et al., 2008;
Khan et al., 2008; Estiu et al., 2010), probably a consequence of di↵erent experimental
conditions during determination of HDAC activity such as HDAC protein source, type of
substrate, as well as pre-incubation time with the inhibitor (Chou et al., 2008; Delcuve
et al., 2012; Vaidya et al., 2012; Hull et al., 2016). Therefore, IC50 values reported by a
single study (Khan et al., 2008) were used as a reference (Tab. 4.1A). To complement
inhibitor/HDAC combinations not tested in the study by Khan et al. (2008), IC50 values
from other publications were used where available (Gurvich et al., 2004; Hess-Stumpp
et al., 2007; Arts et al., 2009) and marked with an asterisk in Table 4.1. Table 4.1 depicts
the inhibitory potency of the chosen deacetylase inhibitors against HDAC1-11 relative
to the respective most sensitive HDAC determined by Khan et al. (2008). The IC50
for HDACs in the group ”strong inhibition” (black) is less than 5 times the IC50 of the
most sensitive HDAC. For the group ”weak inhibition” (dark gray) the IC50 is more than
5 times the IC50 of the most sensitive HDAC and the group ”no inhibition” (light gray)
contains HDACs for which the IC50 is more than 100 times the IC50 of the most sensitive
HDAC. To narrow down the possible candidate HDACs involved in STAT5-mediated
transcription, a concentration of 5 to 10 times the IC50 of the most sensitive HDAC was
selected as a reference concentration for each inhibitor (Fig. 4.3, dashed bars).
To evaluate the e↵ect of the selected deacetylase inhibitors on STAT5-mediated tran-
scription, increasing concentrations of VPA, apicidin, MGCD0103 and MS-275 were
added to rested Ba/F3 cells 30 min before IL-3 stimulation. The inhibitor concentra-
tions were minimally 0.3 times and maximally 100 times the IC50 of the most sensitive
HDAC. TSA treatment was used as a positive control. After 1 h IL-3 stimulation, expres-
sion of STAT5 target and control genes was evaluated at the RNA level by quantitative
RT-PCR (Fig. 4.3). Similarly to the pan-inhibitor TSA (Fig. 4.3A and Rascle et al.,
2003), the selective inhibitors VPA and apicidin specifically inhibited the STAT5 target
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Class I Class IIA Class IIB Class IV
HDAC1 HDAC2 HDAC3 HDAC8 HDAC4 HDAC5 HDAC7 HDAC9 HDAC6 HDAC10 HDAC11
pan-inhibitor:TSA 2 3 4 456 6 nd 5 6 3 12* nd nM
VPA 1.6 3.1 3.1 7.4 1.5* 1.0* * nd mM
Apicidin 120 43 575 nd nd nd nM
MGCD0103 34 34 998 * * 195* nM
MS-275 181 1155 2311 nd 505 * nd nM
 IC
50 unit of
IC
50
selective
inhibitors:
 Class I Class IIA Class IIB Class IV
HDAC1 HDAC2 HDAC3 HDAC8 HDAC4 HDAC5 HDAC7 HDAC9 HDAC6 HDAC10 HDAC11
pan-inhibitor:TSA nd * nd +
VPA * * * nd +
Apicidin nd nd nd +
MGCD0103 * * * -
MS-275 nd * nd -
   stong inhibition    weak inhibition    no inhibition nd    no data available
* data from other publications than Khan et al. (2008)
possible candidate for involvement in STAT5 transactivation
Inhibition
of STAT5
selective
inhibitors:
A
B
Table 4.1: HDAC inhibition profile of selective deacetylase inhibitors
The table was adapted according to Witt et al. (2009), using IC50 values from Khan et al. (2008) as a
reference (A). For HDACs that were not tested by Khan et al. (2008), IC50 values from other publications
(Gurvich et al., 2004; Hess-Stumpp et al., 2007; Arts et al., 2009) were used and marked with an asterisk.
The reported IC50 values were determined in vitro using recombinant human HDACs. The IC50 of the
most sensitive HDAC is underlined and displayed in bold (A). The inhibitory potency of deacetylase
inhibitors relative to the most sensitive HDAC is depicted by gray scale. Strong inhibition: the IC50
is less than 5 times the IC50 of the most sensitive HDAC. Weak inhibition: the IC50 is more than 5
times the IC50 of the most sensitive HDAC. No inhibition: IC50 is more than 100 times the IC50 of
the most sensitive HDAC. The last column in (B) indicates whether STAT5 target gene expression
is inhibited (+), or not (-) by deacetylase inhibitors at a concentration of 5-10 times the IC50 of the
most sensitive HDAC. For inhibitors repressing STAT5 target genes, all strongly inhibited HDACs were
considered as potential candidates and indicated by a check mark in (B). For inhibitors which had no
e↵ect on STAT5-mediated transcription, all weakly and all not inhibited HDACs were considered as
potential candidates and indicated by a check mark. HDACs for which there was no data available
were considered apriori as potential candidates. Those HDACs which were candidates for inhibition of
STAT5-mediated transcription by combining the results from all deacetylase inhibitor experiments are
highlighted by columns framed in bold gray (B).
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Figure 4.3: Selective deacetylase inhibitors a↵ect expression of STAT5 target genes di↵er-
entially
6 h-rested Ba/F3 cells were pre-treated for 15 min with the indicated concentrations of the pan-inhibitor
TSA (A) or for 30 min with the indicated concentrations of the selective deacetylase inhibitors VPA
(B), apicidin (C), MGCD0103 (D) and MS-275 (E). IL-3 was added to the pre-treated cells and the
cells were stimulated for 60 min before analysis of gene expression by quantitative RT-PCR as described
in Material and methods 3.2.1.4, using expression primers for the STAT5 target genes Cis, c-Myc, Osm
and Spi2.1 or for the control genes JunB, c-Fos, SppI and 36b4. All samples in (A), (C) and (D) were
adjusted to 0.02% DMSO. In (B), no DMSO was added since VPA was solved in H2O. In (E) DMSO was
adjusted to 0.02% for 0-5 µM MS-275 and to 0.08% DMSO for 20 µM MS-275. The dashed bar indicates
an inhibitor concentration of 5-10x the IC50 of the most sensitive HDAC, as determined by Khan et al.
(2008) in in vitro deacetylation assays, except for MGCD0103 where a concentration of 15x the in vitro
IC50 of the most sensitive HDAC is marked.
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genes Cis, c-Myc, Osm and Spi2.1, upregulated the control gene c-Fos and left JunB,
Spp1 and 36b4 una↵ected (Fig. 4.3B and C). MS-275 and MGCD0103, by contrast,
were no inhibitors of STAT5 target genes under these experimental conditions (Fig. 4.3D
and E). They did not or only marginally a↵ect expression of STAT5 target or control
genes. The housekeeping gene 36b4 remained una↵ected in all conditions (Fig. 4.3A-E),
indicating that the observed inhibitory e↵ect was not the result of unspecific transcrip-
tional inhibition or the result of toxicity. If STAT5 transcriptional activity was inhibited
at the reference concentration of 5 to 10 times the IC50 of the most sensitive HDAC
(Fig. 4.3, dashed bars), which was the case for TSA, VPA, and apicidin, all HDACs
of the category ”strong inhibition” were considered as possible candidates and indicated
by a check mark in Table 4.1B. For MGCD0103 and MS-275, which were ine↵ective at
the reference concentration, HDACs of the category ”strong inhibition” were excluded as
possible candidates, and all HDACs of the categories ”weak inhibition” or ”no inhibition”
remained possible candidates. In case no data were available for certain inhibitor/HDAC
combinations, the respective HDACs were considered apriori as possible candidates. Af-
ter combining the data from all inhibitors, HDAC3, HDAC5, and HDAC11 were the
most likely candidates for involvement in inhibition of STAT5-mediated transcription
(Table 4.1B, columns framed in bold gray).
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Figure 4.4: Sirtuin targeting drugs do not a↵ect expression of the STAT5 target gene Cis
6 h rested Ba/F3 cells were pre-treated for 30 min with 50, 100 and 200 M of the sirtuin inhibitor
salermide (A) or 10, 50 and 100 M of the sirtuin activator resveratrol (B).The pre-treated cells were
further stimulated with IL-3 for 60 min before analysis of gene expression by quantitative RT-PCR using
expression primers for the STAT5 target gene Cis or the housekeeping gene 36b4, as described in Material
and methods 3.2.1.4. The final DMSO concentration was adjusted to 0.04% in (A) and to 0.02% DMSO
in (B).
Next to the classical HDACs (HDAC class I, II and IV) discussed so far, sirtuins con-
stitute class III histone deacetylases. They use an NAD+-dependent catalytic mechanism
for deacetylation of target proteins and are therefore inhibited by other small molecules
than the classical divalent metal ion-dependent HDACs (Mai et al., 2005; Nechay et al.,
2016). For instance, the small molecule salermide is a sirtuin inhibitor (Lara et al., 2009),
and resveratrol is a sirtuin activating drug (Howitz et al., 2003). To confirm that sirtuins
are not involved in STAT5-mediated transcription, the e↵ect of the sirtuin-targeting drugs
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salermide and resveratrol on expression of the STAT5 target gene Cis was analyzed. The
housekeeping gene 36b4 was analyzed as a negative control (Fig. 4.4). At concentrations
at which they were described to be e↵ective (Howitz et al., 2003; Kaeberlein et al., 2005;
Lara et al., 2009), neither the sirtuin inhibitor salermide, nor the sirtuin activator resver-
atrol showed an e↵ect on the expression of Cis or 36b4 (Fig. 4.4A and B). Thus, in this
experimental setting a role of sirtuins in STAT5-mediated transcription can be excluded.
4.2.2 Inhibition of STAT5-mediated transcription by deacety-
lase inhibitors in Ba/F3 cells is not due to cytotoxicity
Although deacetylase inhibitors did not a↵ect expression of the housekeeping gene 36b4
and showed di↵erential e↵ects on gene expression of the other analyzed genes, it cannot
be excluded that these e↵ects on gene expression are due, at least in part, to cell toxic-
ity. To confirm that the inhibitory e↵ect of the deacetylase inhibitors on STAT5 target
gene expression was not a consequence of cytotoxicity, WST-1 cytotoxicity assays were
performed. The WST-1 assay is based on cellular mitochondrial dehydogenases, whose
activity correlates with the metabolic activity of the cell, and which cleave the WST-1
tetrazolium salt to a reaction product with strong absorption of light at a wavelength
of 450 nm. Cytotoxic compounds reduce the activity of mitochondrial dehydrogenases
and thus lead to less WST-1 cleavage and absorbance at 450 nm. The percentage of
cytotoxicity was calculated relative to vehicle control (0% cytotoxicity) and to a positive
control (1% Triton-X-100 treatment, 100% cytotoxicity).
Rested Ba/F3 cells were pre-treated with increasing concentrations of deacetylase
inhibitors. The highest inhibitor concentration was either equivalent to (TSA, VPA,
apicidin) or 5 times higher (MGCD0103 and MS-275) than in the gene expression studies
(Fig. 4.3). 4-100 µM ↵-bromo-2’,3,4,4’-tetramethoxychalcone (↵-Br-TMC) was included
in the assay as a reference cytotoxic compound at 100 µM (Pinz et al., 2014a). After
30 min inhibitor treatment, WST-1 reagent together with IL-3 was added for 90 min and
absorbance was measured. This setting was chosen to reflect the experimental design of
the gene expression analysis after inhibitor treatment (Fig. 4.1 and Fig. 4.3).
Upon treatment with the positive control, 100 µM ↵-Br-TMC, 78% cytotoxicity was
detected, which confirms the validity of the assay. Treatment with deacetylase inhibitors,
even at the highest concentrations, resulted in no to low (<20%) cytotoxicity (Fig. 4.5).
Therefore, the observed inhibitory e↵ect of TSA, VPA and apicidin on STAT5 target
gene expression was not due to cytotoxicity.
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Figure 4.5: The deacetylase inhibitors are not or only marginally cytotoxic in Ba/F3 cells
6 h rested Ba/F3 cells were pre-treated with deacetylase inhibitors or control compounds for 30 min and
then treated with IL-3 and WST-1 reagent for 90 min. Inhibitor concentrations were as follows: 0.5,
10 and 200 nM TSA, 0.075, 1.5 and 30 mM VPA, 2.5, 50 and 1000 nM apicidin, 0.025, 0.5 and 10 µM
MGCD0103, 0.25, 5 and 100 µM MS-275, or 4, 20 and 100 µM ↵-bromo-2’,3,4,4’-tetramethoxychalcone
(↵-Br-TMC). ↵-Br-TMC served as reference cytotoxic compound (Pinz et al., 2014a). The absorbance
was measured and the percentage of cytotoxicity was calculated relative to vehicle control (0% cytotoxi-
city) and 1% Triton-X-100 treatment (100% cytotoxicity), as described in Material and methods 3.2.3.5.
Vehicle was adjusted to 0.02% DMSO for all samples, except for MS-275 samples and respective vehicle
control (0.4% DMSO) as well as ↵-Br-TMC samples and respective vehicle control (0.1% DMSO).
4.2.3 Most HDAC family members are expressed in Ba/F3 cells
The involvement of specific HDACs in STAT5-mediated transcription would be further
supported by their expression in Ba/F3 cells. To verify whether the HDACs, in particular
the candidates HDAC3, HDAC5, and HDAC11, are expressed in Ba/F3 cells, the mRNA
levels of HDAC1-11 were determined by quantitative RT-PCR. To account for the possi-
bility that HDAC expression in Ba/F3 cells might be IL-3-dependent, HDAC expression
was analyzed in unstimulated or IL-3-stimulated Ba/F3 cells. The conventional protocol
for gene expression analysis, which uses stabilized RNA-containing lysates as template for
cDNA synthesis, led to undetectable Hdac9 and Hdac11 mRNA levels (data not shown
were generated by Dr. Anne Rascle). To increase the sensitivity of the assay, cDNAs were
synthesized from purified total RNA. In agreement with the literature (Dovey et al., 2013;
Kelly & Cowley, 2013), Hdac1 and Hdac2 showed the highest mRNA levels of all HDACs
in Ba/F3 cells (Fig. 4.6A). Hdac3-8 and Hdac10 mRNAs were readily detectable, while
Hdac9 and Hdac11 mRNA levels were at the limit of detection. Hdac9 and Hdac11
mRNA levels were only slightly higher than the respective primer-specific signal detected
in the negative control (Fig. 4.6B). The negative control had been prepared in parallel
to the cDNA reactions. It contained the same amount of RNA preparation (including
possible DNA contaminations), but lacked the enzyme reverse transcriptase so that no
cDNA was synthesized. No apparent e↵ect of IL-3 on HDAC expression was observed
(Fig. 4.6A). Thus the candidates HDAC3 and HDAC5 are expressed in Ba/F3 cells at
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the RNA level, which supports their possible involvement in STAT5-mediated transcrip-
tion. By contrast, the absence of readily detectable HDAC11 mRNA argues against the
involvement of HDAC11 in STAT5-mediated transcription in Ba/F3 cells.
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Figure 4.6: HDAC gene expression in Ba/F3 cells
(A) HDAC expression was analyzed in Ba/F3 cells that had been rested and then stimulated for 2 h with
IL-3 or left unstimulated. For higher sensitivity of the assay, RNAs were purified with MN NucleoSpin
RNA II kit. cDNA synthesis and quantitative RT-PCR were performed as before, using primers for
Hdac1 - Hdac11. (B) The y-axis was adjusted to show Hdac9 and Hdac11 expression of the IL-3-
stimulated cells from (A) (+ reverse transcriptase). In addition, background signals are shown from a
cDNA reaction prepared without reverse transcriptase (- reverse transcriptase). (Data shown in this
figure were generated by Dr. Anne Rascle.)
Since mRNA levels do not always directly correlate with protein levels and since
eventually the amount of protein in the cell is relevant, the protein abundance of the
candidate HDAC proteins was analyzed in Ba/F3 or Ba/F3-1⇤6 cell lysates by western
blot. HDAC3 protein levels were readily detectable in Ba/F3-1⇤6 cells by western blot
using an HDAC3-specific antibody (Fig. 4.7B and Fig. 4.8B). In line with the very low
mRNA level of Hdac11, the HDAC11 protein could not be detected in Ba/F3 cell lysates,
although the available antibody detected HDAC11-FLAG that had been overexpressed
in Cos-7 cells (data not shown were generated together with Dr. Anne Rascle). Due to
its low RNA and protein levels in Ba/F3 cells, HDAC11 was unlikely to be involved in
STAT5-mediated transcription. The HDAC5 protein was also not detectable in Ba/F3 cell
lysates by western blot, probably due to a combination of low HDAC5 protein abundance
and a suboptimal antibody that gave rise to background signals (data not shown were
generated together with Dominik Buob, Bachelor Thesis 2013). Nevertheless, HDAC5 was
still included for further analysis since its RNA level could be quantified. Thus, the data
collected so far suggest that HDAC3 and HDAC5 are the most likely candidates involved
in STAT5-mediated transcription and in inhibition of STAT5-mediated transcription by
deacetylase inhibitors.
67
CHAPTER 4. RESULTS
4.2.4 Knockdown of HDAC gene expression does not a↵ect
STAT5-mediated transcription
Since inhibition of enzymatic HDAC activity represses STAT5-mediated transcription,
depletion of the involved HDAC probably also represses STAT5-mediated transcription.
Therefore, to confirm the involvement of one or both of the remaining putative candidate
HDACs, HDAC3 and HDAC5, in STAT5-mediated transcription, these HDACs were
depleted by siRNA-mediated knockdown, and the e↵ect on expression of STAT5 target
genes was analyzed.
Ba/F3 cells are di cult to transfect with siRNA or plasmid DNA. Among several
tested transfection methods and reagents like X-treme Gene 9 (Roche), or polyethyle-
neamine (PEI) (data not shown), only electroporation allowed to successfully transfect
Ba/F3 cells and was therefore used as transfection method throughout this study for
all Ba/F3-derived cell lines. Electroporation conditions which achieve a higher transfec-
tion e ciency typically lead to a higher cell death rate (data not shown). To prevent
additional cell loss and stress for the cells by IL-3 withdrawal/IL-3 stimulation, which
would be required for analysis of STAT5 target gene expression in Ba/F3 cells, Ba/F3-
1⇤6 cells were used for siRNA transfection experiments. As described above, Ba/F3-1⇤6
cells are well suited to investigate STAT5-mediated transcription (Fig. 4.1). Furthermore
STAT5A-1⇤6-mediated transcription is sensitive to TSA (Fig. 4.1) and should therefore
be sensitive as well to a knockdown of the HDAC responsible for inhibition of STAT5-
mediated transcription by deacetylase inhibitors.
As a control for the knockdown, HDAC2-specific siRNA was used for two reasons:
(i) HDAC2 served as a positive control for e cient knockdown since an e cient HDAC2-
specific siRNA was available and since HDAC2 protein levels are readily detectable by
western blot using an HDAC2-specific antibody. (ii) HDAC2 knockdown served as a
negative control at the level of STAT5 target gene expression, since HDAC2 was none of
the candidates and therefore should not a↵ect STAT5 target gene expression. In addi-
tion, as a non-specific control siRNA, a scramble siRNA (ScI) was used (Rascle & Lees,
2003). Thus Ba/F3-1⇤6 cells were transfected with non-specific scramble siRNA (ScI) or
siRNA directed against HDAC2, HDAC3 and HDAC5. HDAC knockdown e ciency was
analyzed at the RNA level by quantitative RT-PCR and at the protein level by west-
ern blot. Furthermore, the e↵ect of HDAC knockdown on the expression of the STAT5
target genes Cis and c-Myc, as well as the housekeeping gene 36b4 was analyzed. siRNA-
mediated knockdown of HDAC2 and HDAC3 was successful at the RNA level (80% and
73% knockdown respectively) and at the protein level (Fig. 4.7A and B). The HDAC5
mRNA level was reduced by 38% and its protein level could not be verified, as described
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Figure 4.7: HDAC knockdown does not a↵ect STAT5A-1⇤6-mediated transcription
Ba/F3-1⇤6 cells were transfected twice in an interval of 24 h with 0.5 µM siRNA specific for HDAC2
(HD2), HDAC3 (HD3), and HDAC5 (HD5.1 and HD5.2) as described in Material and methods 3.2.3.8.
Scramble siRNA (ScI) served as a non-specific control. Cells were harvested 72 h after the first trans-
fection. (A) Gene expression analysis by quantitative RT-PCR was performed using primers specific for
Hdac2, 3, and 5, for the STAT5 target genes (Cis and c-Myc), or for the control gene 36b4. (B) To verify
the HDAC knockdown e ciency at the protein level, whole-cell Brij lysates were prepared and analyzed
by western blot using antibodies directed against HDAC1, HDAC2, HDAC3 and against the loading
control ↵-tubulin. Because of the high conservation between HDACs, HDAC1 protein levels were also
analyzed to verify the specificity of the knockdown. (Data shown in this figure were generated together
with Dominik Buob, Bachelor Thesis 2013)
above (Results 4.2.3). Expression of the housekeeping gene 36b4 remained una↵ected in
all conditions. As expected, HDAC2 knockdown did not a↵ect expression of the STAT5
target genes Cis or c-Myc (Fig. 4.7A), but unexpectedly, knockdown of the candidates
HDAC3 or HDAC5 also did not reduce expression of these genes. Thus, the involvement
of HDAC3 or HDAC5 in STAT5-mediated transcription could not be confirmed by these
data.
Therefore, a possible functional redundancy of HDAC3 and HDAC5 was considered
and was next investigated by their co-knockdown. As a positive control for a cellu-
lar response upon HDAC knockdown served a co-knockdown of HDAC1, HDAC2, and
HDAC3. HDAC1 and HDAC2 play key roles in the deacetylation of chromatin (Dovey
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et al., 2013; Kelly & Cowley, 2013) and are the most highly expressed HDACs in Ba/F3
cells (Fig. 4.6). HDAC3 also deacetylates histones (You et al., 2013). Simultaneously re-
ducing the protein levels of HDAC1, HDAC2 and HDAC3, should lead to increased global
histone acetylation, which can be detected by western blot using antibodies specific for
acetylated histone H3 and H4.
For siRNA transfection, Ba/F3-1⇤6 cells were used as before. They were transfected
with an siRNA mix targeting HDAC3 and HDAC5, with an siRNA mix targeting HDAC1,
HDAC2 and HDAC3 or with the non-specific siRNA ScI (Fig. 4.8A and B). Knockdown
e ciency was analyzed at the RNA level by quantitative RT-PCR and at the protein
level by western blot. Furthermore, the e↵ect of HDAC knockdown on STAT5 target
gene expression and on global histone acetylation was analyzed. Unfortunately, in the at-
tempted triple knockdown, HDAC1 mRNA as well as protein levels remained unchanged,
although HDAC1 individual siRNA transfection successfully reduced its RNA as well as
protein levels (data not shown). The absence of e↵ect on HDAC1 in the attempted triple
knockdown might be due to a reduced e ciency of HDAC-specific siRNA, an elevated
stability of HDAC1 mRNA and protein, or the lower amount of HDAC1-specific siRNA
in the triple compared to a single knockdown. HDAC2 and HDAC3 mRNA levels were re-
duced by 75% and 85% respectively (Fig. 4.8A) and their protein levels were also reduced
(Fig. 4.8B). This control knockdown showed slightly increased histone H3 and histone H4
acetylation (Fig. 4.8B), suggesting that the knockdown conditions were strong enough for
a global cellular response. Nevertheless, even with a strong HDAC3 and partial HDAC5
co-knockdown (86% and 48% knockdown at the RNA level respectively), expression of
the STAT5 target gene Cis was not reduced (Fig. 4.8A). Thus, neither individual nor
co-knockdown experiments could confirm the involvement of HDAC3 or HDAC5 or both
in STAT5-mediated transcription.
Since the analysis with selective inhibitors might have missed possible candidates,
Ba/F3-1⇤6 cells were transfected with siRNA directed against the remaining HDACs,
namely HDAC4, HDAC6-10 and HDAC11 (data not shown were generated together with
Dr. Anne Rascle and Dominik Buob, Bachelor Thesis 2013, Pinz et al., 2015, fig. S4).
Again, no e↵ect on expression of STAT5 target genes was observed.
Altogether, neither siRNA-mediated knockdown of all individual HDACs nor co-
knockdown of several HDACs inhibited STAT5 target gene expression. This absence
of e↵ect on STAT5 target gene expression might be caused on the one hand by insuf-
ficient knockdown e ciency of each HDAC, which is supported by the weak e↵ect of
HDAC co-knockdown on histone acetylation (Fig. 4.8B), and on the other hand by a
possible functional redundancy of several HDACs in the regulation of STAT5-mediated
transcription.
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Figure 4.8: Co-knockdown of multiple HDACs does not a↵ect STAT5A-1⇤6-mediated tran-
scription
Ba/F3-1⇤6 cells were transfected with siRNA twice in an interval of 24 h and were harvested 48 h after
the first transfection. For the co-knockdown of HDAC1, HDAC2, and HDAC3 (HD1+2+3) and for the
co-knockdown of HDAC3 and HDAC5 (HD3+5) the following concentrations of HDAC (HD)-specific
siRNA were used: 0.25 µM HDAC1 siRNA, 0.1 µM HDAC2 siRNA, 0.25 µM HDAC3 siRNA, and
0.35 µM HDAC5 siRNA (HD5.2). 0.6 µM scramble (ScI) siRNA served as a non-specific control. (A)
Gene expression was analyzed by quantitative RT-PCR using primers specific for Hdac1, Hdac2, Hdac3,
Hdac5, Cis, and 36b4. (B) Whole-cell protein lysates were prepared by freeze/thaw protocol (Material
and methods 3.2.4.2) and analyzed by western blot to determine the HDAC knockdown e ciency at the
protein level and the e↵ect of HDAC knockdown on histone acetylation. For western blot, antibodies
directed against HDAC1, HDAC2, HDAC3, ↵-tubulin, acetylated histone H3 (Ac-H3), acetylated his-
tone H4 (Ac-H4), and against total histone H3 (H3) were used. ↵-tubulin and total histone H3 served
as loading controls.
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In summary, the screen with selective deacetylase inhibitors suggested the partic-
ipation of HDAC3, HDAC5 or HDAC11 in STAT5-mediated transcription. However,
siRNA-mediated HDAC knockdown could not confirm the involvement of one specific
HDAC, but rather supports a model of functional redundancy of several HDACs in the
regulation of STAT5-mediated transcription. A model of functional redundancy is further
supported by the finding that overexpression of individual HDACs through transfection
of HDAC expression plasmids did not a↵ect STAT5 target gene expression (data not
shown were generated together with Philipp Fischer, internship 2013) and by the fact
that selective deacetylase inhibitors which repress STAT5 target genes (TSA, VPA and
apicidin) each target several HDACs simultaneously (Fig. 4.3 and Tab. 4.1).
4.3 Identification of the acetylated substrate
involved in deacetylase inhibitor-mediated
inhibition of STAT5-mediated transcription
In addition to HDACs, their acetylated substrate is very likely also involved in inhibi-
tion of STAT5-mediated transcription by deacetylase inhibitors. To identify the acety-
lated substrate, we investigated if it might be acetylated STAT5, an unknown acetylated
STAT5-specific cofactor or acetylated histones.
4.3.1 Establishment of a GAL4-STAT5A luciferase reporter
assay
STATs, in particular STAT5 and STAT3, are regulated by acetylation (Choudhary et al.,
2009; Ma et al., 2010; Van Nguyen et al., 2012; Wieczorek et al., 2012). Therefore, STAT5
might be the acetylated substrate involved in inhibition of STAT5-mediated transcrip-
tion by deacetylase inhibitors. In case this assumption is true and increased STAT5
acetylation upon deacetylase inhibitor treatment inhibits STAT5-mediated transcription,
STAT5 acetylation would probably inhibit STAT5-mediated transcription per se. To
investigate if acetylation of STAT5 at specific lysines might inhibit STAT5-mediated
transcription, we analyzed whether mutation of specific lysine residues within STAT5 to
glutamine, mimicking the acetylated lysine, or to arginine, mimicking the unmodified ly-
sine, a↵ects STAT5 transcriptional activity. A lysine-to-glutamine mutation of a residue
whose acetylation inhibits STAT5-mediated transcription is expected to inhibit STAT5-
mediated transcription, while mutation of such lysine residue to arginine is expected to
leave STAT5-mediated transcription either una↵ected or lead to increased activity.
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Figure 4.9: Location of mutated lysine residues within STAT5A-1⇤6 and GAL4-STAT5A666
(A) Schematic representation of mouse STAT5A, STAT5A-1⇤6, and GAL4-STAT5A666. The depicted
domain structure is inherent to all STAT proteins. Mouse STAT5A-1⇤6 was expressed from a pcDNA3
expression vector in frame with a C-terminal FLAG tag. The C-terminus of mouse STAT5A, comprising
amino acids 666-793, was cloned in fusion with the Saccharomyces cerevisiae GAL4 DNA binding domain
of the pFA-CMV expression vector to generate the GAL4-STAT5A666 fusion protein. Indicated are the
conserved phosphotyrosine Y694 as well as the two point-mutations MT1 (S710F) and MT6 (H298R)
conferring constitutive activity to STAT5A-1⇤6. Lysines K84, K359, K384, K675, K681, K689, K696,
and K700 were mutated by site-directed mutagenesis to either glutamine or arginine in the context of
STAT5A-1⇤6 or GAL4-STAT5A666. In addition, the lysine residues that are mutated within the double
(2xQ/R), triple (3xQ/R), and quintuple mutants (5xQ/R) to glutamine or arginine are indicated. All
structures are drawn to scale. (B) The alignment of human and mouse STAT3, STAT5A and STAT5B
was generated as described in Material and methods 3.2.8. Conserved lysine residues are indicated
in gray, the phosphorylated tyrosine in bold. P-Y, phosphotyrosine tail segment; TA, transactivation
domain; GAL4 DBD, GAL4 DNA binding domain.
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Five lysine residues located within the C-terminal SH2 and the transactivation do-
main of STAT5 (K675, K681, K689, K696 and K700 of STAT5A) are well conserved
among mouse and human STAT5A and B and to a certain extent between STAT5 and its
paralog STAT3 (Fig. 4.9B). Acetylation of these lysines was reported either for STAT5
(Choudhary et al., 2009; Ma et al., 2010) or for the corresponding lysine in STAT3 (Wang
et al., 2005; Yuan, 2005; Nie et al., 2009) (Fig. 4.9B). Furthermore, K689 and K696 of
STAT5A, or the corresponding lysine in STAT5B, were demonstrated to be critical for
the regulation of STAT5 (Ma et al., 2010; Van Nguyen et al., 2012). The lysines corre-
sponding to K675, K681, K696 and K700 of STAT5A were demonstrated to be critical
for the regulation of STAT3 (Wang et al., 2005; Yuan, 2005; Nie et al., 2009). Together,
this makes K675, K681, K689, K696 and K700 the most likely lysine residues whose
acetylation might regulate STAT5-mediated transcription.
STAT acetylation a↵ects di↵erent initial activation steps within the pathway like
STAT phosphorylation, dimerization or nuclear translocation (Yuan, 2005; Kra¨mer et al.,
2009; Nie et al., 2009; Ma et al., 2010; Gupta et al., 2012). Lysine mutations which dis-
rupt important acetylation sites might thus interfere with STAT5 activity at an earlier
activation step and abrogate further downstream processes such as DNA binding and
transcriptional activation. Therefore, to investigate specifically the e↵ect of lysine mu-
tations on DNA-bound STAT5 at the transcriptional level, an experimental system was
designed, using a GAL4-STAT5 reporter assay, which circumvents the need for initial
STAT5 activation steps. The GAL4 DNA binding domain of the GAL4 transcriptional
activator of Saccharomyces cerevisiae (amino acids 1-147) binds specifically to GAL4
DNA binding sites, so-called GAL4 upstream activator sequences (UAS), but fails to ac-
tivate transcription (Ma & Ptashne, 1987; Kakidani & Ptashne, 1988; Ma et al., 1988).
It can thus be used as part of a fusion protein to confer DNA binding activity to another
protein domain such as the STAT5 transactivation domain, to characterize its ability to
activate transcription of a reporter gene (Ma & Ptashne, 1987; Sadowski et al., 1988;
Moriggl et al., 1996). For the experiments shown here, a Firefly luciferase reporter con-
struct was used, which contains nine repeats of the GAL4 UAS. Transcriptionally active
GAL4 fusion proteins thus induce the production of the Firefly luciferase enzyme, which
can be readily quantified by means of the bioluminescent reaction which it catalyzes.
Therefore, an expression vector was generated for the expression of a fusion pro-
tein between the GAL4 DNA binding domain and the mouse STAT5A C-terminus from
amino acid 666 to amino acid 793 (Stop), comprising the lysines of interest. The result-
ing GAL4-STAT5A666 protein contains part of the STAT5 SH2-domain, its phospho-
tyrosine tail segment, and its complete transactivation domain (Fig. 4.9A). The lysines
corresponding to K675, K681, K689, K696 and K700 of STAT5A were mutated within
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GAL4-STAT5A666 by site-directed mutagenesis to glutamine and to arginine.
The generated expression plasmids encoding either the GAL4-STAT5A666 fusion pro-
tein, or its lysine mutants, or the corresponding empty vector (negative control) were
transiently co-transfected together with the GAL4 UAS luciferase reporter into Cos-7
cells. As an internal control for transfection e ciency, an expression plasmid harbor-
ing a constitutively expressed Renilla luciferase gene was additionally co-transfected for
all luciferase assays in this study. Since Renilla luciferase uses a di↵erent substrate
than Firefly luciferase, both enzymatic activities can be measured in the same lysate
by Dual-Luciferase Reporter Assay (Promega). The measured Firefly luciferase activity
can then be normalized to the respective Renilla luciferase activity. In addition to mea-
suring luciferase activity of the transfected cells, expression of the fusion proteins was
verified by western blot. As shown by western blot using GAL4- and STAT5-specific
antibodies, GAL4-STAT5A666 and its mutants showed similar but low protein levels
(Fig. 4.10A). Accordingly, GAL4-STAT5A666 induced the reporter gene by only 1.9-fold
relative to empty vector control. All GAL4-STAT5A666 lysine mutants activated the
luciferase reporter by 1.5- to 2.3-fold (Fig. 4.10A) and thus with a similar e ciency as
parental GAL4-STAT5A666, arguing against a functional role of these lysine residues in
STAT5-mediated transcription. However, the low protein levels, the weak induction of
the luciferase reporter and the non-physiological experimental system, using Cos-7 cells
which normally do not operate the STAT5 signaling pathway, might be responsible for
this result. Therefore, no definite conclusion could be drawn from these experiments.
Therefore, to use a more physiological experimental system, Ba/F3 cells were used
for the luciferase reporter assays, since the STAT5 pathway is activated in these IL-3-
dependent cells (Rodriguez-Tarduchy et al., 1990; Nelson et al., 2004) and all cofactors in-
volved in STAT5-mediated transcription should be available. Ba/F3 cells were transiently
co-transfected by electroporation with the GAL4 UAS luciferase reporter and the expres-
sion plasmid encoding the GAL4-STAT5A666 fusion protein or the empty control vec-
tor. As a positive control, the GAL4-STAT5A709 construct, comprising STAT5A amino
acids 709-793(Stop) (Watanabe et al., 2001), was used. Similar GAL4-STAT5A fusion
constructs had been successfully used to characterize the STAT5 transactivation domain
(Moriggl et al., 1996; Watanabe et al., 2001). The positive control GAL4-STAT5A709
was well expressed and induced the luciferase reporter almost 8-fold (Fig. 4.10B). The
GAL4-STAT5A666 fusion protein induced the luciferase reporter 3-fold (Fig. 4.10B),
which was higher than in Cos-7 cells, but unfortunately, the protein level of GAL4-
STAT5A666 fusion proteins was below detection level in western blot (Fig. 4.10B and
data not shown). Therefore, it was impossible to properly evaluate the transcriptional
activity of the lysine mutants (data not shown). Another caveat of the GAL4-luciferase
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assay in Ba/F3 cells were the low Firefly relative light units (RLU) measured (up to 800
RLU for GAL4-STAT5A666 in Ba/F3 cells compared to 700,000 RLU in the previous
Cos-7 assay). The low luciferase activity made the assay susceptible to inter-experiment
variation.
With the aim to solve those problems, and in regard of the low transfection e ciency
of plasmid DNA into Ba/F3 cells (data not shown), the Ba/F3-G4-Luc2P cell line was
generated (together with Dr. Anne Rascle), carrying the stably integrated 9x GAL4 UAS
Firefly luciferase reporter. Individual clones were tested for basal luciferase activity and
for inducibility of luciferase activity upon transfection of the positive control GAL4-
STAT5A709. Clone 2.A was chosen for further experiments since it was one of the best
inducible clones (up to 8.5-fold induction with GAL4-STAT5A709, Fig. 4.10C and D).
Furthermore, Clone 2.A showed a basal luciferase activity of about 20,000 RLU, compared
to about 50 RLU of another clone (clone 3.D) (data not shown were obtained from 95 µg
total protein of non-transfected cells during 10 sec measurement time in a luminometer),
so that the obtained RLUs in the luciferase assay were in a well detectable range.
Ba/F3-G4-Luc2P cells were transfected with GAL4-STAT5A666, the 696Q/R and
700Q/R lysine mutants, the positive control GAL4-STAT5A709 or the empty control
vector. The GAL4-STAT5A666 protein was detectable at the protein level by western blot
using STAT5- or GAL4-specific antibodies, but its protein level was still low (Fig. 4.10C).
The protein level of GAL4-STAT5A666 was lower than that of GAL4-STAT5A709, as
revealed by GAL4-specific antibody. In contrast to GAL4-STAT5A709, which induced
the reporter 4- to 8.5-fold relative to empty vector control (Fig. 4.10C and D), GAL4-
STAT5A666 and its mutants failed to activate the reporter (1.2- to 1.6-fold induction,
Fig. 4.10C and D). Thus, no conclusion regarding the e↵ect of lysine mutations on
STAT5-mediated transcription could be drawn.
In summary, we tried but failed to establish a luciferase assay in Ba/F3-derived cells
using the GAL4-STAT5A666 fusion protein. In Cos-7 cells, lysine-mutated
GAL4-STAT5A666 fusion proteins induced the luciferase reporter similarly strong as
parental GAL4-STAT5A666, which argues against an involvement of those lysine
residues in STAT5-mediated transcription. Furthermore, the absence of inhibition of
STAT5-mediated transcription by glutamine mutants, mimicking the acetylated lysine,
argues against an inhibition of STAT5-mediated transcription by lysine acetylation.
However, low protein abundance of GAL4-STAT5A666 concomitant with weak
induction of the luciferase reporter might be responsible for the observed result.
Therefore, no definite conclusion could be drawn from these experiments and an
alternative approach was started.
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Figure 4.10: Mutation of lysine residues does not impair GAL4-STAT5A666 transcriptional
activity in luciferase assays
(A) Cos-7 cells were transiently co-transfected with the GAL4 UAS Firefly luciferase reporter pGL4.35
and with the empty control vector pFA-CMV (-), or a pFA-CMV-based expression plasmid for either
GAL4-STAT5A666 (5A666) or for a GAL4-STAT5A666 lysine mutant (K675Q, K675R, K681Q, K681R,
K689Q, K689R, K696Q, K696R, K700Q, K700R). The cells were analyzed for luciferase activity as
described in Material and methods 3.2.6. Western blot was performed from the same PLB lysate to
confirm expression of the GAL4-STAT5A666 fusion proteins. (Continued on next page)
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Figure 4.10: (Continued) (B) Ba/F3 cells were transiently co-transfected with the GAL4 UAS Firefly
luciferase reporter pGL4.35 and with the empty control vector pFA-CMV (-) or the expression plasmid
for either GAL4-STAT5A666 (5A666) or the positive control GAL4-STAT5A709 (5A709). The cells were
harvested 8 hours after transfection for luciferase assay and 24 h after transfection for analysis of protein
expression from Brij whole-cell lysate by western blot. (C), (D) Ba/F3 cells with stably integrated GAL4
UAS Firefly luciferase reporter (pGL4.35), so-called Ba/F3-G4-Luc2P cells, were transiently transfected
with the empty control vector pFA-CMV (-) or with an expression plasmid for either GAL4-STAT5A709
(5A709), GAL4-STAT5A666 (5A666), or for one of the STAT5A666 mutants as indicated. Luciferase
assay was performed 18 h after transfection. For the western blot in (C), transfected cells were lysed
in Brij whole-cell lysis bu↵er. In (A)-(D), Firefly luciferase activity was normalized to co-transfected
constitutively expressed Renilla luciferase and presented as fold induction relative to empty vector con-
trol. For the western blots shown in (A)-(C), antibodies directed against STAT5 and the GAL4 DNA
binding domain were used. The STAT5-specific antibody is directed against a C-terminal epitope of
STAT5 and thus recognizes endogenous wild-type STAT5 (STAT5 wt) as well as GAL4-STAT5A666 and
GAL4-STAT5A709. The STAT5 signal, especially the shorter exposures in (B) and (C), served as a
loading control. The expected size of the fusion proteins is about 30 kDa, however, in western blot the
protein signals appeared above the 35 kDa marker. Of note, the GAL4 DNA binding domain (17 kDa,
appear in western blot around the 20 kDa marker, Jobst et al., 2016, fig. 2) expressed from empty control
vector was not detectable in (A) and (C) by western blot using a GAL4-specific antibody. The asterisks
in (C) mark unspecific signals overlapping the signal for GAL4-STAT5 fusion proteins. These signals
probably appeared because the blot was developed with the highly sensitive ECL reagent SuperSignal
West Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific).
4.3.2 Mutation of specific lysines of STAT5A-1⇤6 does not a↵ect
STAT5A-1⇤6 transcriptional activity in luciferase assays
As alternative approach, the well-described constitutively active STAT5A-1⇤6 was used
instead of GAL4-STAT5A666 to analyze the e↵ect of lysine mutations on STAT5 tran-
scriptional activity. STAT5A-1⇤6, like GAL4-STAT5 fusion proteins, does not need an
external activation stimulus to mediate transcription. Furthermore, STAT5A-1⇤6 and
wild-type STAT5 are similarly sensitive to TSA (Fig. 4.1), and should therefore be simi-
larly sensitive to mutation of potentially acetylated lysine residues. Thus, STAT5A-1⇤6 is
a suitable model to investigate whether mutation of potentially acetylated lysines a↵ects
STAT5-mediated transcription. In order to investigate a possible functional redundancy
between the investigated lysine residues, double (2xQ/R), triple (3xQ/R) and quintu-
ple (5xQ/R) lysine mutations were created within full-length STAT5A-1⇤6 (Fig. 4.9A),
in addition to the single lysine mutations described above. The 2xQ and 2xR mutants
carry mutations at K696 and K700, the 3xQ and 3xR mutants carry mutations at K689,
K696, and K700, and the 5xQ and 5xR mutants carry mutations at all 5 investigated
lysine residues (K675, K681, K689, K696, and K700) to glutamine (Q) or arginine (R),
as depicted in Figure 4.9A. STAT5A-1⇤6 and all of its mutants were expressed from a
pcDNA3 vector backbone and carry a C-terminal FLAG tag, which can be used to dis-
tinguish these proteins from endogenous STAT5 by western blot using a FLAG-specific
antibody. The activity of the lysine mutants was evaluated in luciferase reporter assays
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using reporter constructs bearing the STAT5-responsive  -casein (Chida et al., 1998) or
Cis (Matsumoto et al., 1997) promoter.
Therefore, STAT5A-1⇤6 or its mutants were transiently co-transfected together with
the rat  -casein-driven luciferase reporter (called  -casein luciferase reporter thereafter)
(Chida et al., 1998) into Ba/F3 cells. To allow optimal recovery of the transfected cells
from electroporation, they were cultured in the presence of IL-3, so that endogenous
STAT5 was at its basal activity in these cells. Western blot analysis using a FLAG-specific
antibody showed that STAT5A-1⇤6 and its mutants were well expressed at the protein
level. The only exception were STAT5A-1⇤6 proteins containing mutations at K675
(K675Q/R and 5xQ/R mutants). These proteins were poorly detectable by western blot,
likely due to protein instability (Fig. 4.11A and B). Therefore, their activity in luciferase
assay could not be evaluated. STAT5A-1⇤6 activated the  -casein luciferase reporter 7-
to 11-fold above endogenous STAT5 (empty vector control) (Fig. 4.11A and B). All well
expressed lysine mutants induced the reporter as e ciently as parental STAT5A-1⇤6 (0.8-
to 1.4-fold relative to STAT5A-1⇤6, Fig. 4.11A and B), suggesting that none of these lysine
residues (K681, K689, K696, and K700) are essential for STAT5-mediated transcription.
Furthermore, since none of the glutamine mutations, mimicking the acetylated lysine,
inhibited STAT5-mediated transcription, acetylation of those lysines is unlikely to a↵ect
STAT5-mediated transcription.
In contrast to the  -casein gene, which is mainly relevant during lactation in the
mammary gland (Groner & Gouilleux, 1995; Chida et al., 1998), the STAT5 target gene
Cis is induced in response to IL-3 and well characterized in the pro-B cell line Ba/F3
(Matsumoto et al., 1997; Rascle et al., 2003; Basham et al., 2008). Therefore, next, a
mouse Cis promoter-driven luciferase reporter (called Cis luciferase reporter thereafter)
was used. To avoid induction of the reporter by endogenous STAT5, transfected cells
were first recovered in the presence of IL-3 and then cultured for the last 12 h under IL-3-
free conditions. Furthermore, these conditions, in which endogenous STAT5 is inactive,
should prevent that a possible inactivity of STAT5A-1⇤6 lysine mutants is concealed by
the formation of hypothetically functional heterodimers consisting of inactive STAT5A-
1⇤6 lysine mutants and transcriptionally active phosphorylated endogenous STAT5. In
addition, as a control to better characterize the experimental system, cells transfected
with wild-type STAT5 and STAT5A-1⇤6 were cultured in the presence of IL-3 through-
out the experiment. Like STAT5A-1⇤6, wild-type STAT5 was also expressed with a
C-terminal FLAG tag from a pcDNA3 vector backbone. As expected in the absence
of IL-3, transfected wild-type STAT5A did not induce expression of the Cis luciferase
reporter (Fig. 4.12A, B, and C). In the presence of IL-3, endogenous STAT5 failed to
activate the reporter (empty vector control, +IL-3) and transfected wild-type STAT5
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Figure 4.11: In  -casein promoter-driven luciferase assays, lysine mutations do not impair
the transcriptional activity of STAT5A-1⇤6
Ba/F3 cells were transiently co-transfected with the Firefly luciferase reporter pGVB- -casein, and with
the empty control vector pcDNA3 (-) or the pcDNA3-based expression plasmid of either mSTAT5A-
1⇤6-FLAG (5A1⇤6) or of one of its mutants (K675Q, K675R, K681Q, K681R, K689Q, K689R, K696Q,
K696R, K700Q, K700R, 2xQ, 2xR, 3xQ, 3xR, 5xQ, 5xR). The cells were cultured in the presence of
IL-3 and harvested 18 h (A) or 19 h (B) after transfection. (A) Part of the cells were lysed in PLB and
analysis of luciferase activity was performed as described in Material and methods 3.2.6. Firefly luciferase
activity was normalized to co-transfected constitutively expressed Renilla luciferase and presented as fold
induction relative to empty vector control. The remaining cells were subjected to Brij lysis (Material and
methods 3.2.4.1) and western blot analysis. An antibody specific for the FLAG tag was used for western
blot, to confirm protein expression of STAT5A-1⇤6 or its lysine mutants. An antibody directed against
↵-tubulin served as a loading control. (B) The experiment was performed as described in (A), except
that all transfected cells were lysed in PLB bu↵er and western blot was performed from this PLB-lysate.
induced the reporter only 4-fold (Fig. 4.12A). By contrast, STAT5A-1⇤6 transfection re-
sulted in a strong activation of the Cis luciferase reporter of 14- to 28-fold in the absence
of IL-3 (Fig. 4.12A, B, and C). The presence of IL-3 did not have an additional a↵ect on
STAT5A-1⇤6-dependent activation of the luciferase reporter (Fig. 4.12A), further demon-
strating the transactivation potential of STAT5A-1⇤6 independently of external stimuli.
As a positive control for an inactivating STAT5A-1⇤6 mutation, the conserved tyrosine
Y694, which is essential for STAT5 phosphorylation and activation (Onishi et al., 1998),
was mutated to phenylalanine (Fig. 4.12C, Y694F mutant). Western blot using a FLAG-
specific antibody revealed low protein abundance of STAT5A-1⇤6-Y694F (Fig. 4.12C).
However, additional experiments confirmed a lack of transcriptional activity of STAT5A-
1⇤6-Y694F while being well expressed (Fig. 4.13A), demonstrating that STAT5A-1⇤6
can be inactivated. Disruption of all STAT5 binding sites within the Cis promoter (Mat-
sumoto et al., 1997) abolished induction of the luciferase reporter (Fig. 4.12A, mut Cis
promoter), confirming the specific induction of the Cis luciferase reporter by STAT5.
Consequently, this reporter assay, constituted by components from one organism - mouse
STAT5A-1⇤6, a mouse Cis-promoter driven luciferase reporter, and mouse Ba/F3 cells
cultured in the absence of IL-3 - is an optimal experimental system to investigate the
e↵ect of lysine mutations on STAT5 transcriptional activity.
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This reporter assay was now used to assess the influence of the triple mutants 3xQ
and 3xR (containing mutations at K689, K696, and K700) on STAT5A-1⇤6 transcrip-
tional activity. The 5xQ/R mutants were not tested due to their weak protein levels
shown previously (Fig. 4.11B). Interestingly, the transfected 3xQ and 3xR mutants in-
duced the luciferase reporter with similar e ciency as STAT5A-1⇤6 (about 1.1-1.6-fold
above STAT5A-1⇤6, Fig. 4.12B), demonstrating that the triple mutations have no ef-
fect on the transcriptional activity of STAT5A-1⇤6. Therefore, the corresponding single
mutants were not tested. The absence of e↵ect of the triple mutations on STAT5A-1⇤6
transcriptional activity confirms that K689, K696 and K700 are indeed not essential for
STAT5-mediated transcription, and provides evidence against a functional redundancy of
these adjacent lysine residues. Furthermore, since the glutamine mutations, mimicking
acetylated lysine residues, did not inhibit STAT5-mediated transcription, an inhibition
of STAT5-mediated transcription by acetylation is unlikely.
Besides the investigated lysine residues, which are all located next to the transacti-
vation domain, there are additional putative acetylation sites in STAT5 at K84, located
within the N-terminal, and K359 and K384, located within the DNA binding domain
(Fig. 4.9A) (Ma et al., 2010; Wieczorek et al., 2012). Acetylation of K359 has been
demonstrated by mass spectrometry and an acetylation-site-specific antibody (Ma et al.,
2010). Mutation of K359 to arginine abrogated the ability of STAT5B to induce a lu-
ciferase reporter in the prostate cancer cell line PC3 (Ma et al., 2010). Acetylation of
K384 was found by two independent high throughput mass spectrometric approaches doc-
umented by PhosphoSitePlus (www.phosphosite.org), an online resource for the study of
post-translational modifications (Wieczorek et al., 2012; Hornbeck et al., 2015), but the
functional relevance of K384 or its acetylation for STAT5 activity has not been inves-
tigated. According to Wieczorek et al. (2012), acetylation of K84 was also described
by PhosphoSitePlus. Furthermore, a nearby lysine residue within STAT3 (K87), has
been shown to be acetylated and essential for STAT3-mediated transcription (Ray et al.,
2005; Nie et al., 2009). No further STAT5 acetylation sites are reported by Phospho-
SitePlus (www.phosphosite.org, February 2017) (Hornbeck et al., 2015). To determine
the relevance of K84, K359, and K384 for STAT5-mediated transcription, these lysine
residues were mutated within STAT5A-1⇤6 to glutamine and arginine and the resultant
mutants were tested for their transcriptional activity in the Cis luciferase reporter as-
say. However, similarly as the other mutants before, these new lysine mutants induced
the luciferase reporter with similar e ciency as STAT5A-1⇤6 (0.9- to 1.3-fold induction
relative to STAT5A-1⇤6, Fig. 4.12C), demonstrating that K84, K359, and K384 are also
functionally dispensable for STAT5-mediated transcription and that acetylation of these
residues is unlikely to a↵ect STAT5-mediated transcription.
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In summary, eight lysine residues within STAT5, which have been previously proposed
to be involved in the regulation of STAT5 or whose corresponding lysines have been
proposed to be essential for the regulation of STAT3, were investigated. Mutating these
lysine residues did not a↵ect STAT5-mediated transcription in luciferase reporter assays,
suggesting that acetylation of these lysine residues, which was mimicked by the mutation
to glutamine, does not inhibit STAT5-mediated transcription. Thus, inhibition of STAT5-
mediated transcription by deacetylase inhibitors is probably not mediated by an increase
in acetylation of STAT5, and STAT5 is probably not the acetylated factor involved in
inhibition of STAT5-mediated transcription by deacetylase inhibitors.
4.3.3 Mutation of specific lysine residues does not a↵ect
STAT5A-1⇤6-mediated activation of endogenous STAT5
target genes
The observation that the investigated lysine residues were not required for STAT5A-1⇤6
activity in luciferase assays doesn’t exclude the possibility that these lysines and their
de-/acetylation a↵ect the activation of endogenous STAT5 target genes in their natural
enhancer, promoter and chromatin context. To address this point, the transactivation
potential of the STAT5A-1⇤6 lysine mutants on endogenous genes was assessed in Ba/F3
cells.
Ba/F3 cells were transfected with the expression plasmids for the STAT5A-1⇤6 lysine
mutants and subsequently maintained in IL-3-free medium to ensure that endogenous
STAT5 is kept in its unphosphorylated, inactive state. To assess the transcriptional
activity of the STAT5A-1⇤6 lysine mutants, mRNA levels of the STAT5 target gene Cis
were measured by quantitative RT-PCR. Furthermore, the protein levels of the STAT5A-
1⇤6 mutants and their activation by tyrosine-phosphorylation were analyzed by western
blot (Fig. 4.13A and B).
All generated single and multiple STAT5A-1⇤6 lysine mutants were tested in this as-
say. A construct encoding wild-type STAT5A, which is inactive in the absence of IL-3,
was transfected as a negative control. Western blot confirmed that endogenous STAT5
(empty vector control) as well as exogenous wild-type STAT5 were unphosphorylated,
as expected in the absence of IL-3. Accordingly, wild-type STAT5 only marginally in-
duced Cis expression. By contrast, phosphorylated and thus active STAT5A-1⇤6 strongly
induced Cis expression (Fig. 4.13A and B). The positive control for a STAT5A-1⇤6 inac-
tivating mutation, Y694F, was well expressed, but did not induce expression of the target
gene Cis, as expected (Fig. 4.13A).
These data confirm the results of the luciferase assays, that none of the investigated ly-
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Figure 4.12: In Cis promoter-driven luciferase assays, none of the mutated lysine residues
is required for STAT5A-1⇤6 transcriptional activity
(A) Ba/F3 cells were transiently co-transfected with the Firefly luciferase reporter construct pGVB-
CisA (wt Cis promoter) or pGVB-CisD (mut. Cis promoter, containing mutated STAT5 binding sites),
and with either the empty vector pcDNA3 (-) or the expression vector for wild-type mSTAT5A-FLAG
(5A), or for mSTAT5A-1⇤6-FLAG (5A1⇤6), or for a mSTAT5A-1⇤6-FLAG mutant (3xQ, 3xR) containing
mutations at K689, K696 and K700. After 12 h recovery in the presence of IL-3, the cells were cultured for
a further 12 h in the absence or presence of IL-3, as indicated. Firefly luciferase activity was normalized
to co-transfected constitutively expressed Renilla luciferase and presented as fold induction relative to the
pcDNA/pGVB-CisA/-IL-3 sample. (B), (C) Ba/F3 cells were transiently co-transfected with the Firefly
luciferase reporter pGVB-CisA, containing the wild-type Cis promoter, and with either the empty vector
pcDNA3 (-) or the expression vector for wild-type mSTAT5A-FLAG (5A), or for mSTAT5A-1⇤6-FLAG
(5A1⇤6), or for a mSTAT5A-1⇤6-FLAG mutant (3xQ, 3xR, K84Q, K84R, K359Q, 359R, K384Q, K384R,
Y694F). After 12 h recovery in the presence of IL-3, the cells were rested for 12 h in IL-3-free medium.
Cell lysis and analysis for luciferase activity were performed as described in Material and methods 3.2.6.
Firefly luciferase activity was normalized to co-transfected constitutively expressed Renilla luciferase
and presented as fold induction relative to empty vector control. Using a FLAG tag-specific antibody,
western blot was performed from the same lysate to confirm protein expression from the di↵erent STAT5
expression vectors. An antibody directed against ↵-tubulin was used as a loading control.
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sine mutations a↵ect STAT5A-1⇤6-mediated transcription. This indicates that increased
STAT5 acetylation (mimicked by the lysine to glutamine mutation), at least at the inves-
tigated lysine residues, probably does not inhibit STAT5-mediated transcription, and this
indicates that, in contrast to our assumption, STAT5 is probably not the acetylated fac-
tor responsible for inhibition of STAT5-mediated transcription by deacetylase inhibitors.
Consequently, the observed inhibition of STAT5-mediated transcription by deacetylase
inhibitors is probably transmitted independently of a change in STAT5 acetylation. Of
note, although K675 mutants in the context of STAT5A-1⇤6 were not detectable at
the protein level, GAL4-STAT5A666 proteins containing a mutation at K675 exhibited
similar protein levels as the other GAL4-STAT5A666-based proteins and also induced
the luciferase reporter similarly strong (Fig. 4.10A). Although the GAL4-STAT5A666
luciferase reporter system is less physiological than the assay based on induction of en-
dogenous target genes by STAT5A-1⇤6, this indicates that K675 does probably also not
a↵ect STAT5-mediated transcription and that acetylation of this residue is probably also
not involved in inhibition of STAT5-mediated transcription by deacetylase inhibitors.
Eventually, the absence of e↵ect of lysine mutations on STAT-mediated transcription
demonstrate that other post-translational modifications of the investigated lysines, such
as SUMOylation or methylation are also unlikely to regulate STAT5-mediated transcrip-
tion in Ba/F3 cells.
The conclusion that deacetylase inhibitors act very likely independently of STAT5
acetylation at the investigated lysine residues implies that they also act independently
of these STAT5 lysine residues themselves. Consequently, deacetylase inhibitors should
inhibit STAT5-mediated transcription irrespective of the absence or presence of STAT5
lysine mutations. To confirm this proposition, the sensitivity of STAT5A-1⇤6 lysine
mutants towards the deacetylase inhibitor TSA was analyzed.
Using the same experimental setting as before, Ba/F3 cells transiently transfected
with expression plasmids for STAT5A-1⇤6, STAT5A-1⇤6-3xQ or -3xR (containing muta-
tions at K689, K696 and K700) and cultured in the absence of IL-3 were treated with
the deacetylase inhibitor TSA or vehicle for 90 min. Protein levels of the transfected mu-
tants, their phosphorylation status and expression of STAT5 target genes was analyzed.
As expected (Fig. 4.1), TSA treatment inhibited STAT5A-1⇤6-induced expression of the
STAT5 target genes Cis and c-Myc (Fig. 4.13C). Importantly, TSA treatment also inhib-
ited expression of Cis and c-Myc induced by the 3xQ and 3xR mutants (Fig. 4.13C). The
control gene 36b4 was not a↵ected by TSA treatment or by transfection of STAT5A-1⇤6
and its mutants. The protein levels of the mutants, as determined by western blot using a
FLAG-specific antibody, were una↵ected by TSA treatment (Fig. 4.13D), demonstrating
that the observed inhibition of STAT5 target genes upon TSA treatment was not a con-
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Figure 4.13: All STAT5A-1⇤6 lysine mutants induce endogenous STAT5 target genes and
retain TSA sensitivity.
(A), (B), Ba/F3 cells were transiently transfected, as described in Material and methods 3.2.3.7, with
8 µg of either the empty vector pcDNA3 (-), or the pcDNA3-based expression vector for mSTAT5A-
FLAG (5A), for mSTAT5A-1⇤6-FLAG (5A1⇤6), or for one of the mutants of mSTAT5A-1⇤6-FLAG
(2xQ, 2xR, 3xQ, 3xR, 5xQ, 5xR, K84Q, K84R, K359Q, 359R, K384Q, K384R, K675Q, K675R, K681Q,
K681R, K689Q, K689R, K696Q, K696R, K700Q, K700R, Y694F). Transfected cells were cultured for
10 h in the absence of IL-3, to prevent activation of endogenous STAT5. Gene expression was analyzed
by quantitative RT-PCR, using expression primers for the STAT5 target gene Cis, as described in
Material and methods 3.2.1.4. Brij whole-cell protein lysate was prepared to analyze expression of the
exogenous proteins by western blot using antibodies against their C-terminal FLAG tag. The phospho-
STAT5-specific antibody served to assess the activation status of the mutants and the ↵-tubulin-specific
antibody served as a loading control. (C) The experiment was performed as in (A) and (B), except that
cells were treated with 200 nM TSA or vehicle (0.02% DMSO) 90 min before the harvest. In addition
to expression of Cis, expression of c-Myc and 36b4 is shown. (D) Western blot of the samples from (C).
An antibody against total STAT5 was used in addition to the antibodies used in (A).
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sequence of altered protein levels. The phosphorylation levels of STAT5A-1⇤6 and of the
mutants were una↵ected by TSA treatment, as expected given the lack of e↵ect of TSA
on phosphorylation of wild-type STAT5 (Rascle et al., 2003). Of note, the 3xQ lysine
mutants repeatedly showed low phosphorylation signals in western blot using a phospho-
STAT5-specific antibody (Fig. 4.13D and data not shown) despite transcriptional activity
of those proteins in luciferase assay (Fig. 4.12A and B) and in endogenous gene expression
assays (Fig. 4.13B). Noteworthy, another phospho-STAT5-specific antibody (Cell Signal-
ing, #4322) did not detect STAT5A-1⇤6 mutants containing a K696Q/R mutation (data
not shown). The lysine mutations of the a↵ected mutants, at K689, K696, and K700, are
close to the Y694 phosphorylation site and are therefore likely to interfere with epitope
recognition by phospho-STAT5-specific antibodies. These results demonstrate that, as
expected, STAT5A-1⇤6-3xQ/R lysine mutants remained sensitive to TSA. These experi-
ments thus confirm that inhibition of STAT5A-1⇤6-mediated transcription by deacetylase
inhibitors is mediated independently of the investigated lysine residues and thus prob-
ably independently of STAT5 acetylation at those residues. Thus, STAT5 is probably
not the acetylated substrate involved in inhibition of STAT5-mediated transcription by
deacetylase inhibitors.
4.3.4 Wild-type latent endogenous STAT5 does not contribute
to STAT5A-1*6-mediated transcription
Analysis of the transcriptional activity of the STAT5A-1⇤6 lysine mutants took place in
IL-3-lacking culture conditions in which latent endogenous STAT5 is unphosphorylated,
inactive (Fig. 4.13A and B), and located in the cytosol. Furthermore, even in the pres-
ence of IL-3, endogenous STAT5 does not significantly contribute to the induction of
a Cis promoter-driven luciferase reporter (Fig. 4.12A, wt Cis promoter, empty vector
control, -/+IL-3). However, we cannot exclude that the observed transcriptional acti-
vation ascribed to the STAT5A-1⇤6 lysine mutants was induced by the co-translocation
of endogenous wild-type STAT5 to the nucleus, possibly through the formation of het-
erodimers.
To confirm that constitutively active STAT5A-1⇤6 does not induce the
co-translocation of latent endogenous STAT5 to the nucleus, the Ba/F3-tet-on-1⇤6 cell
line was used, which permits the doxycycline-induced conditional expression of
STAT5A-1⇤6. Before and after induction of STAT5A-1⇤6 expression in the absence of
IL-3, cytosolic and nuclear lysates were prepared and analyzed by western blot for the
presence of endogenous STAT5B in the nuclear fraction. Ba/F3-tet-on-1⇤6 cells
cultured in the presence of IL-3 throughout the experiment were used as a positive
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Figure 4.14: STAT5A-1⇤6 induction does not lead to an enrichment of latent endogenous
STAT5B in the nucleus of rested cells
Ba/F3-tet-on-1⇤6 cells, conditionally expressing mSTAT5A-1⇤6-FLAG upon doxycycline (Dox) treat-
ment, were grown in the presence or absence of Dox for 23 h. Upon starting the experiment, all cells
were cultured in the presence of IL-3. To turn o↵ endogenous STAT5 in samples indicated as -IL-3,
the cells were washed in RPMI 1640 after 12 h and then kept for the last 11 h in IL-3-lacking medium,
containing doxycycline or not as before. Control Ba/F3-tet-on-1⇤6 cells, indicated as +IL-3, were kept in
IL-3-containing medium without doxycycline throughout the experiment. Cytosolic (C) and nuclear (N)
lysates were prepared as described in Material and methods 3.2.4.3. Equal protein amounts of cytoso-
lic and nuclear lysate were analyzed by western blot using antibodies specific for STAT5B (recognizing
endogenous STAT5B), FLAG (recognizing STAT5A-1⇤6), HDAC1 and ↵-tubulin. HDAC1 served as
nuclear marker and as a loading control, ↵-tubulin as cytosolic marker and as a loading control. The
upward mobility shifted STAT5B band in IL-3-treated nuclear lysate represents tyrosine-phosphorylated
STAT5B. (Data shown in this figure were generated by Dr. Anne Rascle and Christina Seisenberger.)
control for nuclear endogenous STAT5B. As shown using an antibody directed against
the C-terminal FLAG tag of STAT5A-1⇤6, doxycycline treatment led to a strong signal
of cytoplasmic as well as nuclear STAT5A-1⇤6 (Fig. 4.14). In the presence of IL-3,
STAT5B was found in the nucleus of Ba/F3-tet-on-1⇤6 cells, as expected. This nuclear
STAT5B signal disappeared upon IL-3 withdrawal and, importantly, did not increase
upon STAT5A-1⇤6 expression (Fig. 4.14). These data confirm that constitutively active
STAT5A-1⇤6 does not induce the co-translocation of latent endogenous STAT5 to the
nucleus. In addition, no interaction between STAT5A-1⇤6 and latent endogenous
STAT5B was detected in co-immunoprecipitation assays (data not shown were
generated together with Krystina Beer, internship 2013), indicating that no
heterodimers or tetramers between these proteins were formed. This supports the
observed absence of co-translocation. It is therefore unlikely that the observed
transcriptional activation ascribed to the STAT5A-1⇤6 lysine mutants was induced by
the co-translocation of endogenous wild-type STAT5 to the nucleus. Therefore, these
data do not contradict the absence of e↵ect of the lysine mutations on STAT5A-1⇤6
transcriptional activity. Altogether our data argue against the involvement of STAT5
acetylation, at least at the investigated lysine residues, in inhibition of STAT5-mediated
transcription by deacetylase inhibitors.
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4.3.5 TSA does not disrupt soluble nuclear STAT5-containing
protein complexes
Our group demonstrated before (Rascle et al., 2003) that deacetylase inhibitors induce
a loss of components of the transcriptional machinery, RNA polymerase II and TBP,
from STAT5 target genes, suggesting that deacetylase inhibition might inhibit STAT5-
mediated transcription by disruption of protein interactions between STAT5 and essen-
tial components of the transcriptional machinery. This disruption of protein interactions
might be mediated by increased acetylation of STAT5 itself, or of an unknown STAT5-
specific cofactor. Along these lines, acetylation has been shown to disrupt protein inter-
actions of several transcriptional regulators and as a consequence to enhance or to inhibit
transcription (Waltzer & Bienz, 1998; Chen et al., 1999; Munshi et al., 2001; Vo et al.,
2001; Purbey et al., 2009). For example, acetylation leads to transcriptional inhibition
through disruption of the association of coactivator complexes with transcription factors
like T-cell factor (TCF) (Waltzer & Bienz, 1998) and estrogen receptor (Chen et al.,
1999), or through destabilization of the interferon-beta enhanceosome (Munshi et al.,
1998, 2001).
Thus, our model predicts that deacetylase inhibition disrupts protein interactions be-
tween STAT5 and the transcriptional machinery by an increase in acetylation of STAT5
or of a specific STAT5-associated cofactor and that consequently RNA polymerase II and
possibly the unknown acetylated cofactor are lost from STAT5-containing complexes. To
address whether deacetylase inhibition disrupts nuclear STAT5- and RNA polymerase II-
containing protein complexes, and to possibly obtain clues towards the loss of an unknown
STAT5-specific cofactor from STAT5-containing complexes, gel filtration chromatography
was performed using 60 min TSA- or vehicle-treated Ba/F3-1⇤6 cells. Since transcrip-
tionally relevant STAT5-containing complexes are expected in the nucleus, gel filtration
was performed using nuclear lysates. The quality of the nuclear lysates was verified by
western blot (Fig. 4.15A), using HDAC1 as a nuclear marker and ↵-tubulin as a cy-
tosolic marker as before. The nuclear lysates were applied onto a size exclusion-column
to separate proteins and protein complexes by size. Di↵erent elution fractions were col-
lected and analyzed by western blot using antibodies directed against the FLAG tag of
STAT5A-1⇤6 or against total STAT5 or against RNA polymerase II. In the absence of
IL-3, endogenous STAT5 was not co-translocated to the nucleus together with STAT5A-
1⇤6 (Fig. 4.14), so that only STAT5A-1⇤6 should be present in the analyzed nuclear
fraction and consequently the total STAT5 signal should be equivalent to the FLAG sig-
nal. Thus the two antibodies were used to confirm each other. A mixture of purified
thyroglobulin and BSA (bovine serum albumin) served as approximate molecular weight
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standards for the gel filtration. Thyroglobulin, with a molecular weight of 669 kDa,
eluted from the column in fraction 13, while BSA, with a molecular weight of 66 kDa,
eluted in fractions 23 and 24 (not shown). The strongest STAT5 signal of TSA-treated or
untreated cells was found by western blot in fraction 20 (Fig. 4.15B), likely correspond-
ing to the 180 kDa STAT5 dimer. Importantly, no di↵erence was apparent between the
STAT5A-1⇤6 elution profile from TSA- and vehicle-treated cells. Furthermore, the RNA
polymerase II elution profile was also not changed upon TSA treatment. This suggests
that soluble nuclear STAT5-containing protein complexes were not disrupted upon TSA
treatment. Therefore, our data do not support a model in which an increase in acetylation
of STAT5 or of a STAT5-specific cofactor upon deacetylase inhibition disrupts protein
interactions between STAT5 and the transcriptional machinery. Furthermore, these data
do not support the involvement of an acetylated STAT5-specific cofactor in inhibition of
STAT5-mediated transcription by deacetylase inhibitors.
fraction number: inp 2 3 4 5 6 7 8 9 inp 14 15 16 17 18 19 20
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FLAG
STAT5
RNA Pol II
13
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vehicle
TSA
A
B
C N
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α-tubulin
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Figure 4.15: TSA treatment does not a↵ect the composition of soluble nuclear STAT5-
containing protein complexes
(A) Nuclear (N) and cytosolic (C) lysates from 60 min 200 nM TSA- or vehicle (0.02% DMSO)-treated
Ba/F3-1⇤6 cells were analyzed by western blot. To assess the quality of the nuclear lysate, antibodies
against HDAC1 were used as a nuclear marker and against ↵-tubulin as a cytosolic marker. (B) Nuclear
lysate from (A) was fractionated by gel filtration chromatography on a TSK Gel 4000SW column, as
described in Material and methods 3.2.5.8. An equal volume of each elution fraction (and twice as much
input (inp)) was subjected to SDS-PAGE and analyzed by western blot using antibodies directed against
the FLAG tag of STAT5A-1⇤6, against total STAT5 and against RNA polymerase II (RNA Pol II). No
STAT5 signal was detected in fractions 10-12, which were therefore not shown. The molecular weight
marker thyroglobulin (669 kDa) eluted from the column in fraction 13, while the marker BSA (66 kDa)
eluted in fractions 23 and 24 (not shown).
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Of note, the nuclear fraction which was analyzed by gel filtration chromatography
contained mostly soluble nuclear proteins and was largely devoid of insoluble chromatin
and its associated proteins. We can therefore from those results not exclude that deacety-
lase inhibitors might disrupt STAT5-containing protein complexes associated with chro-
matin. Furthermore, we cannot exclude that a STAT5-specific cofactor associated with
chromatin might be involved in inhibition of STAT5-mediated transcription by deacety-
lase inhibitors. Thus, the finding that neither acetylation of STAT5 nor soluble nuclear
protein complex disruption seem to account for the inhibition of STAT5-mediated tran-
scription by deacetylase inhibitors, strengthened the possibility that the inhibition might
take place at the chromatin level.
4.3.6 Inhibition of STAT5-mediated transcription by deacety-
lase inhibitors correlates with rapid induction of global
chromatin hyperacetylation
For reasons stated above, the focus was changed to acetylated histones as possible acety-
lated substrate involved in inhibition of STAT5-mediated transcription by deacetylase
inhibitors. Several arguments, in agreement with the data collected so far, support
a possible involvement of acetylated histones: Acetylated histones are well character-
ized substrates of HDACs, histone acetylation is a↵ected by several partially redundant
HDACs (Jurkin et al., 2011; Dovey et al., 2013; Kelly & Cowley, 2013; Wolfson et al.,
2013; You et al., 2013), histone acetylation is a↵ected by deacetylase inhibitors (Yoshida
et al., 1990; Richon et al., 2000; Rada-Iglesias et al., 2007; Wang et al., 2009), and changes
in histone acetylation are known to a↵ect transcription (Allfrey et al., 1964; Allegra et al.,
1987; Tse et al., 1998; Agalioti et al., 2000; Richon et al., 2000; Deckert & Struhl, 2001;
Aoyagi & Archer, 2007; Lin et al., 2014). Initially, acetylated histones were not considered
the most likely factor involved in STAT5-mediated transcription, since previous work of
our group argued against an involvement of histone acetylation (Rascle & Lees, 2003).
Chromatin immunoprecipitation (ChIP) experiments presented in that work showed that,
while TSA induced histone hyperacetylation at the control gene c-Fos in IL-3-stimulated
or unstimulated cells, TSA did not significantly change histone H3 and H4 acetylation
at the STAT5 target gene Cis (Rascle & Lees (2003), fig. 3C and D). This led us to
the conclusion that deacetylase inhibitors inhibit STAT5-mediated transcription inde-
pendently of local changes of histone acetylation at STAT5 target genes (Rascle & Lees,
2003). However, in that study histone H3 and H4 acetylation levels were not normalized
to total nucleosome occupancy, since no validated ChIP grade H3 antibody as a marker
for nucleosome occupancy was available at that time. Thus, a local e↵ect of TSA on
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histone acetylation and on histone occupancy might have been missed. Therefore, a pos-
sible involvement of acetylated histones in inhibition of STAT5-meditated transcription
was reassessed.
In case an increase in histone acetylation upon deacetylase inhibitor treatment is in-
volved, this increased acetylation should occur within the same time frame as inhibition
of STAT5-mediated transcription. Inhibition of STAT5-mediated transcription is already
evident after 5 min TSA treatment at the level of dissociation of RNA polymerase II
from STAT5 target genes and at 20 min at the level of reduced Cis mRNA levels (Rascle
et al., 2003). Consequently, a rapid increase in global histone acetylation is expected upon
treatment with TSA, VPA and apicidin, which inhibited STAT5-mediated transcription,
but not upon treatment with MGCD0103 and MS-275, which had no e↵ect on STAT5-
mediated transcription (Fig. 4.3). The e↵ect of deacetylase inhibitors on global histone
H3 and H4 acetylation levels was analyzed by western blot. Ba/F3 cells were treated for
0-60 min with selective deacetylase inhibitors using concentrations at which these were
e↵ective (200 nM TSA, 3 mM VPA, 500 nM apicidin) or ine↵ective (1 µM MGCD0103,
5 µM MS-275) in inhibiting STAT5-mediated transcription. Whole-cell lysates were pre-
pared and analyzed by western blot using antibodies directed against acetylated histone
H3 and H4, as well as against total histone H3 as a loading control. Within up to 60 min
treatment with MGCD0103 or MS-275, which did not inhibit STAT5-mediated tran-
scription (Fig. 4.3D and E), no change in histone acetylation was detectable (Fig. 4.16).
By contrast, TSA, VPA, and apicidin, which did inhibit STAT5 target gene induction
(Fig. 4.3A, B, and C), quickly induced an increase in global histone H3 and H4 acetylation
in a time-dependent manner (Fig. 4.16). Changes in histone acetylation were already ev-
ident after 15 min treatment (Fig. 4.16), which is in accordance with the rapid inhibition
of STAT5-mediated transcription by deacetylase inhibitors (Rascle et al., 2003). Thus,
the concomitance of deacetylase inhibitor-mediated repression of STAT5-mediated tran-
scription and of increased histone H3 and H4 acetylation supports the possible involve-
ment of histone acetylation in inhibition of STAT5-mediated transcription by deacetylase
inhibitors.
Noteworthy, in the literature, an increase in histone acetylation was reported after
4-24 h treatment with the benzamide deacetylase inhibitors MGCD0103 or MS-275, at
similar inhibitor concentrations as in the this study (Hu et al., 2003; Fournel et al., 2008;
Khan et al., 2008; Arts et al., 2009; Duque-Afonso et al., 2011). Thus, the absence of e↵ect
of MGCD0103 and MS-275 on histone acetylation presented here might be a consequence
of the short treatment duration of up to 1.5 h. Accordingly, 10 h treatment with MS-275
increased histone acetylation and inhibited expression of the STAT5 target gene Cis in
Ba/F3 cells (data not shown, Dr. Anne Rascle, Pinz et al., 2015, fig. S5).
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Figure 4.16: The deacetylase inhibitors TSA, VPA and apicidin, which inhibit STAT5
transactivation, rapidly induce global histone hyperacetylation
Ba/F3 cells were treated with the deacetylase inhibitors TSA (200 nM), VPA (3 mM), apicidin (500 nM),
MGCD0103 (1 µM) or MS-275 (5 µM) for 0-60 min, as indicated. For histone analysis, freeze-thaw lysates
were prepared as described in Material and methods 3.2.4.2, followed by western blot with antibodies
directed against acetylated histone H3 (Ac-H3), against acetylated histone H4 (Ac-H4), or against total
histone H3 (H3). Total histone H3 served as a loading control. (Data shown in this figure were generated
by Dr. Anne Rascle.)
4.3.7 TSA treatment induces changes in histone occupancy and
acetylation at multiple genes and di↵erentially a↵ects re-
cruitment of RNA polymerase II
Histone acetylation modulates chromatin structure and nucleosome stability (Wire´n et al.,
2005; Shogren-Knaak et al., 2006; Di Cerbo et al., 2014; Felisbino et al., 2014; Frank et al.,
2016), and deacetylase inactivation can lead to nucleosome loss in yeast (Wire´n et al.,
2005; Chen et al., 2012). Therefore, the strong increase in histone acetylation occurring
upon deacetylase inhibitor treatment might a↵ect chromatin organization in Ba/F3 cells.
Furthermore, histone acetylation as well as chromatin structure and nucleosome occu-
pancy a↵ect transcription (Allfrey et al., 1964; Allegra et al., 1987; Lorch et al., 1987;
Han & Grunstein, 1988; Tse et al., 1998; Wyrick et al., 1999; Agalioti et al., 2000; Richon
et al., 2000; Aoyagi & Archer, 2007; Rada-Iglesias et al., 2007; Lin et al., 2014). There do
not seem to be universal changes in chromatin organization upon deacetylase inhibitor
treatment that determine increased or decreased transcription of the modified gene (Ellis
et al., 2008; Halsall et al., 2015). However, at the level of specific genes, local changes
in chromatin organization might be involved in altered transcriptional activity. There-
fore, local changes in chromatin organization at STAT5 target genes upon deacetylase
inhibitor treatment might be involved in inhibition of STAT5-mediated transcription.
This involvement would be further supported if those changes occurred at all STAT5
target genes and if those changes correlated with RNA polymerase II recruitment.
Thus, to identify on the one hand deacetylase-inhibitor induced changes in chromatin
organization in general and on the other hand local changes in chromatin organization at
STAT5 target genes in particular, chromatin immunoprecipitation (ChIP) experiments
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were performed. Nucleosome occupancy, histone H3 and H4 acetylation, and RNA poly-
merase II recruitment were analyzed at the STAT5 target genes Cis and Osm as well as
at the control genes c-Fos and p21. The two STAT5-independent control genes c-Fos and
p21 are both IL-3-inducible, but in contrast to STAT5 target genes which are inhibited,
they are upregulated by deacetylase inhibitors (Xiao et al., 1999; Richon et al., 2000; Ras-
cle et al., 2003; Rascle & Lees, 2003; Sachweh et al., 2013). Besides chromatin alterations
caused by TSA, chromatin alterations might also be caused by STAT5 and by abrogated
transcription. To identify chromatin changes caused by TSA, unstimulated Ba/F3 cells
were used. In that condition, STAT5 target genes are not actively transcribed, so that
chromatin changes detected upon TSA treatment of unstimulated cells are caused only
by TSA treatment, and not by STAT5 or abrogated transcription. The TSA-induced
chromatin organization can then be compared to chromatin organization at the STAT5-
bound actively transcribed gene in the presence of IL-3 and to chromatin organization of
the STAT5-bound inhibited gene (abrogated transcription) in the presence of IL-3 and
TSA.
First, TSA-induced changes of histone H3 occupancy, as a marker for nucleosome occu-
pancy, and RNA polymerase II recruitment were analyzed by ChIP at STAT5 target and
control genes. Rested Ba/F3 cells were treated with TSA or vehicle for 60 min, of which
the last 30 min were in the absence or presence of IL-3. To characterize time-dependent
changes of chromatin alterations caused by TSA in the absence of STAT5-binding or
abrogated transcription, 5, 15 and 30 min TSA-treated, unstimulated Ba/F3 cells were
analyzed in the assay as well. Cells were crosslinked with formaldehyde, chromatin was
sheared by sonication to fragments of about 500 bp DNA length, and immunoprecipita-
tion was performed using antibodies directed against total histone H3 and against RNA
polymerase II. DNA co-precipitated with histones was analyzed by quantitative PCR
using primers covering the proximal promoters of STAT5 target or control genes. At
STAT5 target genes, the investigated locus encompasses STAT5 binding sites. The prox-
imal promoter was chosen for analysis, since changes in chromatin organization at that
locus are most likely to a↵ect (STAT5-dependent) assembly of the transcriptional machin-
ery. DNA co-precipitated with RNA polymerase II was analyzed using primers covering
regions around the transcription start site (TSS) of the investigated genes (Fig. 4.18).
ChIP revealed that histone H3 occupancy at the promoter was higher in unstimulated
than in IL-3-stimulated cells at all four investigated genes. Interestingly, in unstimulated
cells, TSA induced a time-dependent loss of histone H3 at all four promoters. In IL-3
stimulated cells, histone occupancy at the promoter of STAT5 target genes remained at
a similar level irrespective whether TSA was absent or present. Thus, histone occupancy
at inhibited STAT5 target genes upon TSA treatment was similar to histone occupancy
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at transcriptionally active genes. As expected from the IL-3-dependent induction of the
analyzed genes (Fig. 4.2 and Fig. 4.3) and in accordance with previous reports (Richon
et al., 2000; Rascle et al., 2003; Rascle & Lees, 2003), RNA polymerase II association
with all four genes was low in the absence of IL-3 and high upon IL-3 stimulation (Fig.
4.18). Furthermore, in agreement with previous reports (Rascle et al., 2003; Rascle &
Lees, 2003), TSA abrogated recruitment of RNA polymerase II to target genes upon IL-3
stimulation, while it did not a↵ect recruitment of RNA polymerase II to control genes.
Interestingly, at all four genes, TSA treatment led to an increase in RNA polymerase II
association in the absence of IL-3, possibly a consequence of increased DNA accessibility
upon histone loss. However, RNA polymerase II association in TSA-treated, unstimu-
lated cells compared to vehicle-treated stimulated cells remained about 3-fold lower at
STAT5 target genes, while it reached a similar level at control genes (Fig. 4.18 and
data not shown, Dr. Anne Rascle and Samy Unser, Pinz et al., 2015, fig. 8). This sug-
gests that RNA polymerase II is recruited to STAT5 target and control genes by distinct
mechanisms.
Cis ORF
STAT5 bs
+5300+1
C D E FBA G H I
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ORF
STAT5 bs
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Figure 4.17: Schematic representation of the location of ChIP amplicons
Schematic representation of the Cis gene locus as well as the promoter regions of Osm, c-Fos and p21.
Distances along the DNA are drawn to scale. Cis exons (grex boxes) are depicted above its open reading
frame (ORF). In the proximal promoter of Cis there are four STAT5 binding sites (bs) arranged in two
clusters, and there are two STAT5 binding sites in the promoter of Osm. Below the genes, the ChIP
amplicons are depicted and labeled with capital letters A-O.
In summary, local histone occupancy at STAT5 target genes did not correlate with
RNA polymerase II recruitment, and furthermore, histone occupancy of repressed STAT5
target genes was similar as histone occupancy of the active genes, an occupancy that nor-
mally allows recruitment of the transcriptional machinery. Together this suggests that
local nucleosome occupancy is unlikely to be involved in the specific loss of RNA poly-
merase II from STAT5 target genes upon deacetylase inhibitor treatment. When looking
at the general e↵ect of deacetylase inhibitors, the striking loss of histone H3 occupancy
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Figure 4.18: TSA induces a rapid loss of histone H3 occupancy at all investigated genes,
while di↵erentially a↵ecting recruitment of RNA polymerase II to STAT5-dependent versus
-independent genes
Ba/F3 cells were withdrawn from IL-3 for 10 h and then treated with vehicle (0.02% DMSO), or 200 nM
TSA for 5, 15, 30 or 60 min. In addition, part of the 60 min vehicle or TSA treated cells were stimulated
with IL-3 for the last 30 min. Cells were formaldehyde-crosslinked and subjected to ChIP according to
the conventional protocol as previously described (Rascle et al., 2003; Pinz et al., 2014a, 2015), using
antibodies specific for histone H3 or RNA polymerase II. DNA co-precipitated with histone H3 was
analyzed by qPCR using primers specific for the proximal promoter of the STAT5-dependent genes Cis
(amplicon C) and Osm (amplicon J) or the IL-3-inducible STAT5-independent genes c-Fos (amplicon
L) and p21 (amplicon N). In the case of STAT5-dependent genes, the analyzed locus covered STAT5
binding sites (bs). DNA co-precipitated with RNA polymerase II was analyzed using primers specific for
the TSS of the same genes (amplicons D, K, M, O). The location of the respective amplicons C-O are
depicted in Figure 4.17. (Data shown in this figure were generated together with Dr. Anne Rascle and
Samy Unser.)
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upon deacetylase inhibitor treatment at all investigated genes, concomitant to global his-
tone hyperacetylation, suggests that chromatin is reorganized, resulting in similar changes
in chromatin organization at multiple genes. By contrast, the consequences of deacety-
lase inhibitor treatment for the recruitment of RNA polymerase II to these genes were
di↵erent. Together this indicates that RNA polymerase II is recruited by a di↵erent mech-
anism to STAT5 target genes than to control genes. Furthermore, this might indicate
that a chromatin-associated, STAT5-specific factor might be involved in the recruitment
of RNA polymerase II to STAT5 target genes and that this factor might be lost upon
deacetylase inhibitor-induced, global chromatin reorganization.
To better characterize deacetylase inhibitor-induced changes in histone H3 occupancy,
histone H3 occupancy was analyzed along Cis, from basepair -800 to + 4000 relative to the
TSS (data not shown, Dr. Anne Rascle and Samy Unser, Pinz et al., 2015, fig. 7). ChIP
experiments revealed that the same changes of histone H3 occupancy occurred along the
whole gene as at the promoter: The TSA-induced loss of histone H3 in unstimulated cells
occurred uniformly along the gene, and resulted, in stimulated and unstimulated cells, in
a histone H3 occupancy along the whole gene which was similar as histone H3 occupancy
of the transcriptionally active gene. Since this nucleosome occupancy normally allows
RNA polymerase II recruitment, the absence of RNA polymerase II after TSA treatment
has to be explained by di↵erent factors than by local changes of histone occupancy along
STAT5 target genes.
To further characterize the e↵ect of deacetylase inhibitor treatment on chromatin
organization at di↵erent genes, and to investigate whether local changes in histone acety-
lation might be involved in the loss of RNA polymerase II from STAT5 target genes,
acetylation of histone H3 and H4 was analyzed along Cis (data not shown, Dr. Anne
Rascle and Samy Unser, Pinz et al., 2015, fig. 7). To account for changes in nucleosome
occupancy, histone H3 and H4 acetylation signals were normalized to total histone H3
signals. ChIP experiments showed that in untreated cells histone acetylation increased
along the Cis gene upon IL-3 stimulation. In unstimulated cells, TSA treatment evenly
increased histone H3 and H4 acetylation along the Cis gene, in accordance with the
global histone hyperacetylation induced by deacetylase inhibitors. This TSA-induced
acetylation pattern only slightly changed upon IL-3 stimulation and thus was similar for
unstimulated and IL-3-stimulated cells. Importantly, in IL-3-stimulated cells, the TSA-
induced acetylation pattern of the repressed gene di↵ered from the acetylation pattern
of the active gene in the absence of TSA. These acetylation di↵erences might be a cause
of RNA polymerase II loss or a consequence of RNA polymerase II loss or most likely
a combination thereof. Thus, these di↵erences indicate that TSA-induced changes in
chromatin organization might possibly be involved in the impaired recruitment of RNA
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polymerase II to STAT5 target genes.
Analysis of histone acetylation within the promoter of the control genes c-Fos and p21
(data not shown, Dr. Anne Rascle and Samy Unser, Pinz et al., 2015, fig. 8) revealed
similar changes as observed at STAT5 target genes: TSA induced an increase in histone
acetylation in unstimulated cells and this acetylation pattern was only slightly changed
upon IL-3-stimulation of TSA-treated cells, however, the acetylation pattern upon TSA
treatment di↵ered from the acetylation pattern of IL-3-induced genes in the absence of
TSA. Thus, similar changes in histone acetylation upon TSA treatment occurred at all
investigated genes.
Together these data demonstrate that deacetylase inhibitor treatment - probably via
global increase in histone acetylation - induces similar changes in chromatin organiza-
tion, namely loss of histone H3 and altered histone H3 and H4 acetylation levels, at
all genes investigated. Since, furthermore, deacetylase inhibitor treatment had di↵erent
consequences for the transcription of specific genes, our data suggest that chromatin-
associated, gene-specific cofactors might be responsible for transcriptional up- or down-
regulation following deacetylase inhibitor treatment and that these cofactors are possibly
sensitive to histone acetylation. At STAT5 target genes in particular, local changes in
chromatin organization suggest that the function of such proposed chromatin-associated
cofactor is probably not a↵ected by local deacetylase inhibitor-induced histone loss, but
might be a↵ected by local or global changes in histone acetylation.
4.4 BRD2 association with the STAT5 target gene
Cis is lost upon TSA treatment
A chromatin-associated factor that is implicated in the regulation of STAT5, sensi-
tive to histone acetylation and that interacts with the transcriptional machinery, is
bromodomain-containing protein 2 (BRD2). BRD2, a member of the bromodomain and
extra-terminal (BET) protein family, is involved in the regulation of STAT5 activity in
dendritic cells and in leukemia cell lines (Liu et al., 2014; Toniolo et al., 2015) and in-
teracts with acetylated histones (Kanno et al., 2004; LeRoy et al., 2008) and with the
transcription machinery components TBP and RNA polymerase II (Crowley et al., 2002;
Peng et al., 2007; LeRoy et al., 2008). BET proteins such as BRD2 can be inhibited by
the BET-specific inhibitor (+)-JQ1 (referred to as JQ1 thereafter), which binds compet-
itively to the acetyl-lysine recognition motif of BET bromodomains and thus interferes
with binding of BET family members to acetylated histones (Filippakopoulos et al., 2010).
JQ1 interferes with induction of STAT5 target genes in leukemia cells lines (Liu et al.,
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2014), and we could show that JQ1 inhibits IL-3-induced expression of the STAT5 target
genes Cis, Osm, and c-Myc in a dose-dependent manner in Ba/F3 cells (data not shown,
Dr. Anne Rascle, Pinz et al., 2015, fig. 9). This supports a possible involvement of BET
proteins such as BRD2 in the regulation of STAT5-mediated transcription in Ba/F3 cells.
4.4.1 BRD2 binds to Cis and is lost upon TSA or JQ1 treat-
ment
In case BRD2 is required for STAT5-mediated transcription, it probably associates with
actively transcribed STAT5 target genes. Therefore, a possible association of BRD2 with
the STAT5 target gene Cis was analyzed in Ba/F3 cells by ChIP using primers covering
the Cis gene from basepair -800 to + 4000 relative to the transcription start site (TSS)
(data not shown, Dr. Anne Rascle and Samy Unser, Pinz et al., 2015, fig. 11A). Ba/F3
cells were left unstimulated or stimulated with IL-3 for 30 min to activate STAT5. Upon
IL-3 stimulation, a specific recruitment of BRD2 to the transcription start site (TSS) of
Cis was detected, demonstrating that BRD2 is associated with actively transcribed Cis
and suggesting that its recruitment might be STAT5-dependent.
Of note, although the BRD2 signal at the TSS was well above the background signal
obtained using an unspecific rabbit IgG antibody, the co-precipitated DNA was only
0.05% enriched relative to input DNA (data not shown, Dr. Anne Rascle and Samy
Unser, Pinz et al., 2015, fig. 11A). Therefore, to increase the sensitivity of the assay,
the ChIP protocol was optimized to increase the amount of specifically co-precipitated
DNA (refer to Material and methods 3.2.7 and Pinz & Rascle, 2017). In short, the most
relevant di↵erences to the conventional protocol were, first, the enrichment of nuclei from
formaldehyde-crosslinked cells, instead of using whole cells, and second, the fractionation
of chromatin by MNase to obtain DNA fragments of about 500 bp length (Fig. 3.1),
instead of using sonication for DNA fractionation. Immunoprecipitation and analysis of
co-precipitated DNA were performed similarly as in the conventional protocol (Fig. 3.1
and Pinz & Rascle, 2017). This optimized protocol is described in details in Material and
methods 3.2.7 and Pinz & Rascle (2017) and was used for all further ChIP experiments
in this study.
The question remained whether and how deacetylase inhibitors might a↵ect BRD2
function and by that inhibit STAT5-mediated transcription. In case BRD2 is required for
STAT5-mediated transcription, STAT5-mediated transcription is probably inhibited by
loss of BRD2 from STAT5 target genes. This proposition is supported by the inhibition of
STAT5-mediated transcription by the BET-specific inhibitor JQ1, which interferes with
binding of BET proteins such as BRD2 to acetylated histones and like that induces a loss
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of BET proteins from chromatin in general (Filippakopoulos et al., 2010) and possibly
of BRD2 from STAT5 target genes in particular. Thus, JQ1 probably inhibits STAT5-
mediated transcription by inducing a loss of BRD2 from STAT5 target genes. This
suggests that TSA might similarly inhibit STAT5-mediated transcription by inducing a
loss of BRD2 from STAT5 target genes.
In case JQ1 inhibits STAT5-mediated transcription by loss of BRD2 and not by
a↵ecting upstream steps of the STAT5 pathway, DNA binding of STAT5 should remain
una↵ected by JQ1 treatment. Therefore, to validate the above model, we confirmed that
JQ1 treatment does not a↵ect STAT5 DNA binding. STAT5 binding to its binding sites
at the promoter of its target genes Cis and Osm was analyzed in Ba/F3-1⇤6 cells treated
for 60 min with 1 µM JQ1, 200 nM TSA or vehicle (DMSO) by ChIP using antibodies
directed against STAT5A-1⇤6. TSA treatment served as a negative control since it does
not a↵ect DNA binding of wild-type STAT5 (Rascle et al., 2003; Pinz et al., 2014a)
and is unlikely to a↵ect DNA binding of STAT5A-1⇤6 in Ba/F3-1⇤6 cells. In untreated
cells at actively transcribed STAT5 target genes, constitutively active STAT5A-1⇤6 was
bound to its binding sites at the promoter of its target genes Cis and Osm (Fig. 4.19A),
as expected. No association of STAT5A-1⇤6 was detected with the proximal promoter
of the IL-3 inducible control gene c-Fos or with a downstream control locus within the
open reading frame (ORF) of Cis (Fig. 4.19A). Importantly, STAT5A-1⇤6 binding to its
binding sites at the target genes Cis or Osm (Fig. 4.19A) was neither a↵ected by TSA
nor by JQ1. This confirms that JQ1 does not inhibit STAT5-mediated transcription by
impairing DNA binding of STAT5 or by impairing one of the upstream STAT5 activation
steps which would also result in less DNA-bound STAT5. These results are in agreement
with Liu et al. (2014), which demonstrated that JQ1 does not not a↵ect STAT5 binding
to Cis in leukemic cell lines. Thus, our data support the model that JQ1 inhibits STAT5-
mediated transcription via loss of BRD2 from STAT5 target genes.
To further validate above model, the e↵ect of TSA and JQ1 on association of BRD2
with STAT5 target genes was investigated. Therefore, Ba/F3-1⇤6 cells were treated for
60 min with 200 nM TSA, 1 µM JQ1, or vehicle (DMSO), and were then subjected to the
optimized ChIP protocol using antibodies directed against BRD2. DNA co-precipitated
with BRD2 was analyzed using primers covering the Cis gene from basepair -800 to
+ 4000 relative to the TSS, as before. Similarly as in IL-3-stimulated Ba/F3 cells, in
Ba/F3-1⇤6 cells, BRD2 was associated with the transcription start site and the 5’ region
of the open reading frame (Fig. 4.19B). JQ1 strongly reduced BRD2 binding along Cis,
as expected from its inhibitory activity towards BET bromodomains. Strikingly, TSA
treatment similarly reduced BRD2 binding, albeit to a lesser extent than JQ1 treatment.
By contrast, at the control genes c-Fos and p21, BRD2 binding to the transcription start
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Figure 4.19: BRD2 associates with TSS and ORF of the STAT5 target gene Cis and is lost
upon TSA and JQ1 treatment
Ba/F3-1⇤6 cells were treated with vehicle (0.02% DMSO), TSA (200 nM) or the BET inhibitor JQ1
(1 µM) for 60 min before they were formaldehyde-crosslinked and subjected to ChIP. The ChIP assay was
performed as described in Material and methods 3.2.7, using antibodies specific for STAT5A, recognizing
STAT5A-1⇤6 (A), or using antibodies specific for BRD2 (B), (C). In addition, a rabbit-IgG control
antibody was used to determine the background signal. Co-precipitated DNA was analyzed by qPCR
with primers specific for the STAT5 binding site (bs), for the transcription start site (TSS), and for the
open reading frame (ORF) of the indicated STAT5 target or control genes. The respective amplicons
A-O are depicted in Figure 4.17. (Data shown in this figure were generated together with Dr. Anne
Rascle.)
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site was low and remained una↵ected by TSA or JQ1 treatment (Fig. 4.19C). Of note,
equally low BRD2 binding was detected at the transcription start site of the STAT5
target gene Osm, and although BRD2 binding was slightly reduced upon JQ1 treatment,
it remained una↵ected upon TSA treatment.
These data demonstrate that inhibition of STAT5-mediated transcription by TSA and
JQ1 correlates with loss of BRD2 from the STAT5 target gene Cis. This suggests, that
STAT5-mediated transcription of Cis might be inhibited by loss of BRD2 from the gene.
Furthermore, this indicates that BRD2 regulates Cis and possibly other STAT5 target
genes under normal conditions, and that TSA, and JQ1, might inhibit STAT5-mediated
transcription by loss of BRD2 and possibly of other BET proteins from STAT5 target
genes.
4.4.2 BRD2 is depleted from the soluble nuclear fraction upon
TSA treatment, and is possibly relocated to hyperacety-
lated chromatin
To investigate how deacetylase inhibitors might induce a loss of BRD2 from STAT5 target
genes, we analyzed whether TSA a↵ects the subcellular localization of BRD2 in Ba/F3
cells. Given the hyperacetylation induced by deacetylase inhibitors (Fig. 4.16) and given
the preferential binding of BRD2 to acetylated histones (Kanno et al., 2004; LeRoy et al.,
2008), BRD2 is expected to be recruited to the chromatin fraction upon TSA treatment.
TSA-treated or untreated Ba/F3 cells were successively lysed to obtain cytosolic, soluble
nuclear (representing the nucleosol) and insoluble nuclear fractions (containing mainly
chromatin-associated proteins). These fractions were analyzed by western blot (data not
shown, Dr. Anne Rascle, Pinz et al., 2015, fig. 10C). BRD2 was exclusively found in the
nucleus within the soluble and insoluble nuclear fractions. Strikingly, 60 min treatment
with the deacetylase inhibitors TSA, VPA and apicidin at concentrations at which they
inhibited STAT5 target genes and induced an increase in histone H3 and H4 acetylation,
led to a rapid depletion of BRD2 from the soluble nuclear fraction. Treatment with
MGCD0103 and MS-275 under conditions in which they did not inhibit STAT5-mediated
transcription, did not deplete BRD2 from the soluble nuclear fraction. Interestingly,
BRD2 depletion by TSA, VPA and apicidin was accompanied by a specific depletion
of TBP from the soluble nuclear fraction. Unexpectedly, no notable increase in BRD2
protein abundance was detected in the insoluble nuclear fraction and also not in the
cytosol. Since the proteasome inhibitor MG132 did not prevent the depletion of BRD2
upon TSA treatment (data not shown, Dr. Anne Rascle, Pinz et al., 2015, fig. 10A),
proteasomal degradation of BRD2 could be excluded as explanation for BRD2 depletion
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from the soluble nuclear fraction. Since TSA did not a↵ect the mRNA level of Brd2
(data not shown, Dr. Anne Rascle, Pinz et al., 2015, fig. 10B), inhibition of Brd2 gene
expression by TSA can also be excluded as explanation for BRD2 protein depletion.
Thus, the unexpected absence of enrichment of BRD2 in the insoluble nuclear fraction
could be due to the incomplete extraction method, which left behind a pellet that could
not be subjected to SDS-PAGE and western blot analysis. These data strongly suggest
that upon deacetylase inhibitor treatment, BRD2 is not degraded but rather delocalized,
possibly together with TBP and other interacting proteins, away from the soluble nuclear
fraction, probably towards hyperacetylated chromatin.
4.4.3 No direct interaction between STAT5 and BRD2 was ob-
served in solution
To investigate the mechanism of BRD2 recruitment to STAT5 target genes, it was
analyzed whether STAT5 and BRD2 interact directly. Co-immunoprecipitation
experiments from formaldehyde-crosslinked Ba/F3-1⇤6 cells were conducted according
to the optimized ChIP protocol (Material and methods 3.2.7), using antibodies directed
against STAT5A and BRD2. Beside analysis of (co-)precipitated proteins by western
blot, co-precipitated Cis DNA was analyzed by quantitative PCR as a control to
confirm e ciency and specificity of the co-immunoprecipitation. In western blot, no
co-immunoprecipitation between STAT5A and BRD2 was detected after either
STAT5A or BRD2 pull-down (Fig. 4.20A). However, while STAT5 was e ciently
immunoprecipitated by its antibody, no BRD2 was detectable in western blot after
BRD2 immunoprecipitation, despite a similar DNA co-precipitation e ciency and
specificity of BRD2 (and STAT5A) as observed before (Fig. 4.19A and B, and
Fig. 4.20B). The low BRD2 pull-down detected in western blot might contribute to the
overall low DNA enrichment after BRD2 immunoprecipitation (up to 0.16% input
DNA) as compared to STAT5A immunoprecipitation (up to 10% input DNA)
(Fig. 4.19A and B, and Fig. 4.20B). The low BRD2 pull-down is probably the result of
experimental conditions such as bu↵er composition and/or epitope masking in the
formaldehyde-crosslinked cells, which might be suboptimal for the BRD2 antibody. The
weak immunoprecipitation e ciency of BRD2 made it di cult to observe a possible
co-immunoprecipitation of STAT5. Therefore, immunoprecipitation of BRD2 was
repeated, this time from nuclear lysate of non-crosslinked STAT5A-1⇤6-expressing cells.
Now BRD2 was e ciently immunoprecipitated by its antibody, however, no STAT5
co-immunoprecipitation was detected (Fig. 4.20C). Thus, no direct interaction between
soluble STAT5A-1⇤6 and BRD2 could be observed. Therefore, BRD2 seems to be
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recruited to STAT5 target genes by a di↵erent mechanism than by direct interaction
with soluble STAT5.
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Figure 4.20: No direct interaction between BRD2 and constitutively active STAT5A-1⇤6
was observed in solution
(A), (B) STAT5A or BRD2 were immunoprecipitated following the ChIP protocol, as described in
Material and methods 3.2.5.7. The rabbit-IgG control antibody served to determine the background
signal. Immunoprecipitated proteins were analyzed by western blot using antibodies directed against
BRD2, STAT5A, or FLAG (recognizing STAT5A-1⇤6) (A). The asterisk marks an unspecific signal
associated with the bead fractions. Co-precipitated DNA of the Cis locus was analyzed by qPCR using
primers specific for STAT5 binding sites (bs) (amplicon C), for the TSS (amplicon D), or for the distal
ORF (amplicon I) (B). The location of the respective amplicons C, D and I along Cis is depicted in
Figure 4.17. (C) BRD2 was immunoprecipitated from non-crosslinked Ba/F3-tet-on-1⇤6 cells treated for
9 h with doxycycline to induce expression of STAT5A-1⇤6. Immunoprecipitation was performed in mild
bu↵er conditions, as described in Material and methods 3.2.5.7. The immunoprecipitation with rabbit-
IgG control antibody served to determine the background signal. The precipitated proteins were analyzed
by western blot using antibodies directed against BRD2 and STAT5A. I, input; SN, supernatant; B, bead
fraction.
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Discussion
STAT5-mediated transcription is inhibited by deacetylase inhibitors. Characterization
of the underlying inhibitory mechanism should contribute to a better understanding of
the mechanism of transcriptional regulation by STAT5. This thesis aimed to investigate
the mechanism of inhibition of STAT5-mediated transcription by deacetylase inhibitors.
We focused on the identification of the deacetylase involved and of its acetylated sub-
strate. We provide evidence that inhibition of (a) yet-unknown HDAC(s) target(s) his-
tone proteins, resulting in chromatin hyperacetylation, in turn altering the function of the
acetylated-chromatin-associated factor and STAT5-cofactor BRD2, as discussed below.
5.1 Inhibition of STAT5-mediated transcription by
deacetylase inhibitors involves histone but not
STAT5 acetylation
In previous studies we showed that deacetylase inhibitors had only marginal e↵ects on
local histone acetylation at STAT5 target genes (Rascle et al., 2003; Rascle & Lees,
2003), so that we considered that STAT5, instead of histones, might be the acetylated
substrate of the deacetylase involved in inhibition of STAT5-mediated transcription. We
found that lysine-to-glutamine or lysine-to-arginine mutations of selected STAT5 lysine
residues (K84, K359, K384, K675, K681, K689, K696 and K700) potentially targeted
for acetylation did not a↵ect STAT5-mediated transcription. This suggests that STAT5
acetylation does not a↵ect STAT5-mediated transcription and consequently that STAT5
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is probably not the acetylated substrate involved in inhibition of STAT5-mediated tran-
scription. On the other hand, the performed lysine-to-glutamine mutations might not
mimic acetylated STAT5 lysines close enough to exert their potential inhibitory func-
tion. While the mutation to glutamine, similarly as acetylation, neutralizes the positive
charge of the lysine residue, glutamine has a shorter side chain than the acetylated ly-
sine and might therefore not be able to assume structural functions of the acetylated
lysine residue. Thus, although the analyzed lysine-to-glutamine mutations did not a↵ect
STAT5-mediated transcription (Fig. 4.10, Fig. 4.11, Fig. 4.12, and Fig. 4.13), we can-
not exclude that increased acetylation of these lysine residues might possibly modulate
STAT5-mediated transcription. Furthermore, the absence of e↵ect of lysine-to-arginine
mutations, preserving the positive charge of the unmodified lysine, does also not con-
tradict a potential inhibitory role of lysine acetylation in inhibition of STAT5-mediated
transcription by deacetylase inhibitors. In case STAT5 is normally deacetylated when
bound to DNA, a lysine-to-arginine mutation, preventing a potential inhibitory acetyla-
tion, would not induce a derepression of STAT5 and hence no increase in STAT5-mediated
transcription. However, importantly, the lysine mutants remained sensitive to TSA, at
least those mutants containing mutations at K689, K696 and K700 which were analyzed
in the TSA-sensitivity assay (Fig. 4.13C and D). Thus, we can exclude that the inhibitory
e↵ect of TSA on STAT5-mediated transcription is mediated by an increase in acetyla-
tion of STAT5 at the investigated lysine residues. There are further lysine residues in
the STAT5 sequence and their influence on STAT5 transcriptional activity cannot be ex-
cluded, but all lysine residues within STAT5 which were either reported to be acetylated
or whose conserved lysine residue in STAT3 was reported to be acetylated were investi-
gated. Therefore the presented data suggest that TSA does not inhibit STAT5-mediated
transcription by targeting STAT5 via these lysine residues. Thus, acetylated STAT5 is
unlikely to be the acetylated substrate involved in inhibition of STAT5-mediated tran-
scription by deacetylase inhibitors.
Other groups found that lysine mutations regulate STAT5 activity (Ma et al., 2010;
Van Nguyen et al., 2012), which is in apparent contradiction to the absence of e↵ect of
lysine-to-arginine or lysine-to-glutamine mutations presented here (Fig. 4.11, Fig. 4.12,
and Fig. 4.13). However, given the stabilized phosphorylation and possibly enhanced
dimerization of STAT5A-1⇤6 (Onishi et al., 1998), our data do not exclude the possi-
bility that the mutated lysine residues might be required for a STAT5 activation step,
irrelevant to STAT5A-1⇤6, preceding DNA binding and transcription activation. Our
data therefore do not contradict the report by Ma et al. (2010), in which loss of tran-
scriptional activity upon K694R mutation within STAT5B (corresponding to K689 of
STAT5A) is likely a result of abolished STAT5 dimerization. The lack of luciferase re-
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porter gene induction by the lysine mutant in that study is thus likely a consequence of
missing nuclear transcriptionally-competent dimers and not a consequence of impaired
STAT5-mediated transcription. The same explanation of impaired dimerization might
also account for the reduced luciferase reporter induction of a STAT5A K696R mutant in
growth hormone-stimulated mouse embryonic fibroblast (MEF) cells (Van Nguyen et al.,
2012).
The e↵ect of lysine mutations on STAT5-mediated transcription was investigated in
the context of constitutively active full-length STAT5A-1⇤6 (Fig. 4.11, Fig. 4.12, and
Fig. 4.13). Therefore our data remain to be confirmed in the context of wild-type STAT5.
However, the mutations that render STAT5A-1⇤6 constitutively active are likely to a↵ect
only upstream STAT5 activation steps, namely stabilization of tyrosine phosphorylation
and possibly dimerization (Onishi et al., 1998). The proposition that STAT5A-1⇤6 consti-
tutive activity is conveyed through stabilization of its tyrosine phosphorylation (Onishi
et al., 1998) is supported by the abolished STAT5A-1⇤6-mediated transcription upon
mutation of the essential phosphorylation site, tyrosine Y694 (Fig. 4.12 and Fig. 4.13).
Although initial activation steps of STAT5A-1⇤6 might function di↵erently than acti-
vation of wild-type STAT5, both proteins probably use the same transactivation mecha-
nism. This is supported by the similar inhibition of STAT5A-1⇤6-mediated and wild-type
STAT5-mediated transcription by TSA, in terms of persistent STAT5 DNA binding but
abrogated recruitment of RNA polymerase II (Fig. 4.1, Fig. 4.18, Fig. 4.19A, and Rascle
et al., 2003). Therefore, it is highly likely that the results obtained using STAT5A-1⇤6
lysine mutants can be transferred to wild-type STAT5-mediated transcription. To def-
initely confirm our findings on wild-type STAT5 in Ba/F3 cells, an inducible STAT5
knock-down cell line could be used together with the transient transfection of wild-type
or mutant STAT5 expression constructs (rescue experiment). However, lysine residues
which are essential for initial STAT5 activation steps, such as dimerization, cannot be
analyzed for their influence on STAT5-mediated transcription using this system.
Interestingly, inhibition of STAT5-mediated transcription correlated with a rapid in-
crease in global histone acetylation, which was induced by the deacetylase inhibitors TSA,
VPA and apicidin, but not by MGCD0103 and MS-275 (Fig. 4.3 and Fig. 4.16). This
suggests, that global histone hyperacetylation might be involved in inhibition of STAT5-
mediated transcription. The absence of induction of rapid histone hyperacetylation by
the benzamide deacetylase inhibitors MGCD0103 and MS-275 in our study is probably a
consequence of their time-dependent mode of action. A mechanism has been proposed for
benzamides bound to HDAC2 (Bressi et al., 2010), in which an internal hydrogen bond
within the transiently-bound compound is gradually disrupted over time to convert to the
tightly-bound form providing increased deacetylase inhibition. This is in agreement with
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the treatment duration of 4 to 24 h after which MGCD0103 and MS-275 were shown
to induce histone hyperacetylation (Hu et al., 2003; Fournel et al., 2008; Khan et al.,
2008; Arts et al., 2009; Duque-Afonso et al., 2011). Thus, the treatment of 15 min to
1.5 h in the present work might have been too short for the benzamides MGCD0103 and
MS-275 to exhibit their inhibitory function. Accordingly, we found that 10 h treatment
with MS-275 induced histone hyperacetylation in Ba/F3 cells. Together with induction
of histone hyperacetylation, MS-275 inhibited expression of the STAT5 target gene Cis
(Dr. Anne Rascle, Pinz et al., 2015, fig. S5), supporting the involvement of histone
hyperacetylation in inhibition of STAT5-mediated transcription.
The concurrence of increased histone acetylation and inhibition of STAT5-mediated
transcription indicates that local changes in chromatin organization at STAT5 target
genes might possibly be involved in STAT5-mediated transcription. However, the local
loss of histone occupancy observed after TSA treatment in unstimulated Ba/F3 cells,
in the absence of STAT5 DNA binding and in the absence of transcription, led to a
histone occupancy which was similar to that of the actively transcribed gene (Fig. 4.18),
making it unlikely that the histone occupancy established upon TSA treatment inhibits
recruitment of the transcription machinery. It might still be possible that nucleosomes
were shifted, obscuring a DNA position directly or indirectly required for recruitment
of the transcription machinery. However, a previous study of our group (Rascle et al.,
2003) demonstrated that the DNA accessibility at the proximal promoter around STAT5
binding sites up to the transcription start site of the STAT5 target gene Cis did not change
upon deacetylase inhibitor treatment, demonstrating that TSA does not a↵ect nucleosome
positioning at that locus. Thus, local changes in nucleosome occupancy or positioning
are unlikely to be responsible for the inhibition of STAT5-mediated transcription by
deacetylase inhibitors.
Local changes in histone acetylation at STAT5 target genes were reassessed, since in
our initial study no chromatin immunoprecipitation (ChIP)-grade H3 antibody suitable
for normalization of histone acetylation to histone occupancy was available (Rascle &
Lees, 2003). The now observed local changes in histone acetylation at STAT5 target genes
and upregulated control genes upon deacetylase inhibitor treatment did not correlate with
transcriptional activity (Results 4.3.7 and Dr. Anne Rascle and Samy Unser, Pinz et al.,
2015, fig. 8) in agreement with other reports (Ellis et al., 2009; Halsall et al., 2015).
However, since similar local changes in histone H3 and H4 acetylation upon deacetylase
inhibitor treatment were observed at both STAT5 target genes investigated, we cannot
rule out that these local changes, in addition to global histone hyperacetylation, might
contribute to inhibition of STAT5-mediated transcription.
Sirtuins, class III HDACs, which are inhibited by di↵erent small molecule inhibitors
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than the classical HDACs mentioned so far, also deacetylate histones (Vaquero et al.,
2004, 2007; Hsu et al., 2016) which raises the possibility that sirtuin inhibitors might
also inhibit STAT5-mediated transcription via increase in global histone acetylation. By
contrast, we found that the sirtuin inhibitor salermide did not inhibit STAT5-mediated
transcription (Fig. 4.4), suggesting that the global level of histone acetylation was prob-
ably not increased in those experiments. So far, global histone H3 and H4 acetylation
after salermide treatment has only been analyzed after 24 h treatment in a human pan-
creatic cell line (Yar Saglam et al., 2016), and a 2- to 3-fold increase in histone acetylation
was found (while MS-275 induced an up to 4-fold increase in histone acetylation in that
study) (Yar Saglam et al., 2016). Although we used similar salermide concentrations
as Yar Saglam et al. (2016), the shorter treatment of up to 1.5 h in our study might
not have been long enough to induce global histone hyperacetylation and thereby inhibit
STAT5-mediated transcription. However, sirtuin inhibition that induces a global increase
in histone acetylation, as shown for instance by Kim et al. (2015), would be a valuable
tool to confirm whether histone hyperacetylation is su cient to inhibit STAT5-mediated
transcription, or whether additional e↵ects specific for classical HDACs are involved.
5.2 Inhibition of STAT5-mediated transcription by
deacetylase inhibitors probably involves redun-
dant class I HDAC activity
The finding that the e↵ect of deacetylase inhibitors on STAT5-mediated transcription is
probably induced through histone hyperacetylation, suggests that the e↵ect of deacety-
lase inhibitors is probably mediated by class I HDACs, HDAC1, HDAC2, HDAC3, and
HDAC8, since these are the major HDACs responsible for the deacetylation of histones
(Verdel et al., 2000; Fischle et al., 2001, 2002; Lahm et al., 2007; Dovey et al., 2013; Kelly
& Cowley, 2013; Lobera et al., 2013; Wolfson et al., 2013; You et al., 2013; Di Giorgio
et al., 2015; Liu et al., 2015).
Surprisingly, of the four class I HDACs only HDAC3, together with HDAC5 and
HDAC11, was among the candidates for involvement in STAT5-mediated transcription
according to our screen with several selective deacetylase inhibitors (Tab. 4.1). This
result might be (i) due to the di culty to determine accurate in vivo IC50 values of the
inhibitors for the individual HDACs (Chou et al., 2008; Delcuve et al., 2012; Vaidya et al.,
2012; Hull et al., 2016) or (ii) due to the late mode of action of MS-275 and MGCD0103
discussed above (Hu et al., 2003; Fournel et al., 2008; Khan et al., 2008; Arts et al.,
2009; Bressi et al., 2010; Duque-Afonso et al., 2011), which was not taken into account
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during the analysis, so that their targeted HDACs were misleadingly excluded as possible
candidates in the inhibitor screen. However, since the selective deacetylase inhibitors VPA
and apicidin, which induced histone hyperacetylation and inhibited STAT5-mediated
transcription, are class I deacetylase inhibitors, and since after a longer incubation time
the class I inhibitor MS-275 also inhibited STAT5-mediated transcription (Dr. Anne
Rascle, Pinz et al., 2015, fig. S5), the data obtained with these selective deacetylase
inhibitors support the proposed involvement of class I deacetylases in inhibition of STAT5-
mediated transcription.
SiRNA-mediated knock-down of individual HDACs or of combinations thereof failed to
identify the HDACs responsible for inhibition of STAT5-mediated transcription (Fig. 4.7,
Fig. 4.8, and Pinz et al., 2015, fig. S4). Unexpectedly, even co-transfection of siRNAs
targeting the class I HDACs HDAC1, HDAC2 and HDAC3 failed to induce a strong
histone hyperacetylation and to inhibit STAT5-mediated transcription (Fig. 4.8). This
is probably a consequence of the incomplete knockdown of the individual HDACs in that
experiment. Together with the functional redundancy of these class I HDACs regarding
histone deacetylation (Montgomery et al., 2007; Jurkin et al., 2011; Dovey et al., 2013)
and together with the high expression level of HDAC1 and HDAC2 in Ba/F3 cells (Fig.
4.6), the remaining deacetylase activity was probably able to maintain low-acetylated
chromatin.
Alternatively, the di↵erent e↵ects of treatment with deacetylase inhibitors and de-
pletion of HDACs by siRNA-mediated knockdown might reflect the phenomenon that
enzymatic HDAC inhibition and physical depletion of HDACs sometimes induce di↵erent
cellular e↵ects (Mottus et al., 2000; Dejligbjerg et al., 2008; Kra¨mer, 2009; Chen et al.,
2012; Shah et al., 2013). Such di↵erent e↵ects might be due to an HDAC-independent
mode of action of deacetylase inhibitors (Shah et al., 2013), or due to deacetylase activity-
independent, probably structural functions of HDACs in multiprotein complexes (Mottus
et al., 2000; Kra¨mer, 2009; Chen et al., 2012). However, since physical elimination of
HDACs had no e↵ect on STAT5-mediated transcription, our data do not support a pre-
dominantly structural role of HDACs during inhibition of STAT5-mediated transcription.
Isoform-specific deacetylase inhibitors or more e cient HDAC knock-down strategies such
as lentiviral delivery of siRNA expression cassettes might help to confirm the involvement
of one or several HDACs and their exact function during inhibition of STAT5-mediated
transcription by deacetylase inhibitors.
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5.3 Deacetylase inhibitors inhibit STAT5-mediated
transcription by a↵ecting bromodomain and ex-
traterminal domain (BET) protein function
The involvement of histone acetylation in inhibition of STAT5-mediated transcription sug-
gests that chromatin-associated factors which are sensitive to histone acetylation might
be involved in inhibition of STAT5-mediated transcription. The acetyl-histone binding
protein BRD2, a member of the BET protein family, has been shown before to regulate
STAT5-mediated transcription in human leukemia cell lines (Liu et al., 2014). Using
chromatin immunoprecipitation (ChIP), we could now demonstrate for the first time
that BRD2 is directly associated with the STAT5 target gene Cis in a STAT5-dependent
manner, further supporting the involvement of BRD2 in STAT5-mediated transcription.
In addition, our data provided evidence that the BET inhibitor (+)-JQ1 (JQ1) inhibits
STAT5-mediated transcription not only in leukemic cells (Liu et al., 2014), but also in
the non-tumorigenic pro-B cell line Ba/F3 (Dr. Anne Rascle, Pinz et al., 2015, fig. 9).
Therefore, our data strongly support BRD2 and possibly other BET proteins as cofactors
of STAT5-mediated transcription.
The BET inhibitor JQ1 seems to inhibit STAT5 not only at the level of STAT5-
mediated transcription (this work and Liu et al., 2014), but longer treatment with
JQ1 (3-25 h) was shown to reduce the activating tyrosine phosphorylation of STAT5
in monocyte-derived dendritic cells (MO-DCs) and in several leukemia and lymphoma
cell lines (Ott et al., 2012; Liu et al., 2014; Toniolo et al., 2015). However, in agreement
with the absence of JAK kinase inhibitor activity of JQ1 (Liu et al., 2014) and in agree-
ment with the delayed onset of reduced STAT5 phosphorylation, this phenomenon seems
to be a secondary e↵ect of JQ1 treatment. Reduced STAT5 phosphorylation in JQ1
treated cells can be explained at least in part by suppressed transcription of components
of cytokine receptors responsible for STAT5 activation, for instance of the interleukin-7
receptor in B cell acute lymphocytic leukemia (B-ALL) cell lines (Ott et al., 2012) or
of the GM-CSF receptor in MO-DCs (Toniolo et al., 2015). Interestingly, the a↵ected
GM-CSF receptor ↵ chain gene is a STAT5 target gene (Toniolo et al., 2015), indicating
that inhibition of STAT5-mediated transcription by JQ1 might be involved in inhibition
of expression of this receptor subunit. Further support for JQ1-mediated inhibition of
STAT5-mediated transcription is given by the absence of reduction of STAT5 phospho-
rylation in several leukemic cell lines (HEL, K562 and ALL-SIL cell lines) (Liu et al.,
2014). In these cell lines JQ1 inhibited STAT5 target gene expression, confirming that
inhibition of STAT5-mediated transcription by JQ1 occurred independently of impaired
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STAT5 phosphorylation (Liu et al., 2014). While it remains to be confirmed whether
JQ1 a↵ects the interleukin-3-dependent activating phosphorylation of wild-type STAT5
in Ba/F3 cells, our group observed an immediate inhibition of STAT5 target gene ex-
pression (within 1.5 h JQ1 treatment, Dr. Anne Rascle, Pinz et al., 2015, fig. 9), which
is unlikely to be the consequence of a delayed reduction of STAT5 phosphorylation. Fur-
thermore, we could show using ChIP that JQ1 does not a↵ect binding of constitutively
active STAT5A-1⇤6 to its target genes in Ba/F3-1⇤6 cells (Fig. 4.19A). This indicates
that upstream steps of STAT5A-1⇤6 activation were not impaired by JQ1 treatment.
Altogether, and in agreement with the literature (Liu et al., 2014), our data support the
proposition that the immediate inhibition of STAT5 by JQ1 occurs at the level of STAT5-
mediated transcription, which supports BET proteins as cofactors of STAT5-mediated
transcription.
Importantly, we found that TSA treatment resulted in the loss of BRD2 from the
STAT5 target gene Cis (Fig. 4.19B). Similarly, JQ1 treatment also resulted in the loss of
BRD2 from the Cis gene (Fig. 4.19B), as expected from the mode of action of JQ1, which
competitively binds to BET bromodomains and thus interferes with binding of BET
proteins to acetylated histones and to chromatin (Filippakopoulos et al., 2010). Since
STAT5-mediated transcription is inhibited by both compounds, this strongly suggests
that STAT5-mediated transcription can be inhibited by loss of BRD2 from its target
genes. This proposition is further supported by the demonstration that depletion of
the BRD2 protein level also inhibits STAT5-mediated transcription (Liu et al., 2014).
Together, these observations support a model in which deacetylase inhibitors repress
STAT5-mediated transcription by inducing a loss of BRD2 from STAT5 target genes.
The loss of BRD2 from the Cis gene upon deacetylase inhibitor treatment coincided
with a nuclear redistribution of BRD2 (Results 4.4.2 and Dr. Anne Rascle, Pinz et al.,
2015, fig. 10) and with a global increase in histone acetylation (Fig. 4.16). The multiple
newly acetylated histones created upon deacetylase inhibitor treatment probably com-
pete for binding of the acetyl-histone binding protein BRD2 (Kanno et al., 2004; LeRoy
et al., 2008), which might lead to the observed redistribution of BRD2 and to BRD2
loss from the sites it normally binds to such as the STAT5 target gene Cis. Although
we could demonstrate that BRD2 is depleted from the nucleosol as histone acetylation
increases, the expected enrichment of BRD2 in the insoluble chromatin fraction could
not be observed (Results 4.4.2 and Dr. Anne Rascle, Pinz et al., 2015, fig. 10C). This
might be explained by our failure to achieve complete protein extraction from the in-
soluble chromatin fraction, so that part of the chromatin-associated proteins might not
have been included in the analysis. We could demonstrate that deacetylase inhibitor
treatment a↵ects neither BRD2 mRNA abundance nor BRD2 proteasomal degradation.
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These findings are in agreement with a recent proteomics study (Mackmull et al., 2015)
demonstrating that although many bromodomain-containing proteins are downregulated
upon 12-48 h deacetylase inhibitor treatment, protein abundance of BRD2 was rather
increased. Furthermore, fluorescence intensity after photobleaching (FLIP) experiments
(Dey et al., 2003) demonstrated that the mobility of BRD2 decreases upon deacetylase
inhibitor treatment, indicating that a higher fraction of BRD2 is stably associated with
chromatin. Thus, in agreement with the literature, our data strongly suggest that the
loss of BRD2 from STAT5 target genes and its depletion from the nucleosol are no con-
sequence of BRD2 degradation, but rather a consequence of BRD2 redistribution to hy-
peracetylated chromatin. Importantly, further evidence for BET protein relocation after
deacetylase inhibitor treatment is given by the redistribution of BRD4 in a human breast
cancer cell line (Greer et al., 2015). Similarly to what we propose for BRD2, Greer et al.
(2015) demonstrated in a genome-wide approach that BRD4 binding is shifted towards
newly acetylated sites in gene bodies and intergenic regions and away from the highly
acetylated promoters and enhancers it normally binds to. A similar ChIP-sequencing
approach could be performed to demonstrate the genomic distribution of BRD2 before
and after deacetylase inhibitor treatment to confirm the proposed redistribution of BRD2
to hyperacetylated chromatin.
One of the many transcriptional regulators shown to interact with BRD2 is HDAC11
(Denis et al., 2006). Thus, it cannot be excluded that inhibition of HDACs might
contribute to the redistribution of BRD2 by directly disrupting or destabilizing BRD2-
containing protein complexes. This is in accordance with other reports demonstrating
that deacetylase inhibitors can act through protein complex disruption (Brush et al., 2004;
Matsuoka et al., 2007; Kra¨mer, 2009). Since acetylation increases upon IL-3 stimulation
at transcriptionally active STAT5 target genes (Results 4.3.7 and Dr. Anne Rascle and
Samy Unser, Pinz et al., 2015, fig. 7 and fig. 8 and Pinz et al., 2014b, fig. 7), the substrate
of such HDAC within a BRD2 complex would likely be a non-histone protein. Or the
HDAC in such complex could have a rather structural function, in agreement with the in-
dication that catalytically inactive HDAC2 proteins can partially assume functions of the
wild-type protein (Montgomery et al., 2007; Zimmermann et al., 2007; Guan et al., 2009;
Kra¨mer, 2009). Once the HDAC(s) responsible for inhibition of STAT5-mediated tran-
scription are identified, the influence of specific HDAC(s) on BRD2 function at STAT5
target genes can be further elucidated by using HDAC knock-down, catalytically inactive
HDAC mutants or possibly HDAC isoform-specific inhibitors.
The recruitment of BRD2 to Cis seems to be STAT5-dependent, but a mechanism
similar to the transcription factor E2F-1, whose binding to BRD4 is dependent on lysine
acetylation of E2F-1 (Ghari et al., 2016), can be excluded since no potential STAT5 acety-
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lation site a↵ecting its transcriptional activity was identified, and since a direct interac-
tion between BRD2 and STAT5 could not be observed in co-immunoprecipitation assays
(Fig. 4.20). Further indication against a stable complex between BRD2 and STAT5,
in addition to the absence of co-immunoprecipitation of these proteins, is given first by
the absence of alterations of soluble nuclear STAT5 complexes upon TSA treatment in
gel filtration experiments (Fig. 4.15), second by the absence of STAT5 redistribution
together with BRD2 upon deacetylase inhibitor treatment (Results 4.4.2 and Dr. Anne
Rascle, Pinz et al., 2015, fig. 10C) and third by the fact that BRD2 loss from Cis
by JQ1 or TSA treatment did not a↵ect STAT5 DNA binding (Fig. 4.19A and Liu et
al., 2014). Nevertheless, since BRD2 and other BET proteins are part of multiprotein
transcriptional complexes (Jiang et al., 1998; Denis et al., 2006; Rahman et al., 2011),
and since BRD2 seems to be involved in STAT5-mediated transcription, BRD2 is likely
part of a STAT5-containing transcriptional complex. Denis et al. (2000, 2006) reported
that the stability of BRD2-containing complexes is ATP-dependent, while no ATP was
added to the bu↵ers in our co-immunoprecipitation or gel filtration experiments. This
suggests that the formation of a STAT5 and BRD2-containing complex, and thereby the
recruitment of BRD2 to STAT5 target genes, might be ATP-dependent. On the other
hand, our data are also in agreement with a model in which BRD2 recruitment or sta-
bilization is mediated via chromatin. Considering the preferential binding of BRD2 to
acetylated histones (Kanno et al., 2004; LeRoy et al., 2008), its recruitment to STAT5
target genes could possibly be induced by an increase in local histone acetylation. This
proposition is supported by increased histone H3 and histone H4 acetylation at STAT5
target genes upon IL-3 stimulation of Ba/F3 cells concomitant to BRD2 recruitment to
the transcription start site (TSS) of Cis (Results 4.3.7 and Dr. Anne Rascle and Samy
Unser, Pinz et al., 2015, fig. 7, fig. 8, and fig. 11A and Pinz et al., 2014b, fig. 7). Fur-
thermore, blocking BRD2 bromodomains with the small molecule JQ1 leads to BRD2
loss from STAT5 target gene Cis (Fig. 4.19B), indicating that BRD2-acetyl-histone
interactions are important for the association of BRD2 with STAT5 target genes. To-
gether this suggests that the STAT5-dependent recruitment of BRD2 to STAT5 target
genes is ATP-dependent, or takes place at the chromatin level via histone acetylation, or
both. To further elucidate the mechanism of BRD2 recruitment to STAT5 target genes,
STAT5-BRD2 co-immunoprecipitation experiments in the presence of ATP might be car-
ried out. Furthermore, STAT5-containing transcriptional complexes could be analyzed
by ChIP coupled with mass spectrometry (ChIP-MS) to analyze whether BET proteins
are present in these complexes and to identify factors possibly bridging STAT5 to BRD2
or other BET proteins. To show whether increased acetylation at STAT5 target genes
is required for BRD2 recruitment, HAT inhibitors could be used to possibly prevent the
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increase in histone acetylation at STAT5 target genes upon IL-3 stimulation.
BRD2 interacts with transcriptional co-activators, transcription factors, components
of the transcriptional machinery, especially TATA-binding protein (TBP) and RNA poly-
merase II, associates with high-acetylated chromatin of transcribed genes and was pro-
posed to act as a sca↵old (Crowley et al., 2002; Kanno et al., 2004; Denis et al., 2006;
Peng et al., 2007; LeRoy et al., 2008). Furthermore, we found that, together with BRD2
depletion from the nucleosol upon deacetylase inhibitor treatment, TBP is also depleted
from the nucleosol (Results 4.4.2 and Dr. Anne Rascle, Pinz et al., 2015, fig. 10C). Thus,
the redistribution of BRD2 together with its interacting proteins upon deacetylase in-
hibitor treatment is likely to interfere with the proper recruitment of the transcription
machinery to the genes normally regulated by BRD2, such as the STAT5 target gene
Cis. This proposition is supported by the loss of key components of the transcription
complex, RNA polymerase II and TBP, from STAT5 target genes upon inhibition of
STAT5-mediated transcription by deacetylase inhibitor treatment in Ba/F3-1⇤6 and IL-
3-stimulated Ba/F3 cells (Fig. 4.18 and Rascle et al., 2003). In case interactions of BRD2
with the transcription machinery are indeed required for STAT5-mediated transcription,
the overexpression of a BRD2 deletion mutant lacking 26 amino acids required for the
interaction of BRD2 with TBP (Peng et al., 2007) would be expected to impair STAT5-
mediated transcription. Altogether, BRD2 is probably the deacetylase inhibitor-sensitive
factor proposed earlier to be involved in the recruitment of the transcription machinery
to STAT5 target genes (Rascle et al., 2003; Rascle & Lees, 2003), and its loss prob-
ably inhibits STAT5-mediated transcription by interfering with the recruitment of the
transcription machinery. Despite inhibition of the STAT5 target gene Osm by the BET
inhibitor JQ1, BRD2 association with the Osm gene was lower than with the Cis gene
and not a↵ected by TSA treatment (Fig. 4.19C). Thus, the Osm gene might possibly be
regulated by another BET family member. Similarly, while BRD2 was associated with
the enhancer of the STAT5 target gene c-Myc in Ba/F3-1⇤6 cells, no BRD2 was detected
at the enhancer upon IL-3 stimulation in Ba/F3 cells (data not shown, Dr. Anne Rascle,
Pinz et al., 2016, fig. 4). This raises the possibility that several BET family members
are involved in the regulation of STAT5 target genes. BET proteins share high sequence
homology (Belkina & Denis, 2012) and have a certain degree of functional redundancy
(LeRoy et al., 2008; Belkina et al., 2013). On the other hand, the di↵erent isoforms
seem to have specific developmental functions, which cannot be assumed by other family
members (Houzelstein et al., 2002; Gyuris et al., 2009; Shang et al., 2009). Furthermore,
BET proteins seem to influence transcription by various mechanisms: BRD2 loss from
the STAT5 target gene Cis correlated with loss of the transcriptional machinery, while
impairment with BRD4 function does not seem to a↵ect recruitment of the transcrip-
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tional machinery, but rather inhibits transcription elongation (Greer et al., 2015). It is
thus obvious that more e↵ort is required to elucidate specificity versus functional redun-
dancy of BET proteins and their role in the regulation of transcription of di↵erent STAT5
target genes. Knockdown of individual BET proteins followed by cDNA microarray anal-
ysis would show which STAT5 target genes are regulated by individual BET proteins.
ChIP-sequencing of BET proteins would confirm whether the identified BET proteins are
associated with di↵erent STAT5 target genes.
5.4 Model of regulation of STAT5-mediated tran-
scription by BET proteins and of its inhibition
by deacetylase inhibitors
In summary, this work provides evidence that BET proteins such as BRD2 are important
cofactors of STAT5-mediated transcription. We propose that a local increase in histone
acetylation upon STAT5 DNA binding contributes to the recruitment of BET proteins
and that BET proteins assist in the recruitment of the transcription machinery to STAT5
target genes. Furthermore, the data presented here suggest that deacetylase inhibitors
inhibit STAT5-mediated transcription independently of STAT5 acetylation, but instead
via induction of global histone hyperacetylation and concomitant redistribution of the
acetyl-histone-binding protein BRD2, and likely other BET family members, to hyper-
acetylated chromatin. This competition for binding to acetyl-histones would result in the
dissociation of BRD2 from STAT5 target genes (Fig. 5.1). Our group previously demon-
strated that deacetylase inhibitor treatment does not a↵ect STAT5 binding to DNA,
but impairs assembly of the transcription machinery at STAT5 target genes. Therefore,
the loss of BRD2- and likely of other BET family members - probably interferes with
the proper assembly of the transcription machinery at STAT5 target genes (Fig. 5.1C)
and might be responsible for the inhibition of STAT5-mediated transcription following
deacetylase inhibitor treatment. Eventually, the sought HDACs involved in inhibition of
STAT5-mediated transcription by deacetylase inhibitors remain to be identified but our
data suggest that they belong to class I HDACs.
This proposed model is in agreement with genome-wide ChIP-sequencing experiments
which have been published in the meantime (Greer et al., 2015; Halsall et al., 2015).
Those experiments revealed that the transcription start sites of genes which are up- or
down-regulated by deacetylase inhibitors were packed in highly acetylated chromatin be-
fore inhibitor treatment, in agreement with our model of highly acetylated STAT5 target
genes proposed previously (Rascle & Lees, 2003) and in the present study. Furthermore,
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Figure 5.1: Model of regulation of STAT5-mediated transcription by BET proteins and of
its inhibition by deacetylase inhibitors
BRD2 is normally associated with chromatin and present in the nucleosol (A), (B). Following IL-3
stimulation and activation of STAT5, an increase in histone acetylation (Ac) around the transcription
start site (TSS) of the Cis gene probably contributes to the recruitment of BRD2 to the Cis gene (B).
BRD2 in turn probably assists in the recruitment and stabilization of the transcription machinery (pre-
initiation complex (PIC)) (B) and is therefore required for the induction of Cis gene expression. The
deacetylase inhibitors trichostatin A (TSA), VPA, and apicidin induce global chromatin hyperacetylation
(C). The multiple newly acetylated histones compete for binding of BRD2 and are therefore probably
responsible for BRD2 depletion from the nucleosol and from the genes it normally regulates (C). Previous
data demonstrated that deacetylase inhibitor treatment does not a↵ect STAT5 binding to DNA but
prevents the recruitment of the transcription machinery to STAT5 target genes. Together this suggests
that loss of BRD2 from the Cis gene interferes with the recruitment of the transcription machinery
(PIC) (C) and is thus responsible for the inhibition of Cis gene expression. Our data suggest that
besides BRD2, other chromatin associated factors, such as other BET proteins, might be involved in
STAT5-mediated transcription and in its inhibition by deacetylase inhibitors. The HDACs involved in
this model have not yet been identified, but due to the implication of histone hyperacetylation, those
HDACs are probably class I HDACs. Ac, acetylation.
Greer et al. (2015) showed that the highly acetylated genes downregulated by deacety-
lase inhibitors were associated with the BET protein BRD4 before inhibitor treatment.
Upon inhibitor treatment, BRD4 was redistributed towards newly acetylated sites in
gene bodies and intergenic regions and away from the highly acetylated promoters and
enhancers it normally binds to. This mechanism is similar to the association of BRD2
with the deacetylase inhibitor-sensitive STAT5 target gene Cis and to the demonstrated
BRD2 redistribution upon deacetylase inhibitor treatment presented in this thesis. Hal-
sall et al. (2015) suggested that the high acetylation of certain genes is an inherent cellular
adaptive feature to up- or down-regulate these genes in response to increased global chro-
matin acetylation in order to slow cell growth and to allow the cell to adjust to and
counteract hyperacetylation. It is tempting to propose that BET proteins are part of
this cellular adaptive mechanism and play a role in gene downregulation upon chromatin
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hyperacetylation. Inhibition of STAT5-mediated transcription by deacetylase inhibitors
via interference with BET protein function might be one phenomenon of this general
cellular adaptive mechanism to hyperacetylation. Inhibition of proliferation-promoting
STAT5 target genes (Mui et al., 1996; Matsumura et al., 1999; Nosaka et al., 1999; Ras-
cle et al., 2003; Basham et al., 2008) together with other genes implicated in cell growth
(Halsall et al., 2015) might serve to prevent cells with aberrant chromatin acetylation
from growing and proliferating.
To confirm our model of regulation of STAT5-mediated transcription by BET proteins
and deacetylase inhibitors, and to confirm the involvement of the di↵erent BET proteins in
the general cellular response to hyperacetylation, genome wide analysis of the distribution
of the di↵erent BET family members upon deacetylase inhibitor treatment should be per-
formed. Those experiments would confirm whether all BET proteins are predominantly
associated with genes that are downregulated by deacetylase inhibitors and whether the
di↵erent BET proteins show similar genomic redistributions upon deacetylase inhibitor
treatment. Those experiments would also reveal which BET family members are associ-
ated with di↵erent STAT5 target genes. Investigating the mechanism and specificity of
BET protein recruitment to STAT5 target genes would help to further characterize the
mechanism of STAT5-mediated transcription and its regulation by BET proteins.
In conclusion, the novel aspects of the regulation of the oncoprotein STAT5 presented
in this study have wide implication in the clinical field, especially since the other main
players, BET proteins and HDACs, are also implicated in oncogenesis. BET proteins
and HDACs are thus presented here as attractive targets for the development of novel
therapies against STAT5-associated cancers.
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